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Abstract 
 
Nesprins-1 and -2 are multi-isomeric scaffolding proteins. They are highly 
expressed in skeletal and cardiac muscle, and together with SUN (Sad1p/UNC84)-
domain containing proteins and lamin A/C, forming the LInker of Nucleoskeleton and 
Cytoskeleton (LINC) complex at the nuclear envelope (NE). Mutations in nesprin-1/-
2 have previously been identified in patients with autosomal dominant Emery–
Dreifuss muscular dystrophy (EDMD) as well as dilated cardiomyopathy (DCM). 
In my study, three novel rare variants (R8272Q, S8381C, N8406K) in the C-
terminus of the SYNE-1 (nesprin-1) gene were identified in 7 DCM patients by 
mutation screening. These mutants caused nuclear morphology defects, reduced lamin 
A/C and SUN2 staining at the NE and disrupted binding between nesprin-
1/lamin/SUN. Nesprin-1 mutations were also associated with augmented activation of 
the ERK pathway in vitro and in hearts in vivo. During C2C12 myoblast 
differentiation, nesprin-1 protein levels increased concomitantly with kinesin light 
chain (KLC-1/2). GST pull-down assay showed that nesprin-1 and KCL-1/2 bind at 
the NE. Expression of nesprin-1 mutants in C2C12 cells caused defects in myoblast 
differentiation and fusion associated with dysregulation of myogenic regulatory 
factors and disruption of the nesprin-1 and KLC-1/2 interaction. Furthermore, 
expression of nesprin-1α2 WT and mutants in zebrafish embryos caused heart 
developmental and conduction defects that varied in severity. In addition, a novel 
cardiac specific dominant negative nesprin-2 KASH (Klarsicht/ANC-1/Syne-1 
homology) transgenic (Tg) mouse model was generated. Data showed overexpression 
of KASH domain caused disruption of NE-LINC complex and induced a hypertrophic 
response with activated fetal gene re-expression in Tg mice at the basal line, which 
was exacerbated when subjected to pathological hemodynamic stress. 
These findings support roles for nesprin-1/-2 in nuclear organisation and 
myogenesis, which may uncover a novel mechanism whereby disruption of the NE-
LINC complex may contribute to the pathogenesis of DCM.
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Chapter 1: Introduction 
 
Nesprins (nuclear envelope spectrin repeat proteins), are multi-isomeric 
scaffolding proteins [1]. They localise at the nuclear envelope (NE) and interact with 
SUN domain proteins to form the LINC (LInker of Nucleoskeleton and Cytoskeleton) 
complex. The LINC complex provides a stable physical connection between the 
nucleus and the cytoskeleton, and also participates in mechanotransduction via 
transmitting the cellular mechanical force to the nucleus [2]. To date, nesprin-1 and 
nesprin-2 mutations have been identified in Emery-Dreifuss muscular dystrophy 
(EDMD) and Dilated Cardiomyopathy (DCM) patients [3, 4]. In this chapter, I will 
comprehensively review the current research on nesprin proteins, in particular nesprin-
1 and -2, including their structural properties, roles in the LINC complex, and discuss 
any potential mechanisms linking these mutations to muscle specific disorders. 
 
1.1 Cytoskeleton network and spectrin repeat 
superfamily 
 
The cell is the basic unit for structure and function in all living organisms. In 
eukaryotic cells, the cellular architecture is maintained by the cytoskeleton network 
that connects the nucleus to the extracellular matrix (ECM). Three major cytoskeleton 
network components are: microfilaments (Filamentous-actin, F-actin), intermediate 
filaments (IFs) and microtubules, which vary in size and stiffness, all work together 
with their associated proteins to build stable interconnected scaffolds. The 
cytoskeleton network plays important roles in regulating cell shapes and migration, 
transporting intracellular cargo and resisting deformation [5].  
An important family of proteins that connect cytoskeletal elements, cell 
membrane, and the nucleus are the spectrin repeat (SR) containing proteins [6, 7]. This 
superfamily is characterised by multiple arranged SRs arranged in tandem to form the 
coiled-coil rod domain. In addition, the majority of these proteins contain the N-
terminal calponin-homology domain (CH) which binds to F-actin, and the featured C-
terminal protein-binding motif that binds to microtubules, IFs and the nuclear 
membrane [8]. To date, a growing list of proteins have been identified as members of 
this superfamily, which include α-actinin, spectrins, dystrophin/utrophin, 
  21 
spectraplakins/plakins and nesprins. Those proteins can be characterised by various 




Nesprins, the latest identified SR containing proteins, are a novel family of multi-
isomeric scaffolding proteins [1]. To date, six genes (SYNE-1, -2, -3, -4, LRMP and 
KASH5) have been identified encoding nesprins-1, -2, -3, -4, Lymphoid-restricted 
membrane protein (LRMP) and KASH5, localizing on chromosome 6q25, 14q23.2, 
14q.32.13, 19q13.12, 19q10 and 12q12.1 respectively [1, 9-12].  
Full length human nesprin-1 and nesprin-2 are giant SR proteins with molecular 
masses of ~1000kDa and ~800kDa respectively, which are the second and third largest 
known proteins. Nesprin-1, also known as synaptic nuclear envelope-1 (SYNE-1) [13], 
and myocyte nuclear envelope protein-1 (Myne-1) [14], was identified in searching of 
vascular smooth muscle cell (VSMC) differentiation markers using differential cDNA 
screening of rat VSMCs [15]. A 10kb transcript of rat nesprin-1 (1RA1), was highly 
expressed in differentiated aortic VSMCs compared to cultured undifferentiated 
VSMCs [1]. Nesprin-2 was identified in the same differential cDNA screening, sharing 
64% homology with nesprin-1 [1]. Other research groups reported nesprin-2 as SYNE-
2 [13], and nucleus and actin connecting element (NUANCE) [16] that was identified 
via yeast two-hybrid or screening the human EST database using the peptide sequence 
of known α-actinin-related proteins as a query. My research is mainly focused on 
nesprin-1 and -2. 
Nesprin-3 was first isolated from a yeast two-hybrid screen using the actin 
binding domain of plectin-1C as bait, with a molecular mass of 110kDa and around 
22-25% homology with the same region in both mouse and human nesprin-1 and 
nesprin-2 [9]. Nesprin-4 was identified via a BLAST search using the human nesprin-
2 transmembrane domain as probe; however, this protein showed lower similarity 
(26%-36% identical) to nesprin-1/-2/-3 at the protein level. It is a relatively small 
isoform with a molecular mass of 42kDa [10]. LRMP was originally identified in B 
and T cells, localised to the endoplasmic reticulum (ER) membrane via the C-terminal 
KASH homology domain [11, 17, 18]. LRMP was also expressed in a subset of taste 
receptor cells in mammals [19], and rich in zebrafish zygotes [18]. KASH5, also 
  22 
known as Ccdc155, with a molecular weight of 72kDa, was identified using a BLAST 
search with LRMP. It was highly expressed in testes, and is a meiosis-specific KASH 
domain protein [12, 20]. 
1.2.1 Nesprin structure 
 
The typical structure of giant nesprin-1 and -2 consists of three major parts: A 
C-terminal Klarsicht/ANC-1/Syne Homology (KASH) domain that is targeted to the 
NE, an N-terminal paired Calponin Homology (CH) domain that binds to the actin 
cytoskeleton, and a central domain containing multiple SRs that link the CH and 
KASH domains and provide the elasticity needed for protein-protein interactions [21]. 
Of note, there is a highly conserved adaptive domain (AD) at the C-terminus of 
nesprin-1 and -2, between SR71-SR72 of nesprin-1 and SR53-SR54 of nesprin-2 
respectively [22, 23]. The AD region has relatively little secondary structure, but it 
significantly stabilises multiple SRs by increasing their overall helicity, thermal 
stability and cooperativity of folding [23] (Figure 1.1). 
1.2.1.1 Klarsicht/ANC-1/Syne Homology (KASH) domain 
 
Nesprin-1 and -2 show the NE targeting property which relies on the C-terminal 
transmembrane KASH domain. The KASH-domain family includes Kms1 in 
Schizosaccharomyces pombe, Interaptin in Dictyostelium discoideum, ANC-1, UNC-
83 and ZYG-12 in Caenorhabditis elegans (c. elegans) as well as Klarsicht and MSP-
300 (muscle-specific protein 300) in Drosophila melanogaster [24-26]. KASH domain 
proteins are type-II transmembrane proteins that contain a single transmembrane 
segment, followed by an evolutionarily conserved sequence, then a short luminal tail 
that extends into the perinuclear space (PNS) [26]. The KASH domain tails terminate 
with a PPPX motif (this motif is very conserved in mammals where X is variable 
residue), and interacts with luminal Sad1p-UNC84 (SUN) domain proteins [26, 27]
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1.2.1.2 Spectrin repeat (SR) rod domain 
 
A single SR contains three bundled antiparallel α-helices (helix A, B and C) 
separated by two loop regions (called loop AB and BC) (Figure 1.2). SRs link to each 
other via a helix region (the ‘linker’) which connects the last helix of one repeat with 
the first helix of the next [28, 29]. Multiple consecutive SRs are arranged in tandem 
and localise between N- and C-terminal domains. This rod domain not only serves as 
a simple spacer, it is also involved in the formation of the tertiary/quaternary structure, 
interacting with other molecules, and potentially contribute to protein elasticity and 
structural flexibility [7, 29]. 
The central rod domain of nesprins comprises of numerous SRs that tightly link 
the N-terminus to the C-terminus. Full length nesprin-1 is formed of 74 SRs, whereas 
nesprin-2 is formed of 56 SRs. Nesprin-1 and -2 are both typical SRs fold with a high 
proportion of α-helical structure [29].  
Evolutionary conservation of amino acid positions in nesprins reveals both 
nesprin-1 and -2 have a very high similarity in their sequences, and good stability in 
the temperature and denaturation studies [29]. The most conserved SRs are the 
nesprin-1 SR69-SR71 and nesprin-2 SR51-SR53. Interestingly, these SRs are both the 
3rd to the 6th SRs counting backwards from nesprin-1 and nesprin-2 respectively, 
indicating this structure may have some critical function in nesprin proteins. The 
nesprin-1 SR69-SR71 (red coloured SRs) are more conserved than nesprin-2 SR51-
SR53 (pink coloured SRs). This difference results in the distinct electrostatic surface 
and hydrophobic/hydrophilic properties, divergent potential binding sites for the 
interaction partners and different flexibility/elasticity (Figure 1.3) [29].


























Figure 1.1 Structure of giant nesprin-1 and -2 
The giant nesprin-1 and -2 consist of three major parts: C-terminal Klarsicht/ANC-1/Syne 
Homology (KASH) domain targeting to the NE; N-terminal paired Calponin Homology (CH) 
domains binding to the actin cytoskeleton; whilst multiple SRs in the central, linking the CH 
and KASH domains, which maintain elastic properties and mediate protein-protein 
interactions. Noteworthy, an unstructured region named as adaptive domain (AD) localises at 
the C-terminus and helps to stabilise the multiple SRs. 
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Figure 1.2 Ribbon representation of a single SR crystal structure 
Representation of the crystal structure of a single unit SR from chicken brain α-spectrin, which 
consists of three bundle α-helices (helix A/B/C) in an antiparallel manner, and separated by 
two loop regions (loop AB/BC). The SR unit comprises the majority of the nesprin backbone. 
Image adapted from Autore, et al. 2013 [29].










Figure 1.3 Schematic representation of highly conserved SRs in nesprin-1 and 
-2 
The most conserved SRs are SR69-SR71 and SR51-SR53 in nesprin-1 and -2 respectively. 
The colour code indicates the different evolutionary conservation of amino acids in nesprin-1 
SR69-SR74 (A) and nesprin-2 SR51-SR56 (D). Panels B-C and E-F represent the electrostatic 
potential surfaces (side A and side B) of nesprin-1 SR69-SR74 and nesprin-2 SR51-SR56. 
Blue – positive charge potential; red – negative charge potential. The yellow star represents 
the adaptive domain. Image adapted from Autore, et al. 2013 [29].
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1.2.1.3 Calponin Homology domain 
 
CH domain was first identified in the Calponin protein, which is a calcium-
binding protein presents in smooth muscle with a single CH domain [30]. The compact 
globular CH domain comprises of four α-helices in roughly parallel orientation. Each 
α-helix is 11-18 residues in length, linked by the other three helices to form the 
sandwich-like structure [31]. Nesprin-1 and -2 contain two CH domains (CH1 and 
CH2) at the N-terminus in the juxtaposition, functioning as the actin-binding domain 
(ABD). A single CH2 domain is not able to bind to actin filaments, but it acts as a CH1 
enhancer to strengthen the binding with F-actin [32, 33]. 
1.2.2 Nesprin isoforms 
 
SYNE-1 and SYNE-2 genes consist of 146 and 116 exons respectively. Within 
such long genes, there are multiple different starting and termination sites as well as 
alternative splicing allowing them to generate numerous isoforms (Figure 1.4). 
1.2.2.1 Giant nesprin-1 and nesprin-2 
 
Giant nesprin-1 and nesprin-2 localise at the outer nuclear membrane (ONM) via 
the C-terminal KASH transmembrane domain, and connect the NE to the actin 
cytoskeleton through the N-terminal CH domains. Nesprin-1 and nesprin-2 giant 
isoforms make up 80% of the total nesprin mRNA in 20 different human tissues. But 
they were less in cardiac muscle (63%), skeletal muscle (66%) and the spleen (56%), 
suggesting those tissues have a higher proportion of shorter isoforms that may be 
required for tissue-specific functions. The mRNA level of giant nesprin-2 is greater 
than giant nesprin-1 in the majority of human tissues and cell lines, except in brain and 
VSMCs with 81% and 92% of nesprin-1 respectively.






























Figure 1.4 Nesprin isoforms derived from SYNE-1/-2 genes 
By combining the identified 5′UTRs and 3′UTRs with the nesprin-1 giant and nesprin-2 giant, 
different nesprin-1/-2 variants with or without KASH/CH domains can be created. A: Potential 
nesprin-1/-2 KASH domain isoforms; B: Potential nesprin-1/-2 CH domain isoforms; C: 





  29 
1.2.2.2 Nesprin isoforms with KASH domain 
 
The KASH domains between nesprin-1 and nesprin-2 are highly homologous to 
each other with the difference of only 10 out of the total 60 amino acids. To date, by 
alternative combinations of identified 5’UTR with the 3’UTR of the giant nesprin-1 
and nesprin-2, 16 nesprin-1 and 12 nesprin-2 KASH containing isoforms can 
theoretically be generated (Figure 1.4A). These nesprin KASH isoforms exhibit varied 
tissue specific patterns [34]. In muscle, nesprin-1α2 and nesprin-2α1 are highly 
expressed in both heart and skeletal muscle, accounting for 30% of the total mRNA of 
nesprin-1/-2; nesprin-2β is only highly expressed in skeletal muscle, whilst nesprin-
2Ɛ2 is heart specific. In other tissues: nesprin-1β is highly expressed in spleen; nesprin-
2α2 is mainly present in the kidney; nesprin-2Ɛ1 is found in early embryonic cells; and 
nesprin-2γ is present at a low level in all tissues [1, 35, 36] (Table 1.1). 
There is evidence that shows nesprin isoforms are dynamically regulated during 
different cellular activities. In human myoblasts, expression level of nesprin-1α2 is 
very low, whereas it is massively up-regulated around 50-fold after differentiation 
[37].  In vivo, during the transition from immature to mature muscle fibers, nesprin-2 
KASH isoforms partly replaces nesprin-1 KASH isoforms at the NE, and short isoform 
nesprin-1α2 becomes more dominant [38]. 
1.2.2.3 Nesprin KASH less isoforms with CH domains 
 
Hypothetically combining 5’UTR with the alternative 3’UTR of the giant 
nesprin-1 and nesprin-2, 14 nesprin-1 and 5 nesprin-2 CH domains containing and 
KASH less isoforms can be generated (Figure 1.4B). The fully cloned nesprin-1 
P56CH is formed by paired CH domains and the first SR of nesprin-1. It is ubiquitously 
expressed, but exhibits tissue specific localisation. In primary human dermal 
fibroblasts (HDFs), it interacts with F-actin and focal adhesion, while in U2OS cells, 
it surprisingly localise to the nucleolus, and interacts with nuclear actin [34].
  30 
Table 1.1 Summary of the tissue specific nesprin-1/-2 variants 
Variants  Tissue 
Nesprin-1 Nesprin-1α2 Heart and skeletal muscle 
Nesprin-1β1 Spleen 
Nesprin-2 Nesprin-2α1 Heart and skeletal muscle 
Nesprin-2α2 Kidney 
Nesprin-2β Skeletal muscle 
Nesprin-2Ɛ1 Embryonic cells 
Nesprin-2Ɛ2 Heart 
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During ciliogenesis, a 250kDa and a 150kDa nesprin-2 CH domain containing 
isoforms can interact with Meckel syndrome (MKS) proteins through the SRs near N-
terminus at the cell periphery, and bind with F-actin via the CH domains. The 
connections between nesprin-2 CH isoforms with microtubule and actin cytoskeleton 
form the cellular scaffolds to regulate centrosome migration [39]. Loss of MKS protein 
causes a dramatic remodelling of the actin cytoskeleton, aberrant localisation of 
nesprin-2 isoforms to actin stress-fibers and activation of RhoA signalling [39]. These 
findings further highlight that nesprin CH domain isoforms display a non-NE targeted 
localisation, interact with cytoskeletal elements, and play roles in centrosome 
migration and early ciliogenesis. 
1.2.2.4 Spectrin repeat only nesprin isoforms 
 
To date, more alternative 5’UTR and 3’UTR for KASH less isoforms have been 
identified in SYNE-1 rather than SYNE-2, implying nesprin-1 has the potential to 
generate more SR only isoforms than nesprin-2 (Figure 1.4C). 
Nesprin-1 SR containing protein, named Golgi-localized SR-containing protein-
56 (GSRP-56), plays a role in maintenance of the Golgi structure [40]. Recently, 
nesprin-1 p50, a 50kDa isoform with 4 SRs, has been identified from the SYNE-1 gene. 
Nesprin-1 p50 is widely expressed and localises to the processing bodies, acting as a 
microtubule-associated scaffold protein, and participating in miRNA-mediated 
silencing [41]. 
Nesprin-2β KASH less isoform has been detected in the VSMCs. This 75kDa 
nesprin-2 isoform tethers the extracellular signal-regulated kinase 1/2 (ERK1/2) at the 
promyelocytic leukaemia proteinnuclear bodies to form the nuclear complex and 
serves to regulate nuclear signalling. Interference of nesprin-2 function results in 
sustained ERK1/2 signalling which eventually promotes the VSMC proliferation [42]. 
These findings demonstrate that nesprin SR isoform can act like a novel intra-nuclear 
scaffold, involved in cell signalling regulation and cell cycle progression. 
1.2.2.5 Nesprin KASH or KASH less isoforms 
 
Nesprins are multi-isoform proteins, and many antibodies are generated against 
different regions. Thus, the nesprin antibodies are more likely to detect a group of 
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isoforms containing that regions rather than a single isoform. Using the nesprin-2 
antibody that targets SRs towards the C-terminus, nesprin-2 KASH isoform like 
nesprin-2β, nesprin-2γ and other potential nesprin-2 KASH-less isoforms can be 
detected. Immunofluorescence (IF) showed weak NE and nuclear staining, in contrast 
with a strong sarcomere staining in both C2C12 myotube and human skeletal muscle 
[35]. The staining is particularly abundant over the Z-line and A/I junction, indicating 
those isoforms may function in sarcoplasmic reticulum and muscle contraction [35]. 
While the KASH domain isoforms targeted to the NE, the KASH less isoforms could 
potentially form the sarcomeric network in skeletal muscle [35]. In future, further work 
is required to fully characterise these nesprin isoforms and reveal their specific 
functions. 
 
1.3 Nuclear Envelope 
 
In eukaryotic cells, the nucleus is the most featured organelle that contains the 
genetic material and determines cell fate. Like the capital city standing in the crucial 
part of the cell, the nucleus is well guarded by the walls of the nuclear envelope, 
reinforced by the underneath intermediate filaments– nuclear lamina [43]. 
1.3.1 Nuclear envelope structure 
 
The NE consists of two lipid membranes and nuclear pore complex (NPC). In 
mammalian cells, the outer nuclear membrane (ONM) and the inner nuclear membrane 
(INM) are separated by a ~50nm wide lumen called perinuclear space (PNS) [44, 45]. 
These two nuclear membranes are perforated by NPCs, which help to facilitate the 
molecular trafficking between the cytoplasmic and nuclear compartments. The 
transport is bidirectional, allowing the movement of molecules [46]. Proteins which 
are required for nuclear functions are synthesized in the cytoplasm and imported into 
the nucleus, whereas much of the RNA synthesized in the nucleus is transported to the 
cytoplasm [47]. The ONM is continuous with the endoplasmic reticulum (ER). It has 
been shown that there are abundant ribosomes presents at the ONM as well as the ER 
[44]. In addition, the INM consists of a wide range of transmembrane proteins that 
interact underneath nuclear lamina. Proteomics studies suggested that more than 70 
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different INM transmembrane proteins from several species have been identified. 
Some of these proteins present in a tissue-specific manner, which suggest the NE will 
recruit their specialised components to form the cell-type/function associated NE 
complex [48-50]. 
1.3.2 Nuclear envelope proteins 
 
Among the wide range of INM transmembrane proteins, emerin and SUN 
proteins have been extensively characterised and are closely related to my research. 
1.3.2.1 Emerin 
 
Emerin is encoded by the EMD gene located on the X-chromosome. It is 254 
amino acid long and consists of a 220 amino acid N-terminal nucleoplasmic domain, 
followed with a 23-amino acid C-terminal transmembrane domain and a small 11 
amino acid luminal tail [51, 52]. Emerin, along with other INM transmembrane 
proteins like lamin associated polypeptides (LAPs) and MAN1 are founding members 
of the LEM-domain proteins [53]. LEM-domain comprised of 40 amino acids 
(residues 4-40 at emerin N-terminal), is conserved in prokaryotic and eukaryotes. This 
domain can directly bind to a conserved chromatin protein named barrier to auto-
integration factor (BAF), which has essential roles in higher-order chromatin structure, 
nuclear assembly, and gene regulation [54]. Emerin is synthesized in the cytoplasm 
and then diffused from the ER to the nucleus [55]. During integration into the INM, 
emerin is retained through binding to the nuclear lamina. Deletion of lamin binding 
sites in emerin (residues 107–175) cause cytosolic aggregation of emerin [56]. In mice, 
embryonic fibroblasts (MEFs) lacking A-type lamins exhibited, emerin with more 
diffusional mobility, and this can be rescued by restoring the A-type lamins [57]. 
Emerin is ubiquitously expressed and predominately localise at the NE in 
skeletal muscle and heart [53, 58-60]. It has at least 14 binding partners including 
nesprin, nuclear lamina, Sad1/UNC-84 (SUN), BAF and chromatin-silencing enzyme 
HDAC3 (histone deacetylase 3) [61-65]. Notably, emerin binds to the small nesprin 
isoforms nesprin-1α and nesprin-2β within the same region as lamin A/C [66]. 
Evidence shows emerin relies on nesprin-1 and -2 for its proper NE targeting. 
Overexpressing or knocking down nesprin-1α mis-localises emerin from the INM in 
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U2OS and HDFs [3]. Overexpression of nesprin-2β mutants reduces emerin from the 
NE in HDFs [3]. These various partners of emerin suggests it is a critical component 
among the INM transmembrane proteins and is involved in the NE structure, 
chromatin integrity, gene regulation and cell signalling [67]. 
1.3.2.2 SUN 
 
Sad1/UNC-84 (SUN) domain proteins were initially characterised from the 
Schizosaccharomyces pombe Sad1 protein and Caenorhabditis elegans UNC-84 
protein [68, 69]. SUN domain proteins are conserved across eukaryotes including 
fungi, plants and animals [69-71]. So far, five SUN domain proteins have been 
identified in mammals. In addition to the wide expressed SUN1 and SUN2, SUN3, 
SUN4 (also known as SPAG4) and SUN5 are limited to the testes, and function in 
sperm development [72-75]. 
SUN1 and SUN2 have many common features. They are both INM 
transmembrane proteins; They are both comprised of the N-terminal nucleoplasmic 
domain, which can interact with nuclear lamina; a single transmembrane domain 
targets it to the INM; then two coiled-coiled regions that aid in dimerization or 
multimerization in PNS; followed with a highly conserved SUN domain at the C-
terminal and can bind with nesprin [76-78]. SUN1 is the largest SUN protein in this 
family with a molecular mass ~90kDa, while SUN2 is slightly smaller with a 
molecular mass ~80kDa. Due to the alternative splicing site at the N-terminal of SUN1 
gene, it results in 7 different SUN1 variants [79]. Structure analysis speculated these 
SUN1 variants contain different hydrophobic motifs at the N-terminal and these may 
affect the dynamic properties of this molecule [80]. For SUN2, there was no literature 
reporting any potential variants, suggesting it may be more conserved in all cell types. 
With loss of both SUN1 and SUN2, mice die at birth, which is likely due to a 
nuclear migration defect during the central nervous system (CNS) development [81]. 
Interestingly, depletion of either SUN1 or SUN2 in mice exhibit different phenotypes. 
SUN1 null mice are deaf with reduced rod cell number and thinner outer nuclear layer 
in the retina compared with SUN2 null mice [82, 83]. Disruption of SUN1 in mice also 
perturbs telomere attachment to the NE, leading to inefficient homologous chromatin 
pairing and synapse formation during mammalian gametogenesis [84]. SUN1 and 
SUN2 are both rich in the heart and skeletal muscles [85]. Recently mutations in SUN1 
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and SUN2 have been reported in human muscular dystrophies, affecting the cardiac 
and skeletal muscle. Myoblasts or fibroblasts derived from these patients displayed the 
changed expression level of nesprin-2, lamin A/C and emerin, as well as altered 
binding [86, 87]. 
1.3.3 Nuclear lamina 
1.3.3.1 Structure and isoforms of nuclear lamins 
 
The nuclear lamina is the meshwork comprised of type V intermediate filaments 
that link the NE and nucleoskeleton. Many ~3.5 nm thick filaments form a complex 
meshwork at the nuclear periphery, underneath NPCs and these display a pattern of 
sparsely and densely packed regions [88]. Each lamin features a central α-helical rod 
domain flanked by a small head (10-20 amino acids) and a carboxyl-terminal tail (200-
300 amino acids) which contains a nuclear localisation signal, and an immunoglobulin 
(Ig)-like β fold domain and a CAAX motif (C: cysteine, A: an aliphatic amino acid, 
X: a variable amino acid, usually a methionine) [89, 90].  
Nuclear lamins are divided into two classes, A-type and B-type. Lamin A/C and 
lamin B1, B2 are the major isoforms representing A-/B-type lamins respectively [91-
94]. All nucleated cells express at least one B-type lamin at all stage of development 
[95]. Whereas A-type lamins are absent during early pre- and post-implantation 
embryonic stages and in embryonic stem (ES) cells. It starts to appear during tissue 
development [96]. 
1.3.3.2 A-type lamins 
 
Prelamin A, the precursor of lamin A undergoes a series of post-translational 
modifications to become mature lamin A with removal of the modified C-terminal 15 
amino acids via enzyme FACE1 (ZMPSTE24) [97, 98]. Abnormal accumulation of 
prelamin A results in the premature ageing disorder Hutchinson–Gilford progeria 
syndrome (HGPS) [99]. Notably lamin C does not undergo extensive post-translational 
modifications. In mammals, lamin A/C is highly dynamic and undergoes re-modelling 
throughout development. Protein levels of lamin A/C correlates with tissue elasticity 
and lamin A/C is 30-fold higher in stiff tissue relative to soft tissue [100]. Enhanced 
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lamin A/C in a stiff tissue such as muscle, heart, or bone will tend to impede rapid 
nuclear distension during the high stresses and/or stress fluctuations, to stabilise the 
chromosome territories or chromatin-lamina interactions [100]. 
Lamin A/C has numerous diverse interaction proteins. At least 54 binding 
partners and more than 100 indirect interactions have been identified using various 
proteomics-based studies [101, 102]. In general, lamin A/C binding partners can be 
categorized into three groups: chromatin-associated proteins including 
heterochromatin protein-1 (HP-1), H2A-H2B histone dimer and BAF [103-105]; NE 
transmembrane proteins such as nesprin, SUN, emerin, LAP2 [35, 77, 106, 107]; and 
signalling molecules and transcription factors like Phosphorylated-Retinoblastoma 
(pRb), extracellular signal-regulated kinase 1/2 (ERK1/2), c-Fos Proto-Oncogene, AP-
1 Transcription Factor Subunit (c-fos), Sterol response element binding protein-1 
(SREBP1) [108-110]. Those multiple binding molecules indicate the ‘hub’ role of 
lamin A/C in maintaining chromatin structure, gene regulation and cell signalling. 
 
1.4 Nesprins link the nucleoskeleton to the 
cytoskeleton 
 
The nucleus is the most crucial part of a cell. However, it is not isolated and is 
connected to the cytoplasm, cell membrane and extracellular matrix (ECM) via the 
‘bridge’ crossing the NE. The cytoskeleton network was discovered to be specifically 
anchored at the NE by different types of LINC (linker the nucleoskeleton and 
cytoskeleton) complexes. These act as ‘bridges’ to maintain the NE structural integrity, 
regulate nuclear migration and positioning, sense the mechanotransduction and 
participate in gene regulation [2, 111-113]. 
1.4.1 LINC complex structure 
 
The larger nesprin isoforms localise at the ONM, and directly bind to the 
cytoskeleton network including actin filaments, microtubule-dependent motors and 
plectin through their N-terminal domain [9, 10, 25, 114], whilst the C-terminal KASH 
transmembrane domain expands into the PNS and binds with SUN domain proteins 
embedded in the INM [78, 115]. This forms the LINC complex that links the 
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nucleoskeleton to the cytoskeleton. In addition, the nucleoplasmic domains of SUN 
proteins bind with INM transmembrane proteins, including small nesprin isoforms 
(nesprin-1α, nesprin-2β), emerin and nuclear lamina (lamin A/C), forming the NE 
complex which integrates with LINC complex to scaffold the entire cell [1, 35, 63] 
(Figure 1.5). 
1.4.2 SUN-KASH bridge 
 
The central part of the LINC complex is formed by the interaction of the KASH 
domain and SUN domain at the PNS. Recently, a significant insight into this SUN-
KASH bridge has provided us with more details of this fundamental structure [78, 
115]. The crystal structure of SUN-KASH demonstrated that a trimeric SUN domain 
has the capacity to bind three KASH peptides. There are three key points of interaction 
between SUN and KASH domains. Firstly, SUN proteins assemble into trimers. The 
two adjacent SUN domains form a deep groove acting like KASH binding pocket. 
Thus, a trimeric SUN domain is sufficient to bind with three KASH domains. 
Secondly, at the KASH domain, the C-terminal forms several contacting points with 
the SUN domain. Meanwhile, the hydrophobic residues on the KASH domain bind to 
a structure called the KASH-lid across two neighbouring SUN domains. Thirdly, a 
highly conserved cysteine at the KASH domain forms a disulphide bond covalently 
linking SUN and KASH, further enhancing this binding. These findings explain how 
this SUN-KASH bridge can form a high-order complex and serve as the fundamental 
core that can resist the substantial forces that are required for nuclear movement and 
chromosome rearrangements [78, 115, 116]. 
1.4.3 Types of the LINC complexes 
1.4.3.1 Nesprin-1/-2 associated LINC complexes 
 
One of the most characterised LINC complexes is the actin associated nesprin-
1/-2-SUN LINC complex (Table 1.2, Figure 1.5). Not only acting to physically couple 
the cytoplasm and nucleus, the actin LINC complex also defines the mechanical 
properties as propagating the long-distance force through cytoplasm (F-actin) - NE 
(nesprin-1/-2 to SUN1/2) - nucleus (lamin A/C) in the cell [117]. In fibroblasts, this 
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linker specially formed with nesprin-2 is called the transmembrane actin-associated 
nuclear line (TAN line) [118, 119]. Disruption of this LINC complex using: 
depolymerized F-actin, inhibition of F-actin associated Rho kinase, overexpression of 
exogenous dominant negative (DN) KASH, or deletion of nesprin-2 giant results in 
altered nuclear shape, shrinking and mis-positioning of nuclei [118, 120, 121]. 
Another nesprin-1 and -2 associated LINC complex is the microtubule LINC 
complex (Table 1.2, Figure 1.5). Nesprin-1 and -2 interact with dynein/dynactin and 
kinesin-1 to link the nucleus with centrosomes, regulate the nuclear migration and 
positioning in skeletal muscle, retina and brain during development. Perturbing this 
LINC complex result in the nuclear aggregation or mis-localisation, which is similar 
to the phenotype, observed in human disease [83, 114, 122-124]. 
1.4.3.2 Other nesprin associated LINC complexes 
 
In addition to nesprin-1 and -2, four other nesprins including nesprin-3, -4, 
LRMP and KASH5 have been shown to participate with the microtubule LINC 
complex (Table 1.2, Figure 1.5). Nesprin-3 can associate with the microtubule motor 
protein bullous pemphigoid antigen 1 (BPAG1), microtubule–actin cross-linking 
factor (MACF) and breast cancer susceptibility gene 2 (BRCA2), to regulate 
centrosome polarisation and nuclear migration especially under fluid shear stress [125, 
126]. Nesprin-4, LRMP and KASH5 interact with either kinesin-1, dynein or dynactin 
to participate in numerous cell activities such as nuclear migration and localisation, 
centrosome-nucleus movement during spermatogenesis and fertilization [10, 12, 20, 
82, 127, 128]. 
Furthermore, nesprin-3 associates with plectin to form IFs LINC complex [9] 
(Table 1.2, Figure 1.5). It connects the nucleus to the hemidesmosomes at the cell 
surface, which can help the firm attachment of the basal epithelial cells to the 
underneath basement [129, 130]. Overexpression or depletion of nesprin-3 results in 
mis-positioned plectin both in vitro and in vivo [9, 131-133], emphasizing the central 
role of nesprin-3 in recruiting plectin to the NE and maintaining the integrity of IFs 
LINC complex. 
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1.4.3.3 Interaction between different LINC complexes 
 
The actin, microtubule and IFs associated LINC complex have been shown to 
form united LINCs (Table 1.2, Figure 1.5). Evidence shows that F-actin connects with 
microtubules through microtubule–actin cross-linking factor (MACF), whilst 
interacting with IFs through the plectin protein [134]. Multiple nesprin isoforms also 
contribute to this network. For example, the nesprin-1/-2 ABD domain has similar 
binding properties to nesprin-3 SRs [121]. In addition, nesprin-3 directly links to 
plectin and IFs. This intricate interaction of LINC complexes links the whole 
cytoskeleton, KASH-SUN and nucleus tightly together, to maintain nuclear 
morphology, movement and transmission mechanical forces.
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Table 1.2 Types of LINC complexes 
Type  Cytoplasmic factor KASH domain  SUN domain  Functions 
Actin LINC 
complex 






Nuclear size/morphology [121, 135, 136] 
Synaptic and non-synaptic nuclear anchorage in muscle fibers 
[81, 135, 137, 138] 




Plectin Nesprin-3 SUN1 
SUN2 











Centrosome-Nucleus Coupling [123] 
Nuclear migration in skeletal muscle, retinal and brain [83, 114, 
122-124]  
Kinesin-2 (kif3b) Nesprin-1 
 







Nuclear positioning [9, 126]  
Centrosome polarisation and cell migration in endothelial cells 
[125] 
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Cell morphology [10] 
Nuclear positioning in the outer hair cells of the cochlea [82] 
Dynein 
Dynactin 
LRMP SUN Nucleus-centrosome attachment and pronuclear congression 
during fertilization [18] 
Dynein 
Dynactin 
KASH5 SUN1 Meiotic chromosome movement [12, 20, 127, 128] 
nd: not defined 














Figure 1.5 Nesprins form the NE-LINC complex and provide scaffolds for 
multiple sub-cellular compartments. 
At the ONM, nesprin interact directly or indirectly with all three major cytoskeleton network 
to form the LINC complex. F-actin (nesprin-1/-2), microtubule (nesprin-1/-2/-3/-4/KASH5 via 
dynein/dynactin and kinesin-1) and intermediate filaments (IFs) (nesprin-3 via plectin). At the 
INM, small nesprin-1/-2 isoforms targeted to the NE through KASH domain, and interact with 
emerin, SUN and lamin A/C through their SRs at the nucleoplasmic side, forming the NE 
complex. The NE-LINC complex links the nucleoskeleton to the cytoskeleton and maintains 
the cellular structure and stability.
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1.5 Nesprin and diseases 
 
A number of human diseases are associated with mutations in genes coding for 
NE proteins. Mutations in lamin A/C are involved in a wide spectrum of diseases 
referred as laminopathies [140], which include the dilated cardiomyopathy (DCM) and 
Emery-Dreifuss muscular dystrophy (EDMD). In addition, emerin mutations also have 
been reported to cause EDMD [52, 53, 58]. 
DCM is characterised by dilatation and impaired contraction of the left or both 
ventricles, and is an important cause of heart failure and sudden cardiac death, 
particularly in the young. The genetic causes of DCM are extremely complicated and 
over 50 genes have been implicated, many of them encoding components of the 
cytoskeleton and NE [141, 142]. Mutations in the LMNA gene, encoding protein lamin 
A/C, account for 5% of familial DCM patients [143]. 
EDMD manifests with skeletal muscle wasting with a distinctive 
humeroperoneal distribution early in the course of the disease and later extends to the 
proximal limb girdle musculature. Cardiac involvement is another feature of EDMD 
including heart conduction defects (CD) and DCM. Although CD and DCM always 
develop later in the patients’ life, they are the main cause of death [144-147]. There 
are two forms of EDMD, including autosomal dominant and X-linked. The AD-
EDMD has been linked to lamin A/C mutations, whereas the X-linked are associated 
with mutations in emerin [52, 145]. EDMD or EDMD-like phenotypes have variable 
penetrance and phenotypic heterogeneity, suggesting the mutations in presently 
unknown modifier genes may contribute to the variable phenotypic expression of the 
disease [106, 148]. Interestingly, LMNA and EMD mutations only account for 40% of 
EDMD [149, 150], indicating other structurally or functionally related genes may be 
involved. Evidence has shown both lamin A/C and emerin associate with nesprin and 
SUN to form the NE-LINC complex. Therefore, mutations in nesprin and SUN could 
be potential candidates that result in laminopathies. 
1.5.1 Muscle diseases: DCM and EDMD 
 
Reports have demonstrated the mutations in nesprin-1 and -2 have been 
implicated in DCM and EDMD, and SUN1 and SUN2 in EDMD, strengthening the 
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hypothesis that the NE-LINC complex and its associated NE components contribute 
to EDMD and DCM [3, 4, 87, 151, 152] (Table 1.3, Table 1.4 and Figure 1.6). 
Missense nesprin-1 R8212H mutation was identified at the C-terminal of 
nesprin-1 in a 26-year old male patient who underwent a heart transplant. This patient 
had enlarged left ventricular with severe systolic dysfunction and without any skeletal 
muscle defects. HDFs derived from this individual showed strong staining of nesprin-
1 and lamin A/C at the NE, which mimics the findings from EDMD-DCM caused by 
lamin A/C mutations, indicating that the R8212H nesprin-1 mutation perturbs the 
LINC complex, which is crucial to maintaining the cardiomyocytes (CMs) function in 
hearts [4, 60]. 
Furthermore, C-terminal mutations in nesprin-1 (R8095H, V8387L, E8461K) 
and in nesprin-2 (T6211M) and two other N-terminal mutations in nesprin-1 (G2297R 
and N108S) were reported from small kindred families with EDMD and EDMD-like 
phenotypes respectively [3, 151, 152]. The C-terminal regions where these mutations 
were localised were equivalent to the skeletal muscle and heart specific isoforms 
nesprin-1α2 and nesprin-2β. Importantly this is also the binding region for lamin A/C 
and emerin [3]. The clinical phenotypes were variable, ranging from almost 
asymptomatic moderately increased creatinine kinase levels to muscular dystrophy 
combined with severe DCM. Notably, the most severe case was a 26-year old male 
individual harbouring a double heterozygote for nesprin-1 V8387L and nesprin-2 
T6211M, who required a heart transplant. At subcellular level, the changes occurred 
in both HDFs and skeletal muscle, include nuclear morphology defects (convoluted 
nuclei, micronuclei, giant and fragmented nuclei), mis-localisation of endogenous 
nesprin, emerin, lamin A/C, disrupted nesprin/emerin/lamin bindings and reduced 
differentiation ability [3]. Knockdown of nesprin-1 in U2OS cells exhibited a 
separation of the INM from the ONM, suggesting uncoupling the LINC complex, 
which is similar to the phenotypes in muscle tissue from LMNA null mice or other 
fibroblast from Duchenne muscular dystrophy (DMD) or EDMD/Charcot-Marie-
Tooth syndrome (CMT) [2, 3, 153, 154]. 
1.5.2 Other muscle diseases: CMD and AMC 
 
In addition to DCM and EDMD, nesprins also involved in other muscular 
dystrophies (Table 1.3, Table 1.4 and Figure 1.6). A nesprin-1 mutation E7854X from 
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congenital muscular dystrophy (CMD), which results in a premature stop codon to 
delete the KASH domain, were examined using the isolated patient myoblasts [155]. 
The patient displayed clinic symptoms including adducted thumbs, mental retardation 
and cerebellar hypoplasia. Myotube formation showed the nuclei aggregation 
accompanied with reduced protein levels of both nesprin-1 giant and muscle specific 
isoform nesprin-1α2 in the patient cells [37]. 
Two other nonsense nesprin-1 mutations are linked to arthrogryposis multiplex 
congenita (AMC), with the clinic symptoms such as muscular hypotonia associated 
with delayed motor development and persistent contractures of interphalangeal joints 
[156, 157]. The mutations H8105Vfs*8 and R8746X either delete or have a premature 
stop codon on KASH domain, causing deficiency of nesprin-1 KASH domain 
containing isoforms in HDFs from these patients [156]. Loss of KASH function also 
leads to multiple invaginations of the NE, detachment of INM and ONM, and 
abnormal condensation of chromatin structure in the muscle fibers; all of which are 
similar to the subcellular changes in EDMD patients [3, 157]. 
Taken together, the muscle diseases affecting the heart (DCM) and skeletal 
muscle (EDMD/CMD/AMC) can be caused by mutations in either of the NE-LINC 
complex proteins nesprin-1/-2, lamin A/C, emerin and SUN, and they have divergent 
phenotypes. How these ubiquitously expressed proteins lead to muscle specific disease 
is still not clear. However, the evidence shows they all link together to form the NE-
LINC complex, which is particularly important in muscle as it is subject to mechanical 
strain. 
Meanwhile, nesprin-1/-2 isoforms are expressed in a tissue specific manner. For 
example, in human myoblasts, the giant nesprin-1 was present and nesprin-1α2 was 
merely undetectable. During myogenesis, nesprin-1α2 was massively upregulated 
accompanied with 2-time increased nesprin-1 giant [37]. In vitro differentiation 
models showed that both nesprin-1 and nesprin-2 isoforms may re-localise from the 
NE in C2C12 myoblasts to the sarcomere of myotubes during skeletal muscle and CM 
differentiation [35, 158]. In vivo, during the transition from immature to mature muscle 
fibers, nesprin-2 giant partly replaces nesprin-1 giant at the NE, and short isoform 
nesprin-1α2 becomes dominant [38]. These findings indicate that nesprin-1/-2 muscle 
specific isoforms may help to contribute to these mechanistic processes especially in 
the heart and skeletal muscle. 
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1.5.3 Neurological disease: Autosomal recessive cerebellar 
ataxia type 1 
 
Nesprin-1 mutations have been identified in French-Canadian and Japanese 
populations who were diagnosed with autosomal recessive cerebellar ataxia type 1 
(ARCA1) [159-162]. ARCA1 is characterised by progressive problems with cerebellar 
dysarthria, limb and gait ataxia and diffuse cerebellar atrophy, and may be 
accompanied with motor neuron impairment which mimics juvenile-onset 
amyotrophic lateral sclerosis (ALS) [161, 163] (Table 1.3). 
These mutations scatter along the SYNE-1 gene and the majority are homozygous 
non-sense mutations [159-162]. The premature stop codon or frame-shift caused by 
mutations result in many truncated nesprin-1 variants lacking SRs and KASH domain 
or absence of nesprin-1 due to nonsense-mediated decay of mutant mRNA [162, 164]. 
Recently, a nesprin-1 giant KASH less isoform was identified specifically expressed 
in the cerebellum. Its involvement in vesicular trafficking and structural organisation 
of dendritic membrane, emphasises that intact nesprin-1 transcripts is functionally 
important for cerebellum and neurons [165]. 
1.5.4 Other diseases: autism spectrum disorder and bipolar 
disorder 
 
SYNE-1 mutation was implicated as a candidate for autism disorder (ASD) by 
the presence of a de novo single nucleotide variant (Y282C) in an ASD patient [166] 
(Table 1.3). This finding was substantiated by the homozygous missense nesprin-1 
mutation L3206M found in one family. Neuronal ChIPseq and RNAseq data 
demonstrated one transcriptional start site localised just upstream of this mutation, 
suggesting nesprin-1 L3206M mutation may be implicated in ASD via their neuronal 
activity-dependent roles in regulating synaptic strength [167]. Other genome-wide 
association studies reported nesprin-1 was associated with both bipolar disorder (BD) 
and major depression [168] (Table 1.3). 
In summary: the two major diseases related to nesprin-1/-2 mutations affect 
either muscle tendons or the CNS system (Table 1.5). The homozygous nonsense 
mutations identified in ARCA1 or heterozygous missense mutations identified in 
EDMD-DCM lead to reduced or absent nesprin-1/-2 expression or dysfunction of 
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nesprin-1/-2 proteins. The loss or gain of nesprin protein function, affects the NE-
LINC complex, leading to either structural disruption or gene dysregulation. 
Subcellular changes occur such as altered nuclear morphologies, defects in 
microtubule regulated nuclear positioning in muscle tendon or vesicle trafficking in 
CNS, which are linked to the structural disruption hypothesis [3, 122, 165]. In addition 
to the cellular structural changes, abnormal heterochromatin is another main feature 
caused by nesprin mutations [3, 4], indicating the perturbed gene transcription and cell 
signalling which are linked to the gene dysregulation hypothesis. However, both are 
not mutually exclusive, which are potentially underlying molecular mechanisms of 
these diseases and all linked to one key point- importance of the integrity of LINC 
complex.
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Table 1.3 Nesprin mutations and associated diseases 
Gene Encoded proteins Disease Phenotype Ref 







EDMD-DCM Genetically heterogeneous neuromuscular disorder associated with 
early contractures, slowly progressive skeletal muscle wasting and 
weakness, CD, DCM. 
[3, 151, 152] 
SYNE-1 Nesprin-1 CMD Adducted thumbs, mental retardation, cerebellar hypoplasia and 
cataracts. 
[155] 
SYNE-1 Nesprin-1 AMC Muscular hypotonia associated with delayed motor development 
and persistent contractures of interphalangeal joints. 
[156, 157] 
SYNE-1 Nesprin-1 ARCA1 Progressed cerebellar dysarthria, limb and gait ataxia and diffuse 
cerebellar atrophy, may accompanying motor neuron impairment 
which mimics juvenile-onset amyotrophic lateral sclerosis (ALS) 
[159-162] 
SYNE-1 Nesprin-1 ASD Communication deficits, abnormal social interests, and restricted 
and repetitive behaviour. 
[166, 167] 
SYNE-1 Nesprin-1 BD Mental disorder mixed with depression and elevated mood. [168] 
DCM: dilated cardiomyopathy; EDMD: Emery-Dreifuss muscular dystrophy; CD: conduction defect; CMD: congenital muscular 
dystrophy; AMC: arthrogryposis multiplex congenita; ARCA1: autosomal recessive cerebellar ataxia type 1; ASD: autism disorder; BD: 
bipolar disorder. 
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Table 1.4 Nesprin-1 mutations in muscle diseases 
Disease SYNE-1 gene mutation Amino acid substitution 
in nesprin-1 giant 
Ref. 
DCM 25237G>A R8212H [4] 
25417G>A R8272Q [122] 
25743A>T S8381C 
25820C>A N8406K 
25468A>G Y8289C [169] 
EDMD-
DCM 
25983G>A E8461K [3] 
25761G>A V8387L 
24886G>A R8095H 
6889A>G G2297R [151] 
323C>T N108S [152] 
29A>G 5’UTR (1α2) [3] 
525G>A 5’UTR (2α2) 
CMD 23560 G>T E7854X [155] 
AMC 24313-2A>G H8105Vfs*8 [156] 
24577C>T R8193* [170] 
26236C>T R8746X [157] 
fs: frame shift; ins: insert; X: stop codon. 





















Figure 1.6 Nesprin-1/-2 mutations in muscle diseases 
The nesprin-1/-2 KASH containing isoforms are labelled on the SYNE-1 and SYNE-2 genes. 
Reported nesprin-1/-2 associated human muscle diseases (DCM - red, EDMD - dark blue, 
CMD - light blue and AMC - violet) are labelled on this schematic.
a2
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Table 1.5 Nesprin-1/-2 mutations in muscle and CNS diseases 
Category DCM/EDMD/CMD/AMC ARCA1 
Affected tissue Heart and skeletal muscle CNS: cerebellum 
Mutation localisation Mainly at the C-terminal hot 
spot regions (corresponding 
to muscle specific isoform 
nesprin-1α2 or nesprin-2β) 
Scattered along nesprin-1 
Mutation types Heterozygous Homozygous 
Missense mutation Nonsense mutation 
Effects on nesprin 
proteins expression 
and functions 
Dysfunction of nesprin 
proteins, loss or gain of 
functions 
Reduced or absent nesprin 
proteins, loss of functions 
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1.6 Functions of the NE-LINC complex and 
mechanistic basis of nesprin related diseases 
 
The NE-LINC complex, a multi-protein structure, provides a physical 
connection from inside of nucleus to the cytoskeleton and plasma membrane and 
through to the outside of cells, the ECM, and adjacent cell connections. Their multiple 
functions have been fully characterised as three major parts: 1) directly coupling the 
nucleoskeleton with the cytoskeleton to maintain the structural integrity and propagate 
force transmission within a cell; 2) regulating nuclear migration, positioning and 
polarisation; 3) maintaining genome stability and modulating mechanical signalling 
and expression of mechanosensitive gene. 
1.6.1 Linking the nucleoskeleton to the cytoskeleton 
 
The fundamental function of the NE-LINC complex is as a physical linker that 
scaffolds the nucleus and cytoskeleton. The structural integrity is directly related to 
nuclear morphology and force transmission. 
1.6.1.1 Maintaining nuclear size and morphology 
 
Nuclear size varies greatly among different cell types and organisms, with a 
relatively regular spherical or ovoid morphology [171]. Nuclear size and shape are 
largely controlled by LINC complex and its associated components including nuclear 
lamins and chromatin [172, 173]. 
In vertebrates, deletion of nesprin-1 in endothelial cells or nesprin-2 in epithelial 
cells results in increased nuclear size and heavily misshaped nuclear morphology [136, 
174]. Overexpression of nesprin-2 ABD or KASH domain also lead to nuclear 
expansion [136], indicating their important roles in nuclear size/integrity maintenance. 
Conversely, nuclear compaction was observed by overexpression of nesprin-2 mini 
(containing the ABD and KASH domain, but lacking the massive nesprin-2 giant SRs), 
and was exacerbated upon nesprin-3 co-expression. The potential explanation is the 
mini nesprin-2 isoform dislodges the endogenous giant nesprin isoforms from the NE 
and re-organizes a new but tighter (because of its drastically shorter SRs) nesprin-1/-
2/-3 belt that normally encapsulate the NE [121]. Furthermore, the SUN1/2-KASH 
  53 
forms a 45nm length bridge to support spacing in the PNS in mammalian cells. Down-
regulation of SUN1, SUN2 or nesprin-1 causes the nuclear envelope lumen to expand, 
suggesting that the LINC complex controls parallel organisation of the ONM and the 
INM [2, 116]. 
Alongside nesprin, other components related to LINC complex can also alter the 
nuclear size and morphology. Depolymerization of F-actin shrinks the nuclei, while 
depolymerization of microtubules increases nuclear size. Disruption of both F-actin 
and microtubules leads to smaller nuclear size, indicating that nuclear connections with 
the actin cytoskeleton may be dominant in regulating nuclear size [121, 175]. In 
addition, cells with abnormal shaped nuclei are associated with diseases caused by 
defective lamina [146]. Similarly, fibroblast derived from muscle dystrophy patients 
carrying either nesprin-1 or nesprin-2 mutations exhibited a convoluted appearance 
accompanied by chromatin re-organisation [3]. 
All together, these findings illustrate that nuclear shape and morphology are the 
net outcome of complex intrinsic and extrinsic interactions that requires integral LINC 
complex and nuclear lamina. 
1.6.1.2 Force transmission 
 
The LINC complex is essential for transmission of ECM mechanical stimulus 
across the cytoskeleton to the nucleus [112, 176]. The direct mechanical connection 
between the cell membrane and nucleus was demonstrated via applying tensional 
forces on the cell surface adhesion receptor integrin, that resulted in reoriented 
cytoskeletal filaments, distorted nuclei and re-distributed nucleoli along the axis of the 
applied tension field in bovine capillary endothelial cells [177]. 
Recently, studies focusing on the LINC complex provide more evidence about 
the force transmission. Disruption of LINC complex by overexpression of KASH1, 
KASH2 or KASH3 in Swiss 3T3 fibroblasts (Immortal MEFs) resulted in significantly 
reduced elasticity and increased deformation of the cytoplasm that was measured by 
ballistic intracellular nanorheology. Importantly, these changes were comparable to 
MEFs derived from lamin A/C null mice, which displayed the EDMD-DCM 
phenotype. These data strongly suggested the involvement of LINC complexes in 
maintaining cellular force transmission and mechanical stiffness [178]. Furthermore, 
knocking down nesprin-1 in endothelial cells exhibited increased nuclear allowance 
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for deformation under uniaxial pulling stretching on one side of the culture dish, 
indicating increased nuclear strain (deformation) was caused by disconnection of 
sustainable force transmission from F-actin through nesprin to the nucleus [179]. 
Another new approach using biophysical assays was used to detect force transmission 
via precisely applied strain to the cytoskeleton within a cell. Overexpression of 
nesprin-1 KASH or nesprin-2α disrupted the LINC complex, impaired propagation of 
intracellular forces, leading to fewer nuclear and cytoskeletal displacement, reduced 
nuclear deformation and discontinuous and fragmented F-actin and IFs at perinuclear 
regions [112]. 
Due to the different cell types, employment of different methods to disrupt the 
LINC complex and different force application methods, studies have shown that 
disturbed LINC complex can either increase [179] or reduce nuclear deformation 
[112]. However, they all suggested the disruption of LINC complex would result in 
impaired propagation of intracellular forces, caused abnormal nuclear deformation and 
disturbed organisation of the perinuclear cytoskeleton networks. In future, 3-D culture 
and 3-D strains are needed to more accurately mimic the in vivo environment, and 
reveal force transmission through the LINC complex especially in tissues subjected to 
mechanical strain. 
1.6.2 Nuclear migration, positioning and polarisation 
1.6.2.1 Nuclear migration and positioning 
	
Nuclear positioning within a cell is dependent on cell type, stage of the cell cycle, 
migratory state and differentiation status. The LINC complex has been revealed as a 
primary exert force on the nucleus via connections to the NE to maintain the position 
of the nucleus and its movements during cell migration and differentiation [180, 181]. 
The initial models to study nuclear migration and positioning were in lower 
organisms such as C. elegans and Drosophila melanogaster. Most of adult C. elegans 
are covered with four large hypodermal syncytia containing more than 100 nuclei in 
total. ANC-1, the orthologous nesprin-1/-2, interacts with SUN protein ortholog, 
UNC-84, to tether the nucleus to the cytoskeleton and evenly space and anchor them 
in body wall muscle [182, 183]. In ANC-1 or UNC-84 mutated C. elegans, nuclei float 
freely in the cytoplasm, often grouped in large clusters [69, 184]. 
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Similarly, in mammals, deletion or overexpression of the nesprin-1 KASH 
domain in mice abolishes synaptic nuclei aggregation and disrupts even spacing of 
non-synaptic nuclei in skeletal muscle [137, 138]. Furthermore, these mis-positioned 
nuclei are a common feature in muscle fibers derived from EDMD patients carrying 
nesprin-1/-2 mutations, as well as myotubes formed by myoblasts derived from EDMD 
patients carrying SUN1/2 mutations [3, 87]. These findings suggest that cytoskeleton 
dependent nuclear positioning is a contributing factor to muscle disease. 
Indeed, recent data have uncovered more underlying molecular mechanisms 
responsible for myonuclear positioning. Studies from C. elegans revealed that UNC-
83 and UNC-84 form the LINC complex and recruit the microtubule motor protein 
kinesin-1 and dynein to the NE that are needed to drive bidirectional movements 
during nuclear migration [185, 186]. Further studies in mammalian cells confirmed the 
C-terminal region of nesprin-2 mediates myonuclear positioning by attaching the 
microtubule network to the NE during embryonic muscle development [187, 188]. 
These interactions occur via the microtubule motor proteins, dynein and kinesin-1, the 
latter being a heterotetramer of two kinesins heavy chain (KHC) subunits -Kif5A, 
Kif5B, or Kif5C- and two KLC-1/2 subunits. Nesprin-2 was shown to interact with 
KLC-1/2 at the ONM via a newly identified four-residue tryptophan-acidic (W-acidic) 
“LEWD” binding motif within an adaptive domain (AD) at its C-terminus, which is 
present in all muscle-specific isoforms [22, 23, 114]. Disruption of the LINC complex 
with a DN nesprin-2 KASH impaired kinesin-1 association with the NE and induced 
nuclear aggregation in myotubes [114]. As both nesprin-1 and -2 are highly conserved 
in this C-terminal region, it is likely that nesprin-1 may also mediate the nesprin/KLC 
interaction via the “LEWD” binding motif but so far this has not been tested. 
In addition to muscle cells, precise nuclear movement is also crucial for other 
organ development. For example, depletion SUN1/2 or nesprin-2 not only affects 
neurogenesis and neuronal migration during brain development, but also abolishes 
photoreceptor cells migration, which is the critical step for retina development [83, 
123]. 
1.6.2.2 Nuclear polarisation 
	
Besides the nuclear bipolar dynamic movement is driven by microtubule motor 
proteins dynein/dynactin and kinesin-1, nuclei possess self-rotation ability which can 
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facilitate their motility through the complex and crowded cellular environment of 
developing cells, allowing for proper migration and positioning [189]. In fibroblasts, 
nuclear polarity can be observed under stretch induced cytoskeletal re-arrangement. 
However, overexpression of DN SUN1 or nesprin-2 abolished this re-orientation, due 
to loss of actin associated LINC complex [190]. Depletion of nesprin-2 in C2C12 
myoblasts, interferes with the orientation of centrosomes, which failed to adopt 
specific positions relative to the nucleus and perturbed efficient myotube formation 
[191]. Similar results can be seen during depolymerization of the actin cytoskeleton, 
the rearward movement of the nucleus is perturbed during wound-induced fibroblast 
and astrocyte polarisation [192, 193]. Taken together, these studies indicate the LINC 
complex is a powerful toolbox to modulate the proper nuclear migration, positioning 
and cell polarisation. 
1.6.3 Mechanical signalling and mechanosensitive gene 
expression 
 
LINC complex mediated force transmission initiates mechanotransduction 
events, directly contributing to the cell's ability to adapt to its mechanical environment 
by triggering force-induced changes in nuclear structures, downstream signalling and 
gene expression. 
1.6.3.1 Mechanotransductive signalling 
	
The process of mechanotransduction is initiated by a mechanical force passing 
through sub-cellular structures whose conformations change in response to mechanical 
stress, resulting in activation of biochemical signalling pathways and gene expression 
[117]. The LINC complex and its associated proteins engage in a wide network of 
intermolecular interactions that affect numerous mechanical signal pathways, 
including mitogen-activated protein kinase (MAPK), Wnt-β-catenin, nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB), transforming growth factor 
beta (TGF-β) and Notch signalling pathway [194-199]. 
Muscle restricted laminopathies associated with mutations in the LINC complex 
(lamin A/C, emerin, nesprin, SUN) are EDMD and DCM [3, 53, 87, 153]. The initial 
mouse model that recapitulates LINC complex associated EDMD and DCM has been 
  57 
generated with lamin A/C or emerin mutants. Analysis of genome-wide expression 
profiles in hearts from the LMNAH222P and EMD-/- mouse models, showed statistically 
significant differences in expression of genes in the MAPK pathways [194, 195]. 
MAPK signalling has essential roles in cell proliferation, differentiation, survival, and 
death [200, 201]. ERK1/2 and c-Jun NH2-terminal kinase (JNK) are the well-
characterised branches of the MAPKs. In response to stimuli, JNK and ERK1/2 
become phosphorylated and activate their translocation from the cytoplasm to the 
nucleus, to regulate transcription and cell cycle progression [201-203]. 
In LMNAH222P mouse hearts, pERK1/2 and pJNK are induced in CMs, which 
then activate a series of downstream target genes, including bcl-2, Elk1, junD and c-
Jun. Transcription factors encoded by these genes can in turn regulate the expression 
of additional genes, including those encoding proteins involved in sarcomere structure, 
cardiomyofiber organisation and other aspects of heart function [194, 204, 205]. 
Augmented ERK activation is further observed in other cell lines such as COS7 and 
HeLa which were transfected with LMNAH222P, as well as in ex-vivo fibroblasts from 
EDMD/DCM patients carrying lamin A/C mutations [194, 206]. Using ERK 
inhibitors, the EDMD and DCM phenotype is rescued in LMNAH222P mice, which 
further supports the important role of ERK1/2 in the pathogenesis of LINC complex 
related muscle disease [207-209]. Apart from those data, there is evidence showing 
that nesprin-2 directly interacts with ERK1/2 via their SRs and recruits them to 
promyelocytic leukaemia protein nuclear bodies (PML NBs) to regulate the cell cycle 
and DNA damage response in VSMCs [42, 210]. 
1.6.3.2 Mechanosensitive gene expression 
 
The cells response to mechanical strain can be measured by the expression of 
mechanosensitive genes egr-1 and iex-1 [211, 212]. The MEFs from LMNA or EMD 
null mice both showed irregularly shaped nuclei and heterochromatin, with attenuated 
mechanical induction of egr-1 and iex-1 in 2 hours and 4 hours of strain [153, 213, 
214]. Moreover, the altered mechanosensitive genes were evaluated in nesprin-1/-2 
knockout (KO) mice. CMs isolated from those mice presented with blunted 
mechanosensitive response with impaired activation of egr-1, iex-1, c-fos, c-jun [85]. 
Those data underscore the critical role of integral LINC complex in 
mechanotransduction and gene regulation. 
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 1.6.3.3 Nuclear stiffness 
	
Tissue elasticity is quite varied. For example, fat is soft and bone is very stiff. 
This difference will provide opposite stress environments for cells. Mouse proteomic 
analyses reveals the expression levels of lamin A/C scaled with tissue elasticity. 
Human mesenchymal stem cells on soft matrix differentiate into fat cells enhanced by 
low lamin A/C, while on the stiff matrix differentiate into bone enhanced by high lamin 
A/C. Lamin B did not show any significant change during this process. Altered nuclear 
stiffness regulated by shifted lamin A/C levels helps to stabilise the nucleus and protect 
chromatin from excessive strain, in order to preserve chromatin organisation and 
nuclear function [100]. 
How the nucleus responds to mechanical stress was further investigated by using 
isolated single nuclei with removal of all cytoskeletons. Using magnetic tweezers to 
apply force on nesprin-1, nuclear stiffening was induced through recruitment of lamin 
A/C, indicating the reinforcement of the physical connection between lamin A/C and 
the LINC complex will help nucleus to sustain induced tension [215]. This theory is 
further confirmed in fibroblasts from HGPS patients carrying lamin A/C mutations. 
The nucleus is stiffened through the accumulation of a mutant lamin A/C. Cells 
became trapped in the close spacing in 3-D environment with increased nuclear 
stiffness, reduced force generation and decreased nuclear deformability, which both 
lead to reduced cellular motility [216]. This pattern is also evident in culturing 
myoblasts from muscular dystrophy patients carrying either nesprin-1 or lamin A/C 
mutations on the hydrogel that has a similar stiffness to the physiological muscle. 
These mutated cells both showed reduced nucleus thickness and plasticity, in term of 
increased actin cytoskeleton assembly and traction force, indicating the impaired 
muscle cell function [217]. The cell signalling molecules involved in regulation of 
nuclear and ECM elasticity and stiffness include Yes-associated protein (YAP)- Hippo 
pathway, megakaryoblastic leukaemia 1 (MKL1)-serum response factor (SRF) 
pathway and vitamin A/retinoic acid (RA) pathway [100, 215, 218-220]. Increasing 
amounts of studies implicate that applied force or environment stress can directly 
induce nuclear stiffness changes via regulating mechanical signalling. In particular, 
lamin A/C and the LINC complex play central roles in adaptation of cells to their 
mechanical environment. 
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Taken together: the evidence shows that in an intact cell, the LINC complex 
mediates nuclei responses to mechanical transduction. Any disruption in structural 
integrity of cytoskeleton components in the cytoplasm, SUN-KASH interaction at the 
NE, lamin A/C and emerin at the INM may result in dramatic or subtle changes in 
mechanical force propagation from the ECM to the nucleus. Those changes can affect 
nuclear size and morphology, cause defects in nuclear migration, positioning and/or 
polarisation, as well as led to dysregulation of mechanical signalling and gene 
expression among different cell types. 
 
1.7 Nesprin-1/-2 mouse models 
 
To further understand to the roles of nesprins in the LINC complex and nesprin 
related diseases, total 13 nesprin mouse lines have been generated to model the 
muscular and neurological disorders caused by SYNE-1/-2 mutations (Figure 1.7 & 
Table 1.6). 
1.7.1 KASH mouse model 
1.7.1.1 KASH1 mice 
	
There is one transgenic (Tg) KASH1 and two KO KASH1 established mouse 
lines that exhibit altered skeletal muscle, heart and CNS phenotypes [4, 137, 138, 221]. 
The Tg KASH1 mice and the first nesprin mouse line was focused on the 
functions of nesprin in muscles. It was generated by expressing nesprin-1 C-terminal 
344 amino acid including the last SR and KASH domain under the muscle creatine 
kinase (MCK) promoter [137, 222] (Figure 1.7 & Table 1.6). The transgene behaves 
like a DN KASH1 domain to displace endogenous nesprin-1 (and/or nesprin-2, as they 
share a highly homologous sequence of KASH domain) from the NE in the skeletal 
muscle and heart. There are no overt symptoms reported from this model [137]. 
However, in the skeletal muscle fibers, synaptic nuclei fail to aggregate at the 
neuromuscular junction (NMJ) in these transgenic mice. Introducing DN KASH1 in 
the mature muscle at postnatal day 20 (P20) reduced the synaptic nuclei and increased 
presynaptic nuclei [137]. Notably, the function of NMJ and mitochondria localisation 
are not affected. 
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Furthermore, the KASH1 KO mouse model displays a similar phenotype. These 
mice were generated by deletion of the last exon of SYNE-1, resulting in removal of 
KASH1 domain [138] (Figure 1.7 & Table 1.6). The NMJ phenotype is more severe 
than that in DN KASH1 mice, with an almost complete loss of synaptic nuclei [138]. 
The difference may be caused by the low level of endogenous nesprin-1 still present 
in the DN KASH1 mice, which is sufficient to migrate myonuclei at the NMJ, but is 
not sufficient to anchor them when the muscle underwent contractions. In KASH1 KO 
mice, both migration and anchorage processes are abolished due to complete loss of 
nesprin-1. In addition, the non-synaptic nuclei formed clusters and arrays in KASH1 
KO homozygotes, while the heterozygotes still maintained evenly distributed 
myonuclei along the muscle fibers [138]. 
The functions of nesprin-1 in heart are characterised in another global KASH1 
KO mouse model [4, 221]. This model was generated via deletion of the last exon of 
SYNE-1 through inserted LoxP sites, leading to remove of the last two exons including 
KASH domain (Figure 1.7 & Table 1.6). Approximately 50% homozygous KASH1 
KO pups die at or near birth due to un-inflated lungs causing respiratory failure. 
Survived litters exhibit EDMD and cardiomyopathy-like phenotypes including hind 
limb weakness, abnormal gaits, kyphoscoliosis, muscle pathology and conduction 
defect (CD) and heart failure with the increased age. The CD in atria is noted earlier 
than in ventricle; when the mice show both atria and ventricle CD, heart failure is 
evidenced by a reduction of fractional shortening. Those changes in heart mimic 
patients with DCM and conduction system disease. Isolated CMs display elongated 
nuclear shape with large invaginations of the NE, and reduced total amount of 
heterochromatin. The LINC complex components lamin A/C, emerin, SUN2 still 
localise at the NE, while immunoprecipitation (IP) reveals interaction between 
nesprin-1 and SUN2 is abolished, suggesting the disrupted SUN-KASH LINC 
complex in this model could be the trigger of pathological process in heart. Of note, 
unexpected insertion of an extra 61 amino acids occurs during KASH1 deletion, 
although this sequence is not homologous to any known proteins. Therefore, it is not 
clear that the EDMD and DCM like phenotypes in those mice are resulted from the 
additional 61 amino acids or the disruption the LINC complex via deletion of KASH 
domain. In addition, muscle biopsies from these KASH1 KO mice displayed similar 
changes: central nuclei with decreased fiber size in soleus muscle compared with the 
arranged nuclei under the sarcolemma in the WT [221]. These findings are consistent 
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with the observations in muscle from EDMD and DCM patients; further strengthening 
the evidence that nesprin-1 is indispensable in proper anchoring of synaptic and non-
synaptic nuclei and maintaining proper skeletal muscle functions. 
In addition to muscle system, deletion of KASH1 affect the CNS [138]. The 
phrenic nerves display longer branches at innervation sites, suggesting the mis-
localised muscular synaptic nuclei may contribute to maintenance of the innervation 
sites by strengthening the communication between muscle-nerve contacts. 
1.7.1.2 KASH2 mice 
	
Similar to the DN KASH1 mice, the DN KASH2 mice is established by 
overexpression C-terminal 183 amino acids KASH containing domain of SYNE-2 
under the MCK promoter [138] (Figure 1.7). The phenotype of DN KASH2 mice is 
similar to the DN KASH1 mice, including expelling the synaptic nuclei from under 
the NMJ to the peripheral region, without perturbing the non-synaptic nuclei in the 
muscle fibers [137, 138]. The nesprin-1 and -2 has high homology KASH domains, 
therefore expression either KASH1 or KASH2 domain may have a similar dominant 
negative effect to the nesprin-1 and -2 proteins. 
In contrast to DN KASH2 mice, the KASH2 KO mice display major defects in 
the development of CNS rather than skeletal muscle or heart [83, 123, 138]. Targeted 
deletion of the last two exons of SYNE-2 gene, generated nesprin-2 KASH KO mice 
[138] (Figure 1.7). No defects in the synaptic and non-synaptic nuclei in the myofibers 
were observed from this model. Comparing the phenotypes among the four KASH1 or 
2 mouse models, it suggests that nesprin-1 may play a more dominant role in nuclei 
migration and anchorage in the muscle than nesprin-2 [137, 138]. 
The following studies using the same KASH2 KO mice focus on brain 
development. KASH2 KO mice exhibit a smaller cerebellum, disrupted laminary 
structure and pyramidal cell layer, and impaired working memory and abnormally 
active responses to a new environment, which are similar to the cerebellum changes in 
ARCA1 patients [123]. Combining these data with another CNS defects mouse model 
via depletion of SUN1/2, the underlying mechanisms are revealed: nesprin-2 interacts 
with SUN1/2 at the NE to form the LINC complex, which connects to the centrosome 
via microtubule motor proteins dynein/dynactin and kinesin-1, to mediate the neuronal 
migration. Uncoupling the LINC complex through either KO SUN or KASH2, will 
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abolish the centrosome-nucleus mediated nuclear migration during neurogenesis, 
causing CNS development defects [123].  
1.7.2 Nesprin-1/-2 actin binding domain (ABD) KO mice 
 
Nesprin-2 ABD is knocked out by deletion of the 2nd - 4th exon of the SYNE-2 
gene encoded first CH domain [136] (Figure 1.7 & Table 1.6). These mice are well 
developed and have no skeletal muscle or heart defects. However, the epidermis from 
these mice was thicker, which is caused by the increased epithelial nuclear size. 
Isolated primary dermal fibroblasts and keratinocytes from KO mice show heavily 
misshaped nuclei with unevenly distributed emerin, which is similar to nuclear 
deformations characteristic of laminopathies. 
Different from the nesprin-2 CH KO mice, nesprin-1 CH KO mice were 
generated by floxed the 9th exon, which encodes for the second CH domain of nesprin-
1 (Figure 1.7 & Table 1.6). These mice showed normal expression levels and 
localisations of NE-LINC complex protein, without any phenotypes [124]. The 
different phenotypes could arise due to the distinct functions of two CH domains. The 
second CH domain is not able to bind with the actin cytoskeleton, but it acts as a CH1 
enhancer to strengthen binding with F-actin [32, 33]. Therefore, functional ABD is 
still partially retained in nesprin-1 CH KO as it is only knocked out the second CH 
domain, while the function of ABD is completely abolished in nesprin-2 CH KO mice 
via knocking down the first CH domain. 
1.7.3 Nesprin-1 or -2 C-terminal KO mice 
 
This was the first global nesprin-1 KO mice model. It was established by floxed 
deletion of the 16th exon of SYNE-1 and resulted in a premature stop codon at the 13th 
exon (counted backward from the last exon) [135] (Figure 1.7 & Table 1.6). This 
transgenic mouse theoretically will be ablated of all nesprin-1 isoforms containing the 
C-terminal SR region with or without KASH domain, which include nesprin-1α1, 
nesprin-1α2 and nesprin-1β. These nesprin-1 KO mice litters exhibited over 60% 
lethality due to the insufficient feeding caused by muscle weakness. Survived pups 
were marked by growth retardation and increased variability in body weight at the first 
three months [135]. In skeletal muscle: nesprin-1 KO mice showed normal fiber size, 
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but with an excessive number of centrally located nuclei, which is also reported in the 
nesprin-1 KASH KO mice [135, 138]. Nuclear positioning and anchorage is defective 
in the KO mice, and nuclei deformation failed in response to mechanical stress, 
indicating the nesprin-1 forms the critical link to anchor the nuclei to muscle fibers. 
Heart function is specifically characterised by breeding nesprin-1 KO with mice 
carrying cardiac promoter Nkx2.5Cre (Figure 1.7 & Table 1.6). Littermates survived 
over 1 year with normal heart functions [85]. Protein levels of NE-LINC complex 
components lamin A/C, emerin and lamin B1/B2 were unchanged, except the 
upregulation of SUN1, signifying the perturbed LINC complex in CMs [135]. 
Furthermore, the isolated CMs showed irregular nuclear shape including decreased 
nuclear circularity, increased nuclear area/length/perimeter, as well as reduced nuclear 
distance. These changes lead to the failed response of neonatal CMs to the mechanical 
stress and dysregulated biomechanical gene like egr-1 and iex-1 [85]. Additionally, 
the irregular nuclear morphology and the reduction of biomechanical genes were also 
observed in nesprin-2 global KO mice [85]. Nesprin-2 KO mice were generated by 
floxed deletion of the 7th exon of SYNE-2 (counted backward from the last exon), 
which theoretically deletes all the known nesprin-2 isoforms including the muscle 
specific isoforms nesprin-2α1, nesprin-2β and nesprin-2Ɛ2 [85] (Figure 1.7 & Table 
1.6). The two nesprin-1/-2 C-terminal KO mouse models gave insights into the roles 
of nesprins, particularly in maintaining intact mechanotransduction and gene 
regulation in hearts. 
1.7.4 Specific nesprin isoform-nesprin-1α2 KO mice 
 
Global nesprin-1α2 KO mice were generated by floxed the first unique exon of 
nesprin-1α2, then crossed with Sox2Cre delete mice twice to obtain the homozygous 
KO mice (Figure 1.7 & Table 1.6). The lethality is much higher than any other nesprin 
mouse models. Only 2 out of 17 littermates survived at weaning (P21). Extraction 
E18.5 embryos were showed, the nesprin-1α2 KO embryos remained cyanotic and died 
within 5 minutes while the WT turned pink and started to breathe. Those findings 
strongly indicate the nesprin-1α2 is indispensable for embryonic development. 
The two surviving KO mice were small with reduced body weight, and 
developed kyphosis after P21, indicating EDMD-like skeletal muscle dysfunction. The 
skeletal muscle was analysed using the samples isolated from embryonic day 18.5 
  64 
(E18.5). In those nesprin-1α2 null mice, nuclei clustering is the most striking defect 
seen from the tibialis anterior (TA) muscle, which is akin to other nesprin-1 mouse 
models [4, 135, 138, 221]. The LINC complex shows subtle changes with decreased 
SUN1 expression level and diffused localisation away from the NE to the cytoplasm. 
However, surprisingly, the microtubule motor protein kinesin-1 including the subunits 
KLC-1/-2 and kif5b were displaced from the NE [124], revealing that the nesprin-1α2 
is critical to recruiting kinesin-1 to the NE and form the nucleus-microtubule network 
to ensure the proper nuclear migration and positioning in muscle fibers. 
In this mouse model, cardiac dysfunction is not observed in the nesprin-1α2 KO 
embryos. Due to the limited number of surviving individuals, the role of nesprin-1α2 
in heart development is required for further study. 
1.7.5 Nesprin-1 and nesprin-2 double knockout mice 
1.7.5.1 KASH1 and KASH2 double knockout 
	
KASH1 and KASH2 double knockout (DKO) mice were generated by breeding 
the KASH1 KO mice (deletion of the last exon of SYNE-1) with the KASH2 KO mice 
(deletion of the last two exons of SYNE-2) [123, 138] (Figure 1.7). Homozygous DKO 
littermates were born alive but died within 20 minutes due to respiratory failure caused 
by unexpanded lungs. The muscle fibers from DKO mice exhibit the completely 
eliminated synaptic nuclei in NMJ [138]. Further analysis showed a much smaller 
brain at E18.5 with impaired laminar structure. Neuron from DKO lost their migration 
ability due to the detachment with the centrosome [123]. Although the reason of 
lethality is still not clear, the essential function of LINC complex in neuron migration 
have been confirmed and is indispensable for neurogenesis. 
1.7.5.2 Nesprin-1 and nesprin-2 C-terminal double knockout 
	
This nesprin DKO mouse line was generated with cardiac specific nesprin-1 
deletion and global nesprin-2 deletion mice described in 1.7.3 [85] (Figure 1.7 & Table 
1.6).  The DKO mice did not have any significant lethality over 1 year, but display 
early onset cardiomyopathy, which is similar to patients with DCM [85]. The left 
ventricle wall was thinner and fractional shortening was decreased from 10 weeks and 
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deteriorated over time. The fetal gene ANP, βMHC and fibrotic genes procollagen 
1α1, 3α1 were all increased, indicating heart failure and fibrosis. Histology also 
revealed massive fibrosis that started from 10 weeks and TUNEL staining revealed 
increased apoptosis in CMs from 5 weeks [85]. 
The CMs from nesprin-1/-2 DKO have dramatic nuclear deformation compared 
with either KO nesprin-1 or -2, including an increased nuclear area/length/perimeter; 
deceased nuclear circularity and distance; with dense heterochromatin defects. 
Biochemical stimulation of CMs led to attenuated response of biomechanical genes 
such as egr-1, iex-1, c-jun, c-fos and c-myc. Of note, NE-LINC complex associated 
proteins, lamin A/C, emerin were mis-localised from the NE with unchanged 
expression level, indicating the ablation of nesprins compromise the NE complex. All 
these sub-cellular changes are aggravated in hearts from DKO mice comparing with 
knockout either nesprin-1 or -2. 
Together, this model demonstrated that nesprin-1 and -2 are essential for CM 
function. They localise at the NE, forming the NE-LINC complex to maintain CM 
morphology, positioning, mechanotransduction and gene expression under the 
biomechanical load. This provides us with insight into pathology of the 
cardiomyopathy caused by disrupted NE-LINC complex that resulted from nesprin 
mutations. 
1.7.6 Related LINC complex mouse models 
 
Lamin A/C and emerin are the first two mutations associated with the LINC 
complex to cause laminopathies including the EDMD and DCM [143, 149]. Various 
mouse models with knock in or KO LMNA mutants have been established and 
investigated for over twenty years. Those mouse mutants develop the human like 
EDMD and DCM phenotype, which is similar to the muscle disease caused by nesprin-
1/-2 mutations [223]. Therefore, the findings from those LMNA mutation models may 
provide the insights into the common mechanisms underlying EDMD and DCM. 
To date, LMNA mutant mice have been shown to have early postnatal lethality, 
EDMD, CD, and DCM [223]. The CMs derived from LMNAH222P mice (identified in 
EDMD patients) and LMNAN195K (identified in DCM patients) showed structural 
disruption: these mutations resulted in extremely disorganized and fragile nuclei, with 
elongated nuclear shape, deep indentation of nuclear membrane and condensed 
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heterochromatin [224, 225]. The myofibers exhibited a wider variation of size, more 
atrophic and regeneration fibers with internal nuclei [208]. 
Also, abnormal mechanotransduction was evident and gene regulation was 
perturbed: analysis of genome-wide expression profiles in LMNAH222P hearts showed 
activation of the MAPK including ERK and JNK, as well as in the skeletal muscle 
[194]. It was found ERK or JNK inhibitors could reduce fibrosis, promote the heart 
function, increase the skeletal strength and successfully rescue the DCM and EDMD 
phenotype in LMNAH222P mice. Therefore, specific targeted MAPK caused by the 
abnormal mechanotransduction could be a potential therapy for LINC complex 
associated laminopathies [207-209, 226-228]. In addition to these findings, the MEFs 
from LMNA or EMD null mice both showed attenuated mechanotransductive gene like 
egr-1 and iex-1 response [213]. The LMNA null heterozygous had a blunted cardiac 
hypertrophy response to the hemodynamic pressure overload due to the impaired 
mechanosensitive gene egr-1 [229]. 























Figure 1.7 Overview of existing nesprin-1/-2 mouse models 
Various nesprin-1/-2 mouse models were generated via targeting to different regions of SYNE-
1 and SYNE-2 genes. The colours indicate the research group who generated the models (Red 
– Noegel A. [136]; Blue - Han M. [3, 137]; Violet - McNally, E. M. [4, 221]; Green - Ju C. 
[85, 124, 135]. Double KASH KO mice were generated via breeding the KASH1 KO with 
KASH1 KO (Han group). Double nesprin-1/-2 KO were generated via breading nesprin-1 
cardiac KO with nesprin-2 global KO (Ju group). KO: knockout, Tg: transgenic; aa: amino 
acid.
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Mice Target protein Method Phenotype Ref. 
SYNE-1 KO Nesprin-1 Crossed the SYNE-1 KO mice [135] with 
Nkx2.5Cre to conditionally knockout 
SYNE-1 in heart. 
No overt defects in cardiac structure and function. [85] 
SYNE-1 CH 
KO 
Nesprin-1 Floxed exon 9F, encoding for the latter 
CH domain in SYNE-1, and crossed with 
Sox2Cre deleter mice to ablate 
expression of nesprin-1 CH domain 
containing isoforms globally. 
Survived up to 18 months; no overt skeletal 
muscle or cardiac phenotypes. 
[124] 
Nesprin-1α2 
KO (s, m) 
Nesprin-1α2 Floxed the first exon that was unique to 
nesprin-1α2, then crossed with Sox2Cre 
deleter mice to ablate expression of 
nesprin-1α2 globally. 
12% litters survived, nuclei were mis-positioned 
in anterior muscle due to loss the interaction 
between nesprin-1α2 and microtubule motor 





Nesprin-2 Overexpressed 183 amino acids KASH 
containing domain of SYNE-2 under the 
MCK promoter  
In muscle fibers, synaptic nuclei failed to 
aggregate at the NMJ, but with even spaced non-
synaptic nuclei along the muscle fibers; no 





Nesprin-2 Targeted deletion of the last two exons of 
SYNE-2 including KASH domain 
Defects in photoreceptor cell migration in retina, 
thinner out nuclear layer, electrophysiological 
dysfunction; defects in learning and memory; no 
skeletal muscle or cardiac phenotypes reported. 
[83, 123, 
138] 
  70 
Mice Target protein Method Phenotype Ref. 
SYNE-2  
KO 
Nesprin-2 Floxed deletion of the 7th exon of SYNE-
2 (counted backward from the last exon), 
targeted to delete all nesprin-2 isoforms 
containing the C-terminal SR region with 
or without KASH domain. 
Survived up to 18 months; no overt skeletal 




Nesprin-2 Targeted deletion of the 2nd-4th exons of 
SYNE-2 gene encoding the first CH 
domain. 
In skin: thicker epidermis, epithelial nuclear size 
increased and heavily misshaped; No reported 








Crossed the KASH1 KO mice (deletion 
of the last exon of SYNE-1) with KASH2 
KO mice (deletion of the last two exons 
of SYNE-2). 
Newborn litters failed to breathe and died shortly 
after born. The synaptic-nuclei number reduced in 









Crossed the cardiac specific nesprin-1 
KO mice [135] with the global nesprin-2 
deletion mice [85]. 
Heart: reduced LV wall thickness and systolic 
function, mis-positioned nuclei in myocardium, 
dense heterochromatin in CMs; no skeletal 
muscle related phenotype reported. 
[85] 
C: cardiac phenotype; S: skeletal muscle phenotype; M: mis-positioned nuclei 
DN: dominant negative; KO: knockout 
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1.8 Summary and thesis aims 
 
Nesprins are the multi-isomeric scaffolding proteins [1]. They localise at the 
ONM, interact with SUN domain proteins via C-terminal KASH domain at PNS, bind 
with the actin cytoskeleton via N-terminal CH domains [2]; meanwhile, nesprins 
interact with lamin A/C, emerin and SUN1/2 at the INM, thus forming the NE-LINC 
complex [35]. The major functions of NE-LINC complex includes: physical linker and 
force transmitter of the nucleoskeleton and cytoskeleton; roles in nuclear migration, 
positioning and polarisation; and regulation of mechanical signalling and 
mechanosensitive genes [21, 176, 230]. 
Mutations in NE-LINC complex proteins nesprin-1/-2, lamin A/C, emerin and 
SUN1/2 have been identified in EDMD and DCM patients [3, 4, 52, 86, 87, 122, 145]. 
Both in vitro and in vivo studies focused on these mutations have revealed two NE-
LINC complex mechanisms underlying these muscle diseases. Firstly, the structural 
integrity hypothesis is that mutations in the NE-LINC complex will increase nuclear 
deformation and affect the localisation and interaction of the NE-LINC complex 
components. This will then uncouple the nucleoskeleton from the cytoskeleton, 
perturb the mechanical force propagated from the ECM to the nucleus and increase its 
susceptibility to stress. The second hypothesis relates to cell signalling/gene 
dysregulation and that disruption of NE-LINC complex would not only impair 
mechanical cell signalling and mechanosensitive gene expression, but also have a 
direct effect on the chromatin structure and impact on gene transcription. These two 
hypotheses are not mutually exclusive and both contribute to pathogenesis of EDMD 
and DCM. 
In this thesis, I focused on investigating the roles of nesprin-1/-2 and its 
associated NE-LINC complex in the heart. In collaboration with a lab in China, 218 
DCM patients were screened for SYNE-1 and SYNE-2 gene mutations and three novel 
rare variants (R8272Q, S8381C, N8406K) were identified at the C-terminus of the 
SYNE-1 gene from 7 DCM patients. I aimed to use these variants to: 
 
1. Determine the effect of nesprin-1 mutants at the NE-LINC complex in vitro; 
2. Investigate if nesprin-1 mutants affect the myogenesis in vitro; 
3. Generate the cardiac specific nesprin mutant mouse model to elucidate the 
potential pathogenic mechanisms of nesprin-associated cardiomyopathy. 
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Chapter 2: Methods and Materials 
 
2.1 Patient recruitment and mutation screening 
2.1.1 Research Subjects 
 
The study cohort consisted of 218 unrelated individuals with DCM and 210 
healthy controls, collected from the West China Hospital, Sichuan University, China. 
All blood materials of the patients and controls included in this study were taken with 
informed consent for DNA analysis and approval of the local ethics board. The clinical 
characteristic of the patients and controls were summarized in Appendix 1-3. Most of 
DCM patients were men and had significantly larger left ventricular (LV) chamber and 
lower left ventricular ejection fraction (LVEF) when compared with the ethnic and 
age-control samples.  
2.1.2 Mutation analysis 
 
Primer pairs were designed across the intron/exon boundaries and untranslated 
regions of nesprin-1α1 and 1α2, nesprin-2α1, 2 α2, 2β, 2ε1 and 2ε2, i.e., the smaller INM 
localised isoforms of nesprin-1 and nesprin-2 shown to bind emerin and lamin and be 
either highly or specifically expressed in muscle tissue. 180 oligonucleotide primers 
from intronic sequences for 88 exons were designed using the program Primer3Input 
(primer3_www.cgi v 0.2) and used previously [3]. Mutation screening was performed 
using the PCR-based mutation detection technique DHPLC (WAVE 4500B system, 
Transgenomic). Appropriate DHPLC conditions for running temperatures and buffer 
gradients were established for each individual exon. This method and associated 
experiments  were carried out by our collaborator  in  Sichuan University. 
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2.2 Cell work 
2.2.1 Cell culture 
 
All cell lines were cultured in a humidified incubator with 5% CO2 at 37oC. 
Immortal cell lines human osteosarcoma (U2OS), C2C12 mouse skeletal myoblast, 
H9C2 rat cardiac myoblast, human embryonic kidney 293T cells (HEK 293T) and 
primary cell lines Human Lung Fibroblasts (HLFs), Human Dermal Fibroblasts 
(HDFs) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% heat inactivated fetal bovine serum (FBS), 10units/ml 
penicillin, 10µg/ml streptomycin and 200µM L-Glutamine (PSG). 
To induce the formation of myotubes, C2C12 were grown to 80-90% confluency 
and then incubated with DMEM containing 2% horse serum (HS), 1% PSG. Cells were 
observed daily for the formation of myotubes, the characteristics of which include a 
distinct change in morphology from rounded to spindle like cells and the presence of 
multiple nuclei within the cells. 
2.2.2 Cell passage 
 
All the cells were passaged when at 60-80% confluency, except C2C12 which 
were passaged at 60% confluency to prevent terminal differentiation. The culture 
medium was removed, followed by 1 time wash with phosphate buffered saline (PBS). 
Then cells were incubated in an appropriate volume (to cover the whole surface of 
culture flask) of trypsin-EDTA solution for 2-3 minutes in the incubator at 37°C until 
cells detached from the flask surface. U2OS were split 1:6, C2C12 and HEK 293T 
1:10, H9C2 1:4, HDFs 1:3 in fresh culture medium and allowed to adhere. 
2.2.3 Isolation of neonatal rat cardiomyocytes (NRCs) 
 
1- or 2- day old Sprague-Dawley rat pups (10-12 rat pups in total) were 
anesthetized, then the abdomens were sterilized with an antiseptic solution. The 
beating hearts were surgically removed and immediately placed into ice-cold ADS to 
stop beating and general cleaning (removal of blood). Then heart tissue was minced 
with small scissors or a razor blade to less than 1mm3 pieces. Minced hearts were 
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transferred into a 50ml falcon tube with a wide-mouth transfer pipette. After removing 
the supernatant, the heart tissue was subjected to a serious enzymatic digestion. The 
enzyme solution (ES) contained type II collagenase (57.5 U/mL) and pancreatin (1.5 
mg/mL) in ADS buffer was filter sterilized before use. 
First digestion: 5ml of ES was pipetted into tissue and shaken for 5 minutes at 
37°C at 220rpm (revolutions per minute). 1st digestion supernatant was discarded due 
to presence of excess endothelial cells and blood. 2nd digestion: Another 5ml of ES 
was added and shaken for 25 minutes under the same conditions. Supernatant was 
transferred into in a clean 15ml falcon tube with 3ml non-heat inactivated FBS which 
stopped the enzyme reaction. Cells were centrifuged at 400g/660rpm at room 
temperature (RT) for 5 minutes. Pellets were re-suspended in 4 ml FBS, then incubated 
in a humidified incubator with 5% CO2 at 37°C with a loose lid. 3rd and 4th digestion: 
repeat steps as 2nd digestion until all the tissue adequately digested. Next, the cells in 
the incubator were transferred into a 50ml falcon tube through a pre-rinsed cell strainer 
and centrifuged 5 minutes at 400g/660rpm. Then the pellet was re-suspended with 
10ml plating media. All the cells were plated in a 10cm petri-dish, and kept in 
incubator for 1 hour until all fibroblasts had adhered to the dish. Following this, the 
supernatant containing NRCs was counted on a haemocytometer, and then an 
appropriate number of cells were plated on 35mm petri-dishes which were pre-coated 
with 1% gelatin for 4 hours at 37°C. These were left for 24 hours until NRCs had 
attached to the dishes. 
2.2.4 Generation of retrovirus particles 
 
RV were packaged in HEK 293T cells, at 70-80% confluency in a 10cm Petri 
dish (split 3x106 cells/dish 24 hours in advance). 1st day: fresh 6ml DMEM with 10% 
FBS (without antibiotics) was changed 1 hour before transfection. Transfection mix 
was prepared with 4µg plasmid of interest, 4µg DNA RV helper (from Prof. Peter 
Zammit lab, King’s College London) and 1,800µl opti-mem serum reduced medium 
with flick-mix. After 5 minutes incubation at RT, 6µl Lipofectamine Plus reagent was 
added and incubated for another 5 minutes. Then 24µl Lipofectamine LTX was added, 
mixed, and incubated for another 30 minutes. Mixture was added drop-wise to HEK 
293T cells. 2nd day: 10ml fresh DMEM medium with 10% FBS and 2% L-Glutamine 
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was replaced. 3rd day: 48 hours after the transfection, the same medium as 2nd day was 
replaced but volume was reduced to only 6ml. 
RV particles were collected three times at different time points. 1st collection: 12 
hours after last medium changed, which contained the RV at a high titre. All 6ml of 
medium was collected into a 15ml Falcon tube, followed by passing viral supernatant 
through a 0.45µm filter into a fresh 15ml Falcon tube. Then RVs were aliquoted into 
1.5ml Eppendorf tubes and immediately frozen at -80°C. 2nd collection: 6ml of fresh 
culture medium was added to the cells and collected following the previous steps. 3rd 
collection: repeated as previous. Lastly, the HEK 293T cells were discharged with 
detergent treatment as they could not be reused. 
2.2.5 Plasmid transfection 
2.2.5.1 Use of FuGENE HD Transfection Reagent 
 
Cells (excluding NRCs) were counted and plated out at 50% confluency the 
day prior to transfection. The culture medium was changed into DMEM containing 
10% FBS without PSG. For a 24-well plate: one well was transfected with 0.75µg of 
plasmid which was mixed with 37.5µl opti-mem reduced serum medium and 2.5µl 
FuGENE® HD Transfection Reagent. Before adding to the cells, the transfection 
mixture was vortexed thoroughly and incubated at room temperature for 15 minutes 
while transfection complexes assembled, then was added drop by drop to the culture 
medium. Transfected cells were cultured for 24-48 hours before fixation or harvesting. 
2.2.5.2 Use of Escort III Transfection Reagent 
 
One 35mm petri-dish of NRC was transfected with 1µg of plasmid which was 
mixed with 100µl Medium 199 (M199) and 4µl Escort III Transfection Reagent. The 
transfection mixture was vortexed thoroughly and incubated at RT for 15 minutes 
while transfection complexes assembled. NRCs were washed two times with M199, 
then 0.8ml NRC transfection medium was added. Finally, transfection complex was 
added drop by drop to NRCs and swirled gently. NRCs were incubated for 6 hours 
before replacing with regular maintenance medium. Transfected cells were cultured 
for 36 hours before fixation. 
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2.2.6 siRNA transfection 
 
Small interfering RNA (siRNA) transfection complex was prepared at the initial 
step. For a T25 flask: 2.5µl RNA (20µM) was added into 1ml opti-mem and then mixed 
with 50µl HiPerFect Transfection Reagent. The transfection mix was mixed 
thoroughly and incubate for 10 minutes to form the transfection complexes. Cells were 
trypsinised, counted and added to the transfection mix in a final volume of 5ml 
(2*105/T25 for C2C12, 7* 105/T25 for human lung fibroblast) with the siRNA mix in 
T25 flask. Cells were left to adhere and grow for a set time. In C2C12 differentiation, 
siRNA transfection medium was replaced every two days, mixing with the 
differentiation medium, until the terminal time point. Of note, two control groups were 
performed together in each experiment. One was MOCK control in which the cells 
were subjected to the transfection medium only in the absence of siRNA oligos. The 
other control was using Allstars Negative Control siRNA, which had no homology to 
any known mammalian gene.  
2.2.7 RV infection 
 
The RV only infects actively proliferating cells. The cell density is not an issue, 
as long as the cells have enough space to proliferate. The RV has to be defrosted on 
ice and used straight away. Before infection, C2C12 cells medium was changed to 
minimum volume (1.5ml fresh culture medium for T25) 1 hour in advance. Polybrene 
infection reagent was added to the RV aliquot at a final concentration of 4µg/ml. Then 
drop-wise the RV mix was added to C2C12. After 4 hours infection, 3ml fresh culture 
medium was added to one T25. Cells were then cultured for 48 hours before the next 
experimental step.
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2.3 Protein techniques 
2.3.1 Cell lysate 
 
Adherent cells were put on ice and washed three times with ice-cold PBS. Proper 
amount of IP buffer-1 with 2µl/ml protease inhibitor cocktail (PIC) was used to harvest 
cells by using cell scrapers. Cell lysates were transferred to a pre-cooled 1.5ml 
Eppendorf and sonicated for 10 seconds at 4oC to break the cell membrane and NE to 
release all the proteins. Cell debris was pelleted by centrifugation at 12,100g speed for 
10 minutes at 4oC. Clear supernatant was transferred to a fresh tube and the pellet was 
discarded. 
2.3.2 DC protein assay 
 
The protein concentration was measured by Bio-Rad DC Protein Assay. 
Standard curve was made by the serial dilution of 1.54mg/ml BSA in a 96-well plate. 
5µl of cell lysis and standard were incubated with 25µl of Bio-Rad DC Assay Reagent 
A for 5 minutes at RT to allow the reaction between protein and copper in an alkaline 
medium. Then, 200µl Bio-Rad DC Assay Reagent B (Folin reagent) was mixed to 
promote the reduction-oxidation reaction of the protein-copper complex and that 
produced a blue colour which can be measured at 710nm. The protein concentration 
was calculated according to the ratio to the standard proteins. 
2.3.3 Western blotting (WB) 
 
Gel preparation: SDS-PAGE consists of stacking gel and resolving gel. They can 
separate the proteins based on the difference of their molecular weight [231]. Different 
concentrations (8%-15%) of resolving gel was made according to the various size of 
proteins of interest, whereas the stacking gel was always 4%. 
Sample preparation: Protein lysate was diluted into the same concentration by 
mixing with 4*sample loading buffer and deionized water (DiH2O). Then proteins 
were denatured via boiling at 95oC for 10 minutes. 
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Protein separation by gel electrophoresis: equal amount of protein sample was 
loaded to each well, along with the molecular weight marker. Polymerised gel was 
submerged into running buffer and ran at 120 volts for 90 minutes. 
Transferring the protein from the gel to membrane: Protein was transferred from 
the gel to the PVDF membrane with 0.45µm pore size. The PVDF membrane was 
activated in 100% methanol for 15 seconds in advance. The gel, membrane and filter 
paper were sufficiently pre-soaked in the transfer buffer. Then, the gel was packed in 
the ‘transfer sandwich’ structure (filter paper-PVDF membrane-gel-filter paper) and 
placed horizontally between two plate electrodes in a semi-dry transfer apparatus, ran 
at 25 volts for 1 hour. After transfer, the gel was stained with Coomassie blue to check 
the efficiency of the transfer. 
Antibody incubation and detection: The membrane with immobilized proteins 
were blocked in 5% skimmed milk powder (Marvel) in TBST at RT for 1 hour, 
followed by incubation with the primary antibody which was diluted into the blocking 
buffer according to the manufacturer’s recommended ratio at 4oC overnight (ON). The 
next day, membrane was washed with 3 x 5 minutes in TBST, then subjected to the 
horseradish peroxidase (HRP) conjugated secondary antibody which was diluted in the 
blocking buffer at RT for 1 hour. The excess secondary antibody was removed by 
washing 3 x 10 minutes in TBST. Finally, protein bands were detected by ECL 
chemiluminescent development onto X-ray films. X-ray films were scanned and saved 
as 300bp TIFF format image and the density of WB bands were analysed using ImageJ 
software (1.48V). 
Stripping and reprobing: the used membrane was stripped with stripping buffer 
at RT for 30 minutes, followed by re-blocking, primary antibody targeting to the 
protein of interest, secondary antibody addition and development. 
2.3.4 Protein binding techniques 
2.3.4.1 GST pull-down 
 
Glutathione S-Transferase (GST) fused proteins encoded by pGEX vectors were 
transformed into E. coli strain BL21. Single colonies were cultured in 5ml of LB broth 
containing ampicillin antibiotics at 37oC/220rpm ON. Next day, 5ml of bacteria 
containing GST fusion proteins or GST alone was amplified in 100ml of LB broth for 
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2 hours at 37oC, followed by addition of 0.2mM isopropyl-1-thio-β-d-
galactopyranoside (IPTG) to further induce expression of GST fused proteins for 
another 2 hours at 30oC. Bacteria was centrifuged at 4000g for 45 minutes at 4oC. The 
pellet was re-suspended was in 5ml ice-cold PBS with PIC, followed by a 10 seconds 
sonication. 
500µl 10% Triton (in PBS) was added in the lysate as a non-ionic surfactant to 
further lyse the bacteria. After 10 minutes rotation and 30 minutes 4000g 
centrifugation, the debris pellet was removed and supernatant containing GST fused 
protein was purified by incubating with GST beads for 1 hour at 4oC. The expression 
of recombinant beads-proteins was confirmed by SDS-PAGE and coomassie blue 
staining. In addition, cell lysate was acquired as protocol described in Section 2.3.1. 
Briefly, 200µg extracts from U2OS or C2C12 myoblasts/myotubes were incubated 
with 50µl beads with constant rotation for 16 hours at 4°C. Bound proteins were 
washed and eluted into sample buffer, followed by WB. In particular, to investigate 
the interaction between nesprin-1 and its NE binding partners, protein lysates from 
Myc-SUN2 transfected (for SUN binding) and untransfected U2OS cells (for lamin 
A/C and emerin binding), C2C12 myoblast and myotubes (for KLC-1/2 interaction) 
were harvested and subjected to pull down using either GST-WT or mutant nesprin-
1α2 SR1-6 beads (GST-nesprin-1α2 R8272Q, S8381C, N8406K were previously 
generated in our lab, GST-nesprin-1α2 LEAA was generated by our collaborator Dr. 
Sue Shackleton from Leicester University). To further confirm the bindings, U2OS 
cells were transfected with either GFP-nesprin-1α2 WT or mutants, protein lysates 
were harvested and subjected to pull-down using either GST-lamin A (amino acids 
356-665) or GST-emerin (amino acids 1-176). 
2.3.4.2 Co-immunoprecipitation (Co-IP) assays 
 
U2OS cells were transfected using GFP-nesprin-1α2 WT/mutants with HA-
KLC-1/2 WT/ mutant respectively, harvested about 24 hours later and kept in IP 
buffer-2 with protease inhibitor cocktail on ice for 30 minutes, followed by 10 seconds 
sonication and centrifugation at 8,300g for 10 minutes. 500µg of protein was pre-
cleared with Protein A and/or G sepharose beads for 1 hour at 4°C. Beads were 
removed by centrifugation and 2.5µg primary antibody was added to lysates and left 
rotating at 4°C for 16 hours ON. Next day, A/G sepharose beads were then added to 
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reactions rotating at 4°C. After 2 hours incubation, the formed beads-antibody-protein 
complexes were pelleted by centrifugation. The supernatant was discarded, and pellets 
were washed 3 times with IP-PIC buffer and re-suspended in sample buffer, heated at 
95°C for 10 minutes and analysed by WB as described in Section 2.3.3. 
 
2.4 Microscopy work 
2.4.1 Immunofluorescence (IF) microscopy 
 
Cells grown on coverslips in 24-well plates or 30mm petri dishes were washed 
three times with ice-cold PBS, then fixed and permeabilized with different reagents 
according to different experimental aims and various primary antibodies. In general, 
there were two fixation and permeabilization methods used in this study: 1) Fixed by 
pre-warmed 4% paraformaldehyde (PFA) for 10 minutes at RT, washed 3 x PBS, then 
permeabilized with either 0.0001% Digitonin or 0.5% NP-40 for 3 minutes at RT; 2) 
Fixed and permeabilized with pre-cold methanol - acetone fixative at -20°C for 10 
minutes. Then, all cells were washed 3 x 5 minutes in PBS, and the water repelling 
circle was drawn along the inner petri dish to reduce the quantity of reagents used for 
IF. Samples were blocked in 3% bovine serum albumin (BSA) solution or 5% goat 
serum for 1 hour at RT, then directly subjected to the primary antibodies diluted in the 
same blocking buffer ON at 4°C. The following day, excess primary antibodies were 
washed off with three changes of PBS for 5 minutes each time. Then the cells were 
incubated with appropriate secondary antibodies diluted in the same blocking buffer 
for 1 hour at RT followed by another 3 x 10 minutes in PBS. Samples were then stained 
with 4’,6’-Diamidino-2-Pheylindoledihydrochloride (DAPI), followed by three 
washes with PBS (each time 5 minutes). For the last step, each coverslip, petri dish or 
slide was mounted with the appropriate size of cover glass on the top using Mowiol 
mounting media. 
Confocal images were captured using a Leica SP5 laser scanning confocal 
microscope. All confocal images were taken with 63X oil immersion objective lenses. 
Laser power (5-8%), gain and offset were adjusted accordingly to ensure image 
acquisition efficiently and avoid image saturation and sample bleaching. Z-stacks were 
taken throughout the height of samples and restored using Leica confocal software 
(LAS AF Lite.). ‘Analyse particles’ function in ImageJ (1.48V) was used to measure 
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circularity of cell nuclei, with circularity values given between 0 and 1 (values closer 
to 1 being more circular in shape) [232]. Cell membrane of individual CM was 
manually drawn and the cell size were quantified under ‘measurement’ function in 
ImageJ (1.48V).  
2.4.2 Histology and brightfield microscopy 
2.4.2.1 Haematoxylin and Eosin staining 
 
Frozen heart tissue sections were removed from -80°C and dried in RT for 30-
60 minutes. Sections were fixed with pre-warmed 4% PFA at RT for 10 minutes. After 
three washes with DiH2O, the samples were subjected to 1% Aqueous Eosin for 10 
seconds for cytoplasmic staining, then washed again with running tap water for 5 
minutes. The sections were again emerged in Harris’ haematoxylin solution for 30 
seconds to stain the nucleus, and the excessive staining was removed under running 
tap water for 5 minutes. Finally, the slides were dehydrated and cleared in successively 
higher concentration of ethanol and absolute xylene respectively. Coverslips were 
mounted using DPX and allowed to dry overnight. 
2.4.2.2 Masson’s trichrome staining 
 
Frozen heart tissue sections were removed from -80°C and dried at RT for 30-
60 minutes. The samples were fixed with pre-cold acetone at 4°C for 15 minutes. Then, 
the protocol from the Masson’s trichrome staining kit was followed. First, samples 
were further fixed in Bouin’s solution at RT ON to improve the staining quality. Next 
day, excess picric acid was removed from the slides under running tap water for 5 
minutes. Then all the samples were subjected to Weigert's iron haematoxylin working 
solution for 10 minutes to stain the nucleus with black colour. Next, Biebrich scarlet - 
acid Fuchsin solution (5 minutes) stained all acidophilic tissue elements such as 
cytoplasm, muscle, and collagen with red colour, followed by using phosphotungstic 
- phosphomolybdic acid solution (10 minutes) to diffuse the collagen colour while 
retaining the cytoplasmic and muscle red colour. Application of aniline blue (5 
minutes) stained the collagen with blue colour, after which, 1% acetic acid (1 minute) 
was applied to differentiate the tissue sections. Finally, the slides were dehydrated and 
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cleared in successively higher concentrations of ethanol and absolute xylene 
respectively. Coverslips were mounted using DPX and allowed to dry overnight.  
2.4.2.3 Brightfield microscopy 
 
Images of histology tissues were obtained under brightfield microscopy (Leica 
ICC50 W Microscope). All images were taken with 4-/10- X objective lenses and 
saved as TIFF format. The intensity of illuminator and obtain gain were adjusted 
according to selected objective lens and different histological stainings.  
 
2.5 Nucleotide techniques 
2.5.1 RNA extraction 
 
Cells grown in T25 flasks were washed three time with ice-cold PBS, and 
scraped together with 1ml of RNA STAT-60, then transferred into 1.5ml Eppendorfs. 
Heart tissues were homogenized by Lysis Beads in 1ml of RNA STAT-60 and 
suspensions were transferred to 1.5ml Eppendorfs. Samples were stored on ice for 5 
minutes for complete dissociation of nucleoprotein complexes. Next, 200µl of 
chloroform was added to each reaction and shook vigorously for 15 seconds. After 2-
3 minutes standing at RT, all samples were centrifuged at 12,000g for 15 minutes at 
4°C. There were two phases presented in the tube: a lower red phenol chloroform phase 
containing DNA and proteins, while the upper colourless aqueous phase (60% of total 
volume) contained the RNA. The aqueous phase was carefully transferred to a fresh 
tube with 500µl of isopropanol. RNA precipitation occurred within 30 minutes and 
this was pelleted by centrifugation at 12,000g for 10 minutes at 4°C. The RNA white 
pellet was washed with 1ml of 70% pre-chilled ethanol solution (in 
diethylpyrocarbonate (DEPC) treated water) and centrifuged at 7,500g for 5 minutes 
at 4°C. The RNA pellet was briefly dried in the air and re-suspended in 50µl (for cell) 
or 100µl (for tissue) DEPC treated water. The RNA concentration was measured by 
Nano drop and stored in -80°C. 
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2.5.2 Reverse transcription 
 
2µg of RNA was used for reverse transcription. This process consists of three 
steps. 1ST step: RNA, 0.5µl Oligo dT primer, 0.5µl Oligo Random primer, 1µl dNTP 
were mixed and heated at 65°C for 5 minutes to melt the secondary structure within 
the RNA template, then cooled down immediately to 4°C to prevent secondary 
structure from reforming. 2nd step: 5µl 5X reaction buffer, 1µl of RNasin ribonuclease 
inhibitor, DEPC treated water (added to equal final volume of 24µl) were added to step 
1 mix, and incubated at 37°C for 3 minutes to allow the efficiently binding of primers 
and RNA template, then cooled down to 4°C. 3rd step: 1µl Moloney Murine Leukemia 
Virus Reverse Transcriptase (M-MLV RT) was added after 2nd step and heated in a 
thermocycler to 25°C for 10 min, 37°C for 50 min and cooled to 4°C. The synthesized 
cDNA was finally diluted to 200µl total volume with DEPC treated water with a 
resulting concentration of 10ng/µl. 
2.5.3 Quantitative polymerase chain reaction (qPCR) 
 
qPCR is a very sensitive and reliable method to quantify RNA expression level. 
It is based on detection and quantification of fluorescence emitted from a reporter 
molecule during each cycle of PCR process [233, 234]. 
qPCR reaction was performed in a 20µl reaction which consisted of 10µl 2*Sybr 
green qPCR master mix, 1µl of Forward primer (5µmol), 1µl of Reverse primer 
(5µmol), 2µl of cDNA template (10ng/µl), and 6µl DEPC treated water. Prior to qPCR, 
designed primers had been examined using Taq polymerase based PCR to ensure the 
amplified product was unique with the right size. Reactions were performed on 
RotorgGene-3000 by Corbett. Initial step was denaturation of the template at 94°C for 
8 and half minutes, then followed with 35-40 combined cycles of 94°C for 15 seconds 
(denaturation) and 60°C for 1 minute (annealing and extension). The threshold of 
significant and specific amplification starting points was manually set as 0.5. The cycle 
threshold (Ct) for each gene was obtained according to the threshold. ΔCt was 
calculated by the difference between ΔCt target gene and ΔCt internal control gene, while ΔΔCt 
was calculated by the difference between ΔCt treated sample and ΔCt control sample. qPCR 
primers used for this study are described in 2.8.5. 
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2.5.4 Polymerase chain reaction (PCR) 
 
PCR is a simple and widely used technique to amplify a specific DNA fragment 
from a template plasmid or a complex pool of DNA [235]. 
For generating nesprin-1α constructs, GC-RICH PCR kit was used for more 
efficient and accurate amplification. PCR reaction was composed of two mixes. Mix 
1 (35µl) consisted of 19µl PCR grade water, 2µl dNTP mix, 2µl Forward primer 
(5µmol), 2µl Reverse primer (5µmol), 5µl GC-RICH resolution solution and 5µl 
template (10ng/µl). Mix 2 (15µl) consisted of 4µl PCR grade water, 10µ GC-RICH 
reaction buffer and 1µl GC-RICH enzyme mix (Taq DNA polymerase and 
proofreading polymerase). Then the total content of PCR reaction (50µl) was mixed in 
a thin-walled PCR tube and the reaction was carried out in a thermocycler by utilizing 
the following conditions: Initial denaturation 95°C for 3 minutes, denaturation 95°C 
for 30 seconds*, annealing 60°C for 1 minute*, extension 72°C for 1 minute per kb*, 
(*repeated for 30-40 cycles) and final extension 72°C for 10 minutes and held at 4°C. 
For the rest of PCR reactions, the DNA fragment was amplified with Tag 
polymerase. Each reaction (20µl) was composed of 10µl 2*GoTaq green master mix, 
2µl template (10ng/µl), 0.5µl Forward primer (5µmol), 0.5µl Reverse primer (5µmol), 
7µl DiH2O. The cycling parameters were same as GC-RICH reaction. 
After amplification, PCR products were mixed with 6× DNA loading buffer and 
separated by 1% agarose gel electrophoresis. Then PCR products were visualized by 
UV detection before being purified. 
2.5.5 Site directed mutagenesis 
 
In vitro site-directed mutagenesis is achieved by using the QuikChange Site-
Directed Mutagenesis Kit which allows site-specific mutation in any double-stranded 
DNA plasmid. This works by using a designed pair of complementary primers with a 
mutation. During PCR cycles, these primers anneal to the template DNA, replicating 
the plasmid DNA with the mutation [236]. The paired synthetic oligonucleotide 
primers were designed to be between 25 and 45 bases in length, with a melting 
temperature (Tm) of ≥78°C. PfuUltra high-fidelity (HF) DNA polymerase was utilized 
to ensure the precise extension of mutation containing strand without primer 
displacement. The total volume of each reaction was 50µl consisting of 5µl 
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10*reaction buffer, 1µl plasmid template (50ng/µl), 1.25µl Forward primer (100ng/µl), 
1.25µl Reverse primer (100ng/µl), 1µl dNTP mix, 3µl Quicksolution, 37.5µl DiH2O 
and 1µl PfuUltra HF DNA polymerase. Cycling parameters were: Initial denaturation 
95°C for 3 minutes, denaturation 95°C for 30 seconds*, annealing 55°C for 1 minute*, 
extension 68°C for 1 minute per kb*, (*repeated for 18 cycles) and final extension 
68°C for 20 minutes and held at 4°C. After the temperature cycling, the PCR products 
were treated with endonuclease Dpn I (target sequence: 5´-Gm6ATC-3´, for 
methylated and hemimethylated DNA) which was used to digest the parental DNA 
template and select the mutation containing DNA. The template plasmid was isolated 
from E. coli which was dam methylated and susceptible to Dpn I digestion. The vector 
DNA containing the desired mutations was transformed into XL1-Blue super-
competent cells and isolated for DNA sequencing.  
2.5.6 Agarose gel electrophoresis 
 
PCR products were mixed with 6*DNA loading dye and separated by 1-2% TAE 
agarose gel electrophoresis. According to the size of PCR products, the 1kb or 100bp 
DNA ladder was used. Electrophoresis was performed at 120 volts for 30-50 minutes 
until the separation of bands were adequate. The PCR products were bound by the 




DNA sequence of interest were either amplified from the template plasmid by 
PCR or isolated from the plasmid by restriction enzyme digestion. 
2.5.7.1 Agarose gel extraction 
 
The PCR product separated by agarose gel electrophoresis was cut under the UV 
transillumination and extracted by QIAquick Gel Extraction Kit. Briefly, the Buffer 
QG was added 3 volumes to 1 volume of gel weight and incubated at 50°C until the 
gel slice was completely dissolved (around 10 minutes). Then 1 gel volume of 
isopropanol was added to form the DNA participate. The sample was gone through the 
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provided collection tube and DNA was bound to the filter. After wash with 750µl 
Buffer PE, the DNA was eluted into a clean Eppendorf with 15µl DiH2O at maximum 
centrifuge speed. The final step can be repeated twice to increase the final 
concentration. The DNA concentration was measured by Nano drop and then used for 
the ligation step. 
2.5.7.2 Restriction enzyme digestion 
 
2µg DNA plasmid was digested with 10-20 unit of each restriction enzyme. The 
reaction buffer for more than two enzymes were chosen according to the tool of 
‘double digest finder’ online to ensure the most efficient digestion process. In general, 
digestion was performed in a 37°C water bath for 2-3 hours. For cloning, at the end, 
the digested vector was treated with 1µl of Antarctic Phosphatase (AnP) at 37°C for 
30 minutes, and heat-inactivated at 80°C for 2 minutes. This step could 
dephosphorylate of 5´ and 3´ ends of DNA phosphomonoesters and prevented re-
ligation of linearized plasmid DNA. The digested products could be purified by 
agarose gel electrophoresis and gel extraction as described in Sections 2.5.6 and 
2.5.7.1. 
2.5.7.3 DNA ligation 
 
For sequencing and cloning purposes, the PCR product or digested DNA 
fragment of interest was ligated directly into the pGEM T-easy vector. The pre-
linearized pGEM T-easy vector contains 3´-T overhangs at the insertion site to provide 
a compatible overhang for the ligation products. The α-peptide coding region for β-
galactosidase is inactivated by the inserted fragment and can be used to identify the 
blue (un-inserted) / white (inserted) colonies on the plates. The insert/vector molar 
ratios were ideally to be 3:1, 6:1 or 9:1. Ligation was carried out in a final 10µl volume: 
5µl 2*ligation buffer (or 1µl 10*ligation buffer), 1µl pGEM T-easy vector (50ng/µl), 
1µl T4 DNA Ligase (3 Weiss units/µl), Xµl insert, DiH2O to a final volume of 10µl. 
The reaction was incubated longer at 4°C ON to increase the number of transformants.  
For the constructs using retroviral vector MIG, mammalian expression 
pcDNA3.1(-): The MIGplus vector was a kind gift from Prof. Peter Zammit [237], 
which was modified from the retroviral backbone pMSCV-puro (Clontech, Mountain 
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View, CA), in which the puromycin selection gene was replaced with eGFP to create 
pMSCV–IRES–eGFP, served as the RV control vector and eGFP as a reporter for 
retroviral infection. pcDNA3.1(-) vector was purchased from Invitrogen. These 
vectors were linearized by restriction enzyme digestion with EcoRI and NotI, and 
ligated with DNA fragment nesprin-1α2 WT and mutant (amino acids 1-977, 
equivalent to nesprin-1 giant 7875-8796) which were digested from the pGEM T-easy 




Different competent cells were chosen for different experiment targeting. In 
general, GST fused constructs were transformed into BL21, the site directed 
mutagenesis constructs were transformed into XL1-Blue, others were chosen either 
DH5α or JM109. Briefly, 30-50µl competent cells were thawed on ice, and incubated 
with 2µl plasmid for 30 minutes.  The following heat shock step was dependent on the 
accurate temperature and time. Heat shock occurs in a calcium rich environment to 
counteract the electrostatic repulsion between the plasmid and bacteria cellular 
membrane. A sudden increased temperature creates pores in the bacteria cell 
membrane and allow the plasmid DNA to enter. No mixing or shaking was allowed 
during the heat shock. BL21 needed exactly 30 seconds in the 42°C water bath, XL1-
Blue required 45 seconds at 42°C, whereas DH5α and JM109 needed 20 seconds at 
42°C. After heat shock, the tubes were immediately placed on ice for 2 minutes. The 
300µl pre-warmed S.O.C medium was added into the tubes and left to shake in a 37°C 
incubator at 200-220rpm for 1 hour. The bacteria were plated out onto LB agar plates 
with appropriate antibiotics. X-gal and IPTG were added together when blue/white 
selection was needed. The plate was incubated at 37°C ON to allow colonies to grow. 
2.5.7.5 LB broth medium and LB agar plates 
 
LB broth medium was used for bacteria culture. It was made by mixing 20g LB 
powder and 1L DiH2O. The relevant antibiotics (20µg/ml Kanamycin, 150µg/ml 
Ampicillin) were supplied after LB broth had cooled down post-autoclave. 
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LB agar was made by dissolving 35g LB Agar powder with 1L DiH2O. This 
mixture was autoclaved for purification. When solution cooled to 55°C, the relevant 
antibiotics (20µg/ml Kanamycin, 150µg/ml Ampicillin) were added and mixed well. 
Then this mixture was poured into petri dishes. 
Either LB broth or LB Agar plates could be stored for 1 month in darkness at 
4°C. 
2.5.7.6 Plasmid isolation 
 
For obtaining small yields of purified plasmid: Individual round and white 
colonies were selected and cultured in 5 ml of LB broth (with appropriate antibiotic) 
at 37°C, 200-220rpm ON. 3ml of the culture was used for plasmid isolation using the 
Promega Pure Yield Plasmid Miniprep System. Briefly, the bacteria were pelleted by 
centrifugation at 12,300g for 1 minute. Then the pellets were completely re-suspended 
in 600µl DiH2O, lysed in added 100µl Cell Lysis Buffer and the reaction was stopped 
by adding 350µl of cold (4°C) Neutralization Solution. The mixture was centrifuged 
at 12,300g for 3 minutes at RT and the supernatant was transferred to a Pure Yield 
minicolumn. The plasmid was captured onto a minicolumn and washed with 200µl 
Endotoxin Removal Wash and 400µl Column Wash Solution. For the last step, the 
plasmid was eluted by incubating the minicolumn with 15-30µl of DiH2O for 1 minute.  
The eluted plasmid was collected in a clean 1.5ml Eppendorf tube by centrifugation at 
12,300g for 1 minute. 
For isolating large amounts of plasmid: a single colony was picked from the plate 
and cultured in 5ml of LB broth (with appropriate antibiotic) at 37°C, 200-220rpm for 
8 hours. 1ml of starter culture was diluted into 200ml selective LB broth medium at 
37°C for vigorous shaking (200-220rpm) ON. Next day, bacteria cells were harvested 
by centrifugation at 4,000g for 45 minutes at 4°C. Plasmids were isolated using the 
Qiagen Endofree Plasmid Maxiprep kit according to the manufacturer’s instructions. 
First, the bacteria were lysed in 10ml of lysis buffer, which was then neutralized by 
the addition of 10ml of neutralization solution. Subsequently, the plasmid was 
separated from cell debris by passing the mixture through a filtered syringe and then 
was incubated with 2.5ml of endotoxin removal buffer for 20 minutes on ice. Next, the 
plasmid was eluted in 15ml of elution buffer and precipitated with 10.5ml isopropanol 
followed by centrifugation as 4,000 g for 1 hour at 4°C. The DNA was washed again 
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in an ethanol-containing wash buffer and re-pelleted by centrifugation at 4,000 g for 
30 minutes at 4°C. Finally, the pellet was air dried and re-suspended in 200µl of 
DiH2O. 
The DNA concentration was measured by Nano drop and stored at -20°C. In 
addition, the bacteria glycerol stock can be made by mixing 700µl bacteria solution 
and 300µl 70% glycerol (autoclaved) and stored in -80°C for long-term storage. 
 
2.6 Animal work 
2.6.1 Generation of a cardiac specific KASH2 Transgenic 
mouse model 
 
All the mice used in this study were C57BL/6 strain. The original Transgenic 
(Tg) KASH mouse strain (CAG-LacZ-V5/EGFP-KASH2) was generated by our 
collaborator Dr. Didier Hodzic in Washington University [238, 239]. The Tg KASH 
mouse harbours a genetic construct consisting of an open reading frame (ORF) 
encoding mouse nesprin-2 KASH domain fused to EGFP (EGFP-KASH2) cloned 
downstream of a Lox-flanked ORF encoding β-galactosidase fused to a V5 epitope 
(LacZ-V5) with a flanked STOP codon at the end. Myosin light chain 2 ventricular 
(MLC2V) is a muscle regulatory myosin light chain isoform which is the earliest 
ventricular-restricted marker presented at E8 during mammalian cardiogenesis [14]. 
MLC2V involved in maintaining the cardiac contractility and ventricular chamber 
morphogenesis [15, 16]. By breeding MLC2V Cre mice [17] with Tg KASH mice, Cre 
recombinase-mediated somatic excision of the LacZ/V5 ORF and STOP codon, and 




The new born mouse litters were genotyped after weaning. Ear biopsies were 
acquired. DNA was prepared by boiling the samples in 300µl 50mM NaOH at 95°C 
for 10 minutes followed by vortexing and addition of 25µl Tris at pH 8.0. The reactions 
were left at 4°C ON and used as template for next day PCR which was described in 
Section 2.5.4. The specific primers designed for in vivo study were listed in Table 2.4. 
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Identification of offspring was achieved by performing three separate PCRs: one to 
identify expression of the transgene GFP-KASH2 and one to identify Cre recombinase, 
GAPDH served as internal control. Mice positive for both GFP-KASH2 and Cre were 




Echocardiography is a quick, reliable and non-invasive measurement of cardiac 
function, which can assess the size and shape of the heart, blood flow and systolic and 
diastolic functions in murine models [240]. In this study, the heart function was 
accessed using the Vevo 2100 ultrasound system (Visualsonics, Toronto, Canada) 
equipped with a high-frequency (30 MHz) linear array transducer. Mice were 
examined at week 15, 30, 52. Briefly, mice were given a quick anaesthesia induced by 
5% isoflurane/95% oxygen, then were maintained under the 1.5% isoflurane/98.5% 
oxygen level. Mice were placed supine on an electrical heating pad (37°C), and the 
physiological parameters were monitored. Continual ECG was obtained via limb 
electrodes and heart rate were >450 beats per minute (bpm) while respiratory rate was 
~100 breaths per minute for the duration of the study. The chest hair was removed by 
applying hair removal cream. The echocardiographic study was performed 
predominantly in parasternal and suprasternal notch long-axis. All views were digitally 
stored in cine loops consisting of 300 frames. Subsequent analysis was performed off-
line on a Vevo 2100 software (version 1.4.0) workstation. 
2.6.4 Transverse aortic constriction (TAC) 
 
Transverse aortic constriction (TAC) in the mouse is a widely used experimental 
model for pressure overload induced cardiac hypertrophy and heart failure [241]. The 
TAC procedure was performed by a professional experienced technician in 
collaboration with Prof. Ajay Shah’s lab (King’s College London). Briefly, the aorta 
was well exposed after dissecting the muscle surrounding the trachea. The aortic 
binding used a 6-0 nylon suture ligature to tie around the transverse aorta tightly 
against a 27-gauge needle. The binding site was positioned at the bifurcation of the left 
common carotid and innominate arteries. For Sham, the aorta was exposed and touched 
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by surgical instrument as previous steps, without any binding. All the mice were 
monitored post-surgery every day and abnormal behaviours were recorded. The 
termination point was two weeks after surgery. 
2.6.5 Harvesting of mouse heart 
  
Mice were quickly and deeply anaesthetised with 5% isoflurane/95% oxygen. 
The unconscious mice were removed from the chamber and it was ensured that they 
were fully anaesthetised via absence of pedal reflex prior to dissection. Mice were 
placed supine and all limbs were taped. The xiphoid was lifted to allow a cut through 
the abdominal muscle just caudal to the rib cage. Then the visualized diaphragm was 
cut away from the ribs and the extended lateral cutting was along the lower curve of 
the rib cage on both side. The chest cavity was open and lifted by the Mosquito forceps 
via holding the xiphoid. Prior to harvesting, the beating heart was stopped at diastole 
via injecting 300µl salt solution containing 5% KCL directly to the heart chamber. 
Then, the heart was disconnected from the aorta roots and placed in ice-cold PBS. 
Cotton buds were used to press the heart to remove extra blood from the chamber. The 
extra connective and fatty tissue around the heart was carefully removed, and the 
whole heart was weighed. Both right and left atrium as well as right ventricle were 
removed and weighed, the rest left ventricle was weighed and dissected from the 
middle of long axis. The part close to heart base was embedded with Optimal cutting 
temperature compound (OCT compound) on the disc cork, and gradually frozen by 
placing it above the liquid nitrogen. The other part toward the apex, was cut from the 
short axis into two equal parts for WB and RNA analyses respectively. These two parts 
were sealed in the tubes and immediately frozen using liquid nitrogen. The tibia was 
dissected out and cleaned of all soft tissue. The length was determined using a 
micrometer. Meanwhile, the tail biopsy (around 5mm) was cut to further confirm the 
genotyping. The frozen tissue was well preserved at -80°C. 
2.6.6 Whole heart perfusion and embedding 
 
The mice chest cavity was open as described in Section 2.6.5 and the heart 
beating was stopped at the diastole. A tiny hole was incised with scissors at the right 
atrium (RA). 5ml of ice-cold PBS was injected from the apex of LV via a 27-gauge 
  92 
needle to remove the blood inside of the chambers (The PBS flowed out from the RA). 
The heart was pale, indicating efficient removal of blood. Then another 5ml ice-cold 
4% PFA was injected from the same site at the LV for fixation. The soft tissue was 
removed and whole heart was merged into 4% PFA for ON fixation at 4°C. Next day, 
hearts were rinsed in PBS and dehydrated in successively higher concentration of 
sucrose solutions from 10% to 20%. The heart was embedded by the OCT compound, 
slowly frozen on the dry ice and stored at -80°C. 
2.6.7 Sectioning of cryopreserved tissue 
 
Heart tissue was removed from storage at -80°C and allowed to equilibrate in 
the cryostat chamber temperature (-20°C) for approximately 30 minutes. The disc cork 
connected to the tissue was mounted onto the stage of a cryostat with OCT compounds. 
The stage temperature was set to -22°C while the knife was set to 2 degrees above. 
The frozen tissue was sectioned into 8µm thick and mounted onto high quality 




The nesprin-1α2 WT and mutants in mammalian expression vectors were 
generated as methods described in PCR, site directed mutagenesis and cloning. This 
part of work was completed by me. However, the methods described below and 
associated experiments during zebrafish embryos developments were performed by 
our collaborators in Sichuan University.   
2.6.8.1 Zebrafish Embryos 
 
WT embryos from AB strain were used. Embryos were obtained by natural 
matings and cultured in embryo medium [242]. Staging of the embryos was carried 
out as described by Kimmel et al [243]. Ethical approval was obtained from the Animal 
Care and Use Committee of Sichuan University. 
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2.6.8.2 In vitro synthesis of mRNA and microinjection 
 
Capped GFP and nesprin mRNAs were synthesized using mMESSAGE 
mMACHINE® Kit (Ambion); Synthetic capped mRNAs were injected into single-cell 
embryos. Injection dose (60mg) was an optimised amount received by a single embryo. 
2.6.8.3 Zebrafish whole-mount in situ hybridization 
 
Whole-mount in situ hybridization was carried out as previously described [244, 
245]. After linearization by appropriate restriction enzymes, antisense RNAs for in situ 
hybridization were synthesized using DIG RNA Labelling Kit (SP6/T7) (Roche) and 
purified by MEGAclear (Ambion). Signal area of whole-mount in situ hybridization 
was measured by software ImageJ (1.48V). 
 
2.7 Statistical analysis 
 
Cell counts for statistical analysis were performed on n= 100-200 cells/n=10 
confocal microscope fields (63x magnification) for each control and experimental 
group. All the results were verified in at least 3 independent experiments. The data 
were analysed using GraphPad Prism software by the Student’s t-tests, One way or 
Two-way analysis of variance (ANOVA) with Dunnett’s multiple comparison test or 
Turkey’s post-test for two independent groups or multiple comparisons, respectively. 
The values are expressed as mean ± standard error of mean (SEM). The p-values<0.05 
were considered statistically significant. 
 
2.8 Primer sequence 
2.8.1 Primers for V5 tagged nesprin-1α2 WT and KASH 
 
Primers were designed to amplify V5 tagged nesprin-1α2 WT and KASH and 
cloned into MIG retroviral vector. V5 sequence was at the N-terminal of these 
translated proteins. Primers used for V5 tag nesprin-1α2 WT and KASH are shown in 
Table 2.1. 
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2.8.2 Primers for Flag tagged nesprin-1α2 WT  
	
Primers were designed for amplified Flag tagged nesprin-1α2 WT and cloned 
into mammalian pcDNA3.1(-) vector. Flag sequence was at the N-terminal of the 
nesprin-1α2 WT. Primers used for Flag tag nesprin-1α2 WT are shown in Table 2.2. 
2.8.3 Primers for Nesprin-1α2 mutagenesis 
	
Primers for site directed mutagenesis were designed to be between 25 and 45 
bases in length with the mutated site in the central region of the primers. Primers used 
for nesprin-1α2 mutants R8272Q, S8381C, N8406K are shown in Table 2.3. 
2.8.4 Primers for genotyping 
	
Primers for genotyping the cardiac specific KASH2 overexpression transgenic 
mice were shown in Table 2.4. Primers for GFP-KASH2 were obtained from the mice 
strain’s original creator Dr. Didier Hodzic in Washington University, while the primers 
for Cre and GAPDH were from the colleague Dr. Daniel Brayson (King’s collage 
London). 
2.8.5 Primers for qPCR 
 
Primers sequence for myogenic regulatory factors were from our collaborator 
Prof. Peter Zammit (King’s collage London). Primers sequence for NE-LINC complex 
associated proteins and mechanosensitive genes were from Prof. Ju Chen (University 
of California San Diego). Other primers were designed via the online tool 
‘Primer3Input Program’. Primers used for qPCR are listed in Table 2.5. 
	
2.9 siRNA oligos 
 
siRNA oligos of KLC-1/-2 group A were obtained from a paper authored by Dr. 
Holzbaur [114]. siRNA oligos of KLC-1/-2 group B/C were purchased from Qiagen. 
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siRNA oligos of SUN2 was from colleague Dr. Derek Warren. siRNA oligos used in 
this thesis are listed in Table 2.6.
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Table 2.1 Primers used for V5 tagged nesprin-1α2 WT and KASH 
 Forward primer (5’ to 3’) Reverse primer (5’ to 3’) 
V5 nesprin-1α2 WT ATA GCG GCC GCC ACC 
ATG GGA AAG CCT ATT 
CCT AAT CCT CTT CTA 
GGT CTA GAT TCT ACT 
GGC GGA GGC GTG GTG 
GCG GAG GAC 
TAT AGA ATT CTC 
AGA GTG GAG GAG 
GGC CAT TC 
V5 nesprin-1 KASH ATA GCG GCC GCC ACC 
ATG GGA AAG CCT ATT 
CCT AAT CCT CTT CTA 
GGT CTA GAT TCT ACT 
GGC GGA GGC CGC GGC 
TTC CTG TTCA 
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Table 2.2 Primers used for Flag tagged nesprin-1α2 WT 
 Forward primer (5’ to 3’) Reverse primer (5’ to 3’) 
Flag nesprin-1α2 WT ATA GCG GCC GCC ACC ATG 
GAC TAC AAA GAC GAT GAC 
GAC AAG GGC GGA GGC GTG 
GTG GCG GAG GAC CTG 
TAT AGA ATT CTC AGA 
GTG GAG GAG GGC CAT 
TC 
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Table 2.3 Primers used for nesprin-1α2 mutagenesis 
 Forward primer (5’ to 3’) Reverse primer (5’ to 3’) 
R8272Q CGG TCA GGA CAA GAC ACC 
CCA 
TGG GGT GTC TTG TCC 
TGA CCG 
S8381C GCT GGG CGA ATG CTG TAG 
CAG TAT AGA 
TCT ATA CTG CTA CAG 
CAT TCG CCC AGC 
N8406K CTG GCT TTG TTA AAC TGC 
ATA GTA CCG 
CGG TAC TAT GCA GTT 
TAA CAA AGC CAG 
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Table 2.4 Primers for genotyping 
 Forward primer (5’ to 3’) Reverse primer (5’ to 3’) 
GFP-KASH GGA GTT CGT GAC CGC CGC CGG 
GAT CAC TCT CAG 
TTT AAA CGG GCC CCC TAG 
GTG GGA GGT GGC 
Cre TGC CAG GAT CAG GGT TAA AG CCC GGC AAA ACA GGT AGT TA 
GAPDH CCT AGA CAA AAT GGT GAA GG GAC TCC ACG ACA TAC TCA GC 
  100 
Table 2.5 Primers for qPCR 
 Forward primer (5’ to 3’) Reverse primer (5’ to 3’) 
Myogenin TGT TTG TAA AGC TGC CGT CTG A CCT GCC TGT TCC CGG TAT C 
MHC AGA GCT GAC GTG CCT CAA TG ATG CCT CTT CTT GCC CTT 
GT 
MyoD GCC GCC TGA GCA AAG TGA ATG CAG CGG TCC AGG TGC GTA 
GAA G 
V5 ATA TCC TCG TTC GAC CCC GCC TCA TTA AGC TTT CTC TGT 
ATT TCT TCC GAG 
GFP GGT CGA GCT GGA CGG CGA CGT 
AAA 
CAC CAG GGT GTC GCC CTC 
GAA CTT 
Nesprin-1α2 TCC TCA TCC AGG AAG GAC TG CAA CCA GCG TCT CCT TTA 
GC 
KASH1 TCC TGC TGC TGC TTA TTG GAC 
TCA 
TCC TCT TAC TGC CTG CAC 
TTG TGT 
KASH2 TCC TTC CTC TCA AGG GTG ATC 
AGG 




AGC AGT TGC CTC GGG ATA AAG 
GAT 
AGG CCA AGG ATA ATG GAC 
GGG TTT 
Lamin A/C CCT TCG CAT CAC TGA GTC TG AGT CCC CCT CCT TCT TGG T 
Emerin TTG GGC CCT GTC TGT AGG TAG GAG AAT GAA GAA GAT 
GAC GAG T 
SUN1 ATG GAA CAC ATT CCA AAG ACA 
CTA T 
GAG CTC TAC TAT CTG GAA 
GGC TTG 
SUN2 CAC TCG CTA CTC TCA GGA TGA 
TAA 
TAG GAC TCT CGA ACC ACA 
GAC TC 
ANP GAT AGA TGA AGG CAG GAA GCC GC AGG ATT GGA GCC CAG AGT 
GGA CTA GG 
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BNP TGT TTC TGC TTT TCC TTT ATC 
TGT C 
CTC CGA CTT TTC TCT TAT 
CAG CTC 
αMHC CTG CTG GAG AGG TTA TTC C TCG GGA AGA GTG AGC GGC GCA 
TCA AGG 
βMHC TGC AAA GGC TCC AGG TCT GAG 
GGC 
GCC AAC ACC AAC CTG TCC 
AAG TTC 
Procollagen1α1 TCA CCA AAC TCA GAA GAT GTA 
GGA 
GAC CAG GAG GAC CAG GAA G 
Procollagen3α1 ACA GCA GTC CAA CGT AGA TGA AT TCA CAG ATT ATG TCA TCG 
CAA AG 
egr-1 CCT ATG AGC ACC TGA CCA CA TCG TTT GGC TGG GAT AAC 
TC 
iex-1 TTA TAG GGT CGG TAA GAC AGA 
GTT G 
GAC GGA GTG TTA CCC CTA 
ATC TTA T 
c-myc ATG CCC CTC AAC GTG AAC TTC GTC GCA GAT GAA ATA GGG 
CTG 
c-jun TTC CTC CAG TCC GAG AGC G TGA GAA GGT CCG AGT TCT 
TGG 
c-fos AGC CCC TGT GTA CTC CCG TG GCC TTG CCT TCT CTG ACT 
GC 
18S CCC AGT AAG TGC GGG TAC TAA GGT TTA GTG AGG CCC TCG G 
GAPDH CGT GCC GCC TGG AGA A CCC TCA GAT GCC TGC TTC 
AC 
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Table 2.6 siRNA oligos 
 Sequence (5’ to 3’) 
KLC-1A GAG TAT GGC GGC TGG TAT A 
KLC-1B CAG AGA GTG GCT GAA GTG CTA 
KLC-1C AGG GAT CAG AAC AAG TAT AAA 
KLC-2A TGT AGA AAT AAA GAC GAT 
KLC-2B CAG CTG GTA CAA AGC CTG TAA 
KLC-2C AAA GAC GAT TTG AAT CTG AAA 
SUN2 CCT GAG GGC CTT CGA CAA A 
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2.10 Antibodies 
2.10.1 Primary antibodies 
 
All the primary antibodies used in this thesis were obtained from different 
manufacturers. The catalogue numbers and the dilution information for both WB and 
IF are listed in Table 2.7.	
2.10.2 Secondary antibodies 
 
The secondary antibodies used in this thesis were obtained from different 
manufacturers. The catalogue numbers and the dilution information for WB and IF are 
listed in Table 2.8 and 2.9 individually.
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Table 2.7 Primary antibodies 
 Catalogue number WB IF 
β-actin A5316, Sigma 1:10,000 - 
α-actinin A7811, Sigma - 1:500 
α-tubulin Ab5266, Abcam 1:1000 - 
emerin NCL-EMERIN, Novocastra 1:200 1:40 
GAPDH SC-25778, Santa Cruz 1:1000 - 
GFP Ab290, Abcam 1:1000 - 
GFP Ab13970, Abcam - 1:1000 
HA Ab1424, Abcam For Co-IP  
KLC-1/2 63-90, gift from Prof. S. Brady 1:500 1:100 
Lamin A/C 2320S, Cell signalling  1:1000 1:100 
Nesprin-1 
(C-terminal region 
of nesprin-1 giant) 
MANNES1A  - 1:2 
MANNES1E 1:10 - 
Myogenin  SC-576, Santa Cruz 1:200 - 
MHC  A4.1025, Alexis Corporation 1:1000 1:150 
pELK 9181, Cell signalling 1:1000 - 
pERK 4370, Cell signalling 1:1000 1:100 
SUN1 Gift from Prof. S. Shackleton 1:1000 - 
SUN2 Ab124916, Abcam 1:1000 - 
SUN2 Gift from Prof. S. Shackleton - 1:100 
tERK 9120, Cell signalling 1:1000 - 
V5 R96025, Invitrogen 1:500 1:100 
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Table 2.8 Secondary antibodies for WB 
HRP-conjugated secondary antibodies Catalogue number Dilution 
Amersham ECL Mouse IgG, HRP-linked whole Ab (from 
sheep) 
NA931, GE 1:3000 
Amersham ECL Rabbit IgG, HRP-linked whole Ab (from 
donkey) 
NA934, GE 1:3000 
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Table 2.9 Secondary antibodies for IF 
HRP-conjugated secondary antibodies Catalogue number Dilution 
Goat anti-Chicken IgY (H+L), Alexa Fluor 488 A11039, Invitrogen 1:500 
Goat anti-Mouse IgG (H+L), Alexa Fluor 488 A11001, Invitrogen 1:300 
Goat anti-Rabbit IgG (H+L), Alexa Fluor 488 A11008, Invitrogen 1:300 
Goat anti-Mouse IgG (H+L), Alexa Fluor 546 A11030, Invitrogen 1:300 
Goat anti-Rabbit IgG (H+L), Alexa Fluor 546 A11035, Invitrogen 1:300 
Goat anti-Mouse IgG (H+L), Alexa Fluor 647 A21236, Invitrogen 1:500 
  107 
2.11 Laboratory materials 
2.11.1 Stock materials 
 
100bp DNA ladder Biolab N3231L 
1kb DNA ladder Biolab N3232L 
4-(2-Hydroxyethyl) piperazine-1-




Acetone Sigma 439126 
Acrylamide/Bis solution 30% Bio-Rad 161-0158 
Agarose Sigma A5093 
AllStars Negative Control siRNA QIAGEN SI03650318 
Amersham ECL Mouse IgG, HRP-linked 
whole Ab (from sheep) 
GE NA931 
Amersham ECL Rabbit IgG, HRP-linked 
whole Ab (from donkey) GE NA934 
Ammonium Persulfate Bio-Rad 161-0700 
Ampicillin sodium salt Sigma A0166 
Antarctic Phosphatase Biolab M0289 
Bio-Rad DC Protein Assay Reagent A & B Bio-Rad 
5000113 & 
5000114 
BioSafeTM Coomassie Stain Bio-Rad 161-0787 
Bovine serum albumin Sigma A4503 
Cell Scraper 24cm/30cm TPP 99002/99003 
Cell strainer 40µm BD Falcon 352340 
Chloroform Sigma 288306-1L 




DABCO (1,4-Diazabicyclo [2.2.2] octane) Sigma D2522 




Deionized H2O (DiH2O) 18.2Ω Millipore purification system 
DEPC (diethylpyrocarbonate) treated water Invitrogen 750023 
DH5α™ Competent Cells Invitrogen 18265017 
Digitonin Sigma D141 
Disc cork for Cryostat use 20mm diameter x 
3mm depth 
ThermoFisher 12688566 
dNTP mix Eurogentec NU-0010-10 
DPX Mounting Media Merck 10197905000 
Dried Skimmed Milk Marvel  
Dulbecco’s Modified Eagle’s Medium 
(DMEM) 
Sigma D5671 
ECL™ Prime Western Blotting System GE Healthcare RPN2232 
EcoRI enzyme Biolab R0101S 
Eosin Raymond A Lamb Lamb/100d 
Escort III Transfection Reagent Sigma L3037-1ML 
Ethanol (CH3CH2OH, EtOH) Fisher 10428671 
Ethylenediaminetetraacetic acid disodium 
salt dehydrate (EDTA) 
Sigma E5134 
Fetal Bovine Serum - heat inactivated FBS ThermoFisher 16140071 





FlexiTube GeneSolution for Klc1 QIAGEN GS16593 
FlexiTube GeneSolution for Klc2 QIAGEN GS16594 
FuGENE® HD Transfection Reagent Promega E2311 
Fujifilm Corporation™ RX NIF Sheet X-ray 
Film Fuji 12715325 
GC-RICH PCR System Roche 12140306001 
Gel loading dye, Purple (6X) Biolab B7024S 
Gelatin 2% Sigma 
G1393-
100ML 
Glacial acetic acid Sigma 537020 
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Glucose Sigma G8270 
Glutathione Sepharose 4B beads GE 17075601 
Glycerol Fisher Scientific BPE229-1 
Glycerol Sigma G5561 
Goat serum blocking solution Vector S1000 
GoTaq® Green Master Mix Promega M7122 
Harris’ Haematoxylin Raymond A Lamb Lamb/230d 
HiPerFect Transfection Reagent Qiagen 301707 
Horse Serum (HS) Sigma H1270 
Isopropanol (C3H8O) Sigma 19516 
Isopropyl-1-thio-β-d-galactopyranoside 
(IPTG) Sigma I1284-5ML 
JM109 Competent Cells Promega L2001 
Kanamycin disulphate salt Sigma K1876 




LB Agar Sigma L2897 
LB Broth Sigma L3022 
Lipofectamine™ LTX Reagent with 
PLUS™ Reagent ThermoFisher 15338100 
M-MLV Reverse Transcriptase Promega M1701 
M199 medium Sigma M4530 
Magnesium sulphate (MgSO4) Sigma M7506-500G 
Masson’s trichrome staining kit Polysciences 25088-100 
Methanol (CH3OH, MeoH) Fisher 10428671 
Millex-HV Syringe Filter, 0.45µm/0.22µm Millipore 
SLHV033RS/
SLGP033RS 
Mowiol 4-88 Calbiochem 475904 
Nancy-520 Sigma 1494 
Nonidet P-40 (NP-40) Alternative Calbiochem 492016 
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NotI enzyme Biolab R1089S 
Oligo (dT) 15 primer Promega C1101 
Opti-MEM® I Reduced Serum Medium ThermoFisher 1158021 
Optimal cutting temperature compound 
(OCT compound) VWR International 720-1731 
Pancreatin from porcine pancreas Sigma P3293-25G 
Paraformaldehyde (PFA) Sigma P6148 
pGEM T-easy vector system II Promega A1380 
Phosphate buffered saline (PBS) Sigma D8537 
Phosphate Buffered Saline (PBS) Tablets Oxoid BR0014G 
Polybrene Infection/Transfection reagent Millipore TR-1003-G 
Potassium Chloride Sigma P9333-500G 
Precision Plus Protein™ All Blue Prestained 
Protein Standards 
Bio-Rad 1610373 
Protease Inhibitor Cocktail Sigma P8340 
Protein A-Sepharose® 4B Sigma P9424-5ML 
Protein G-Sepharose® 4B Sigma P3296-5ML 
PureYield™ Plasmid Miniprep System Promega A1222 
PVDF membrane with 0.45µm pore size Millipore IPVH00010 
QIAquick Gel Extraction Kit QIAGEN 28706 
QuikChange® Site-Directed Mutagenesis Kit Stratagene 200518 
Random primer Promega C1181 
Recombinant RNasin® Ribonuclease 
Inhibitor 
Promega N2511 
Restore™ Western Blot Stripping Buffer ThermoFisher 21059 
RNA STAT-60 Amsbio CS-110 
S.O.C. Medium Invitrogen 15544034 
Sodium Chloride (NaCl) Sigma S7653 
Sodium dodecyl sulphate solution (SDS) 
20% in H2O 
Sigma 5030 
Sodium Hydroxide (NaOH) Sigma S8045 
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Sodium phosphate monobasic (NaH2PO4) Sigma S8282-500G 
Sucrose Sigma 839 
Superfrost Slides white VWM 48311-601 




TEMED Bio-Rad 492016 
Tris base Sigma 10708976001 
Triton-X 100 Sigma X100 
Trypsin 1×-EDTA solution Sigma T3924 
Tween-20 VMR 437082 
X-gal solution ThermoFisher R0941 
XL1-Blue Competent Cells 
Agilent 
Technologies 200249 
XmnI enzyme Biolab R1094S 
Xylenes Sigma 534056 
 






 1µl DAPI, 10ml PBS 
ADS buffer  116mmol/L NaCl, 20mmol/L HEPES, 
0.8mmol/L NaH2PO4, 5.6mmol/L glucose, 
5.4mmol/L KCl, 0.8mmol/L MgSO4, 
pH=7.35, filtered 
Agarose gel 1-2% (100ml)  1-2g agarose, 100ml 1× TAE, boiled, add 
5µl Nancy-520 
APS (w/v) 10% (1ml):  10mg Ammonium persulfate, 1ml DiH2O 
Bovine serum albumin (BSA) 3% 
(50ml) 
 1.5g BSA, 50ml PBS 
Ethanol 70% for RNA wash (50ml)  35ml Ethanol, 15ml DEPC treated water  
Goat serum blocking solution 5% 
(50ml) 
 2.5ml Goat serum, 47.5ml PBS 
IP buffer-1:  10mM Tris pH=7.4, 150mM NaCl, 1mM 
EDTA, 1% Triton 
IP buffer-2  10mM Tris pH=7.4, 50mM NaCl, 5mM 
EDTA, 1% Triton 
LB Broth (medium)  20g LB Broth, 1L DiH2O, sterile 
Methanol - Acetone fixative (100ml)  50ml Methanol, 50ml Acetone  
Mowiol Mounting medium  2.4g Mowiol 4-88, 6g Glycerol, 6ml 
DiH2O, mix and rotation ON; 12ml 
200mM Tris pH=8.5, stir at 50°C until 
dissolved, then add 2.5% DABCO 
NP-40 (100ml) 0.5%:  500µl NP-40, 100ml PBS 
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NRC Enzyme solution (ES) (25ml)  20.5mg Collagenase, 15mg Pancreatin, 
25ml ASD buffer, filtered 
NRC Maintenance medium (500ml)  DMEM 375ml, M199 100ml, HS 10ml, 
PSG 5ml, L-glutamine (200mM) 10ml 
NRC Plating medium (500ml)  DMEM 337.5ml, M199 82.5ml, HS 50ml, 
FBS 25ml, PSG 5ml 
NRC Transfection medium (100ml)  73ml ASD, 21ml M199, 4ml HS, 2ml 
200mM L-Glutamine  
PFA 4% (50ml)  2g paraformaldehyde, 50ml PBS 
Potassium Chloride (KCL) 5% 
(50ml) 
 2.5g KCL, 50ml PBS, through a 0.22µm 
syringe filter 
Resolving PAGE gel 8% (~ 15ml):  7ml DiH2O, 3.75ml 1.5M Tris pH=8.8, 
4ml 30% acrylamide, 150µl 10% SDS, 
200µl 10% APS, 8.5µl TEMED 
Resolving PAGE gel 10% (~ 15ml):  6ml DiH2O, 3.75ml 1.5M Tris pH=8.8, 
5ml 30% acrylamide, 150µl 10% SDS, 
200µl 10% APS, 8.5µl TEMED 
Resolving PAGE gel 12% (~ 15ml):  5ml DiH2O, 3.75ml 1.5M Tris pH=8.8, 
6ml 30% acrylamide, 150µl 10% SDS, 
200µl 10% APS, 8.5µl TEMED 
Resolving PAGE gel 15% (~ 15ml):  3.5ml DiH2O, 3.75ml 1.5M Tris pH=8.8, 
7.5ml 30% acrylamide, 150µl 10% SDS, 
200µl 10% APS, 8.5µl TEMED 
Running buffer 10 X (500 ml)  72.2 g Glycine, 15.15g Trizma, 10ml 20% 
SDS, DiH2O to 500ml 
Sample loading buffer (4×)  40% Glycerol, 240mM Tris/HCl pH=6.8, 
8% SDS, 0.04% bromophenol blue, 5% β-
mercaptoethanol 
Sodium Hydroxide (NaOH) 200mM 
(500ml) 
 4g NaOH, 500ml DiH2O 
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Sodium Hydroxide (NaOH) 50mM 
(500ml) 
 1g NaOH, 500ml DiH2O 
Stacking PAGE gel 4% (~ 10ml):  6ml DiH2O, 2.5ml 0.5M Tris pH=6.8, 
100µl 10% SDS, 1.7ml 30% acrylamide, 
200µl 10% APS, 8.5µl TEMED 
Sucrose 10% (50ml):   5g Sucrose, 50ml DiH2O 
Sucrose 30% (50ml):   15g Sucrose, 50ml DiH2O 
Transfer buffer 10× (500ml):   72.2g Glycine, 15.15g Tris, DiH2O to 
500ml 
Transfer buffer 1× (500ml):   50ml 10× Transfer buffer, 100ml 
Methanol, 350ml DiH2O 
Tris-acetate-EDTA (TAE) Buffer 
50X (1000 ml):  
 242g Tris, 57.1ml glacial acetic acid, 18.6g 
EDTA, 943ml DiH2O 
Tris-Buffered Saline (TBS) 10× pH 
8.0 (1000ml):  
 24.5g Tris, 175g NaCl, DiH2O to 1000ml 
TBS-T (500ml) 1×:   50ml 10X TBS, 1.5ml Tween-20, DiH2O to 
500ml 
Triton 10% (50ml):   5ml Triton, 45ml PBS  
Western blocking buffer (100ml):  5g Dried skimmed milk, 100ml 1× TBS-T  
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2.11.3 Laboratory equipment 
 
Branson Sonifier 150D 
Clifton Water Bath 95825 
Corbett RotorGene-3000 qPCR Machine 
ThermoFisher CryoStar NX70 
Eppendorf Centrifuge 5415R Microcentrifuge 
FastPrep® Lysis Beads & Matrix Tubes for Sample Disruption 
Bio-Rad Horizontal Electrophoresis Chamber 
InforsHT Ecotron Bacterial Shaker 
InforsHT Ecotron Incubator Shaker 
Leica ICC50 W Microscope 
Leica SP5 Confocal Microscope 
NanoDrop ND-1000 
Eppendorf Mastercycler® Pro 
Olympus CKX41 Inverted Microscope 
Bio-Rad PowerPac™ HC High-Current Power Supply 
Bertin Instruments Precellys®24 Homogenizer 
Bio-Rad Protein Electrophoresis Chamber / Vertical 
Rodwell Phoenix 40E Autoclaves PHX40 
Tecan Genios Pro Fluorescence 
Thermo Scientific HERAcell 150 Incubator 
Thermo Scientific Heraeus Multifuge 3SR+ Centrifuge 
Trans-Blot® SD Semi-Dry Transfer Cell, Bio-Rad 
UVP Bio Spectrum AC Imaging System 
Visualsonics Vevo 2100 Ultrasound System
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2.11.4 Online tools 
 
DNA Sequence Reverse and Complement 
http://www.cellbiol.com/scripts/complement/dna_sequence_reverse_comple
ment.php 





FuGENE HD Transfection database 
https://www.promega.com/techserv/tools/FugeneHdTool/ 
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Chapter 3: Novel nesprin-1 mutants disrupted 





The giant nesprin-1 and -2 isoforms bind to actin cytoskeleton via paired N-
terminal CH domains, and are targeted to the ONM via a C-terminal KASH domain. 
The KASH domain interacts with the SUN domain of INM proteins SUN1/2 forming 
the SUN-KASH bridge that spans the PNS. Meanwhile, SUN1/2 bind to lamin A/C 
via their N-terminal nucleoplasmic domains, thus providing a physical connection 
between the nucleus and actin cytoskeleton [2, 27, 77]. The small nesprin-1 and -2 
isoforms that have a truncated N-terminal but share SRs in common with the C-
terminal regions of the giant proteins also localise at the INM where they bind to 
emerin, lamin A/C and SUN1/2, forming the NE complex [35]. These small isoforms, 
in particular, nesprin-1α2 and nesprin-2α1, are highly expressed in cardiac and skeletal 
muscle [1, 36]. The NE-LINC complex maintains the cellular structure and nuclear 
morphology, regulates the nuclear migration and positioning, propagates the 
mechanical force and participates in cell signalling and gene transcription [111, 112, 
127, 176]. 
Mutations in the C-terminal region of the SYNE-1/-2 (nesprin-1 and -2) have 
been identified in EDMD patients with DCM from small kindred families. HDFs 
derived from EDMD patients display defects in nuclear morphology, loss of NE 
integrity and mis-localisation of NE-LINC complex proteins lamin A/C, emerin and 
SUN2, as well as the altered binding between nesprin and those proteins [3]. A 
missense mutation in the C-terminal region of nesprin-1 was identified in a DCM 
patient, which resulted in the increased expressions of nesprin-1 and lamin A/C, 
indicating a perturbation of the LINC complex [4], suggesting these mutations are 
likely to play a key role in muscle-specific laminopathies.
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3.1.1 Identification of three novel nesprin-1 mutants in DCM 
patients 
 
In order to study the roles of nesprin-1/-2 in cardiac disease, in collaboration 
with a lab in China, we recently screened the SYNE-1 and SYNE-2 genes in 218 
sporadic DCM patients and 210 ethnically matched controls (Appendix I). 23 exons 
for nesprin-1 corresponding to nesprin-1α1 and 1α2 and 16 exons for nesprin-2 
corresponding to isoforms nesprin-2α, 2β and 2ε were screened. This screening 
strategy was based on high and specific expression of these isoforms in cardiac and 
skeletal muscle as well as mapping of the lamin A/C, emerin and SUN1/2 binding sites 
to domains within these isoforms [36, 61, 66]. Twelve single nucleotide 
polymorphisms (SNPs)/variants in SYNE-1 were identified, which included intronic 
sequence variations (n=2), synonymous (n=5) and non-synonymous, amino acid 
exchanges (n=5). Eight of the variants were not present in 420 control alleles of an 
ethnically matched reference population (Appendix II). None of nesprin-2 
SNPs/variants were identified in the region screened. Interestingly, three of the 
identified nesprin-1 mutations were unique DNA variants, which resulted in R8272Q, 
S8381C, N8406K amino acid exchanges in the C-terminus of nesprin-1 giant as well 
as within the muscle specific isoform nesprin-1α2 (equivalent to nesprin-1 giant 7875-
8796), and identified in 7 unrelated DCM patients (Figure 3.1A, Appendix III). The 
amino acids changed by these missense mutations were in regions that were 
evolutionarily well conserved and within the mapped emerin and lamin A/C binding 
domains [22] (Figure 3.1). The rarity of these variants and their conservation and 
positioning suggest they may be causative for DCM in the patients examined. An 
ExAC database search revealed that population frequencies for the R8272Q allele were 
0.0002145 (26/121204). Further in silico functional analyses showed that all three 
variants were predicted to cause significant functional impairment for nesprin-1 
(Polyphen-2: possibly damaging, SIFT: damaging and Mutation Taster: disease 
causing). 
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In this chapter, I will focus on investigating if these three novel nesprin-1 
mutations cause any impact on the structural and functional integrity of the NE-LINC 
complex: 
1) Any nuclear morphology changes caused by these nesprin-1 mutations; 
2) Any changes of NE-LINC complex components including their 
localisation at the NE and interactions with nesprin-1; 
3) Any defects in mechanical signalling caused by any structural changes in 
the NE-LINC complex identified in Aim 2. 















Figure 3.1 Identification of nesprin-1 variants in DCM patients 
Mutation screening in SYNE-1 and -2 genes was performed in 218 DCM patients and 210 
healthy controls, and identified 7 patients harbouring three novel nesprin-1 mutations 
(R8272Q, S8381C, N8406K, coloured in red and bold) in the C-terminus of nesprin-1 giant 
(A), equivalent to nesprin-1α2, within an evolutionally conserved region containing the lamin 
A/C and emerin binding domains (A, B). Previously identified nesprin-1 mutants in DCM 
(R8212H, in red) [4] and EDMD-CD patients (R8095H, V8387L and E8461K, in blue) [3] 
were also shown (A).
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3.2 Results 
3.2.1 Overexpression of nesprin-1 mutants disrupted 
nuclear morphology 
 
A defective nuclear morphology is a common feature observed in muscular 
tissue or HDFs derived from EDMD/DCM patients carrying by lamin A/C, emerin or 
nesprin-1/-2 mutants [3, 246, 247]. Therefore, the impact of the three nesprin-1 
mutations on nuclear morphology was our first objective. We previously generated 
GFP tagged WT and mutant R8272Q, S8381C, N8406K constructs in the context of 
muscle specific isoform nesprin-1α2 (amino acid 1-977), which is equivalent to 
nesprin-1 giant SR69-74 with KASH domain (nesprin-1 giant 7875-8796) where these 
mutations identified/localised (Figure 3.2A). U2OS cells were transfected with those 
plasmids and the nuclei were visualised using DAPI staining. Either exogenous 
nesprin-1α2 WT or mutants were present at the NE, whilst GFP-only distributed 
through the cell (Figure 3.2B). In contract to the normal ovoid or spheroid morphology 
seen in the majority of control cells, abnormalities in nuclear morphology were seen 
following overexpression of the three novel nesprin-1α2 mutants, especially in S8381C 
(Figure 3.2B & 3.2C). These analyses were based on counting cell circularity in more 
than 100 transfected nuclei in each experiment and in total three individual 
experiments were performed. 
3.2.2 Nesprin-1 mutants reduced lamin A/C and SUN2 
staining at the NE in U2OS cells 
 
Previous experiments showed the mis-localisation of NE binding partners lamin 
A/C, emerin and SUN2 caused by the nesprin-1 and -2 mutations in HDFs derived 
from EDMD patients [3]. Thus, we set out to investigate whether these three mutations 
affected the localisation of nesprin binding partners lamin A/C, emerin and SUN2 at 
the NE. Initial experiment and quantification were done in U2OS cells. IF staining 
showed that lamin A/C was dramatically reduced or absent from the NE in cells that 
expressed exogenous mutants, especially S8381C (Figure 3.3A & 3.3C), while all 
three mutants caused weaker staining of SUN2 at the NE, when compared with WT 
  122 
nesprin-1α2 (Figure 3.3B & 3.3C). In addition, emerin was mis-localised by both WT 
and mutants when compared with GFP alone (Figure 3.3C). 








Figure 3.2 Overexpression of nesprin-1 mutants caused abnormal nuclear 
morphology. 
GFP-tagged nesprin-1α2 WT and mutants are shown schematically (A). The full length of this 
isoform is 977 amino acids, equivalent to amino acids 7875-8796 in nesprin-1 Giant. U2OS 
cells were transfected with either GFP-nesprin-1α2 WT or mutants. IF staining showed 
overexpression of mutants, especially S8381C, led to abnormalities in nuclear morphology (B, 
arrowed). The misshapen nuclei were measured by circularity. Graphical representation of the 
frequency of misshapen nuclei caused by all three mutants (C). At least 100 transfected nuclei 
were counted in more than three individual experiments and the results were analysed by 
Student’s t-tests, shown as mean±SEM. (*: P<0.05 compared with WT). Scale bar=12.5µm.
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Figure 3.3 Overexpression of nesprin-1 mutants reduced NE staining of lamin 
A/C and SUN2 in U2OS cells. 
IF showed exogenous expression of GFP tagged mutants, especially S8381C, caused weaker 
staining of lamin A/C at the NE (A, arrowed). Scale bar=12.5µm.
N8406K








Figure 3.3 Overexpression of nesprin-1 mutants reduced NE staining of lamin 
A/C and SUN2 in U2OS cells. 
All three mutants caused weaker staining of SUN2 at the NE (B, arrowed) when compared 




























Figure 3.3 Overexpression of nesprin-1 mutants reduced NE staining of lamin 
A/C and SUN2 in U2OS cells. 
Mis-localisation of lamin A/C, SUN2 and emerin in the transfected cells was quantified by 
comparing the NE staining in non-transfected cells on the same slide. Graphical representation 
of the frequency of defects in lamin A/C, SUN2, and emerin at the NE caused by all three 
mutants (C). At least 100 transfected nuclei were counted in each experiment and three 
individual experiments in total were performed. The results were analysed by one-way 
ANOVA, shown as mean±SEM (*: P<0.05 compared with WT; #: P<0.05 compared with GFP 












































  127 
3.2.3 Nesprin-1 mutants reduced lamin A/C and SUN2 
staining at the NE in neonatal rat cardiomyocytes 
 
As these mutations were originally identified from DCM patients, we further 
confirmed their effects on neonatal rat cardiomyocytes (NRCs). NRCs were isolated 
from the neonatal rat hearts and stained with α-actinin as the sarcomeric marker to 
distinguish CMs from the potentially mixed fibroblasts. The same GFP tagged nesprin-
1α2 WT and mutants were transfected in NRCs. IF staining showed that both lamin 
A/C and SUN2 staining was present continuously at the NE in the CMs that 
overexpressed either GFP alone or nesprin-1α2 WT, while in the cells transfected with 
all three mutants, lamin A/C (Figure 3.4A) and SUN2 (Figure 3.4B) was reduced or 
absent at the NE, indicating nesprin-1 mutants affected the localisation of their NE 
binding partners. 
3.2.4 Nesprin-1 mutants disrupted the interactions between 
nesprin-1, lamin A/C and SUN2 within the NE complex 
 
To investigate whether these mutants affected the bindings between nesprin-1 
and its NE binding partners, GST pull-down assays were performed. GST-tagged WT 
and mutant nesprin-1α2 constructs lacking the KASH domain (equivalent to nesprin-1 
giant amino acids 7875-8662) were previously generated in our lab (Figure 3.5A). GST 
tagged nesprin-1 WT and mutants conjugated to sepharose beads were mixed with 
equal amount of protein lysates from untransfected U2OS cells (for lamin and emerin 
binding) or transfected cells with Myc-SUN2 (full length). All three mutants had 
significantly reduced binding to lamin A/C and SUN2, but not emerin when compared 
with WT nesprin-1α2 (Figure 3.5B & 3.5C). 
Furthermore, a reverse GST pull-down was also performed to confirm their binding. 
Protein lysates from U2OS cells transfected with either GFP-nesprin-1α2 WT or each 
of three mutants were subjected to pull-down using either GST-lamin A (amino acids 
356-665, containing nesprin-1/2 binding domain) or GST-emerin (amino acids 1-176, 
lacking the TM domain). The results confirmed all three mutants had significantly 
reduced binding to lamin A (Figure 3.6B), but not emerin (Figure 3.6A). Taken 
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together, these data indicated that these nesprin-1 mutations in the 1α2 region cause 
disruption of the lamin A/C, SUN2 and nesprin-1 complex at the INM.







Figure 3.4 Overexpression of nesprin-1 mutants reduced NE staining of lamin 
A/C and SUN2 in NRCs. 
IF showed lamin A/C (A) staining was reduced at the NE in the NRCs transfected with three 
mutants compared with nesprin-1α2 WT and GFP only. Scale bar=15µm.











Figure 3.4 Overexpression of nesprin-1 mutants reduced NE staining of lamin 
A/C and SUN2 in NRCs. 
IF showed SUN2 (B) staining was reduced at the NE in the NRCs transfected with three 
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A.          B. 
 
 














Figure 3.5 Nesprin-1 mutants affected the interaction between nesprin-1α2 and 
lamin A/C or SUN2 
GST-tagged WT nesprin-1α2 SR1-6 (equivalent to nesprin-1 giant SR 69-74) and mutants 
were previously generated and shown schematically (A left panel, labelled with *), which 
constructs consisted of 837 amino acids, lacking KASH domain, equivalent to amino acids 
7875-8662 of nespin-1 giant. GST pull-down using either GST-WT or mutant nesprin-1 beads 
showed all three mutants affected binding between nesprin-1 and lamin A/C or SUN2, but not 
emerin (A, B). The binding for each mutant was quantified by densitometry with respect to 
the input material and expressed as a ratio of the value obtained for WT protein. Three 
independent experiments were performed shown as mean±SEM, *P<0.05 using one-way 
ANOVA analysis. Coomassie blue staining gel also showed equal amount of GST-nesprin 1α2 
WT and mutants beads used. (The bindings experiments between nesprin with emerin and 
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A. 















Figure 3.6 Nesprin-1 mutants affected the interaction between nesprin-1α2 and 
lamin A/C 
Reverse GST pull-down by transfecting either GFP-nesprin-1α2 WT or each mutant and using 
either GST-lamin A (amino acids 356-665) (A) or GST-emerin (amino acids 1-176) beads (B). 
The binding for each mutant was quantified by densitometry with respect to the input material 
and expressed as a ratio of the value obtained for WT protein. Three independent experiments 
were performed shown as mean±SEM, *P<0.05 using one-way ANOVA analysis. Coomassie 
blue staining gel also showed equal amount of GST-lamin or emerin beads used. (This 
experiment was done by Chen Li, King’s College London.)
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3.2.5 Nesprin-1 mutants augmented ERK activity in EDMD 
patients 
 
LMNAH222P knock-in and EMD KO mouse models exhibited EDMD and DCM 
phenotypes [194, 195], which is similar to the muscle disorder caused by nesprin-1 
and -2 mutations [3]. Analysis of genome-wide expression profiles in hearts from these 
mice revealed statistically significant differences in expression of genes in the MAPK 
cascades, including ERK and JNK. The hyperactivation of ERK and JNK can be 
rescued by using ERK and JNK inhibitors [207-209, 227, 228]. 
Up to date, there has been no evidence showing nesprin-1/-2 mutations’ 
involvement in the augmentation of MAPK kinase in muscle disease. As we did not 
have access to the DCM patient samples, we started to examine if there were any 
changes of ERK pathway using the HDFs derived from EDMD patients carrying either 
nesprin-1, lamin A/C or emerin mutations. The control HDFs were derived from the 
healthy donors without any muscle defects. These cells were cultured and harvested at 
passage numbers restricted to between 11 and 14, to reduce the culture artefact caused 
by different passage numbers. Immunoblotting showed an increase of ERK1/2 in all 
the EDMD patients compared with other 3 individual controls (Figure 3.7A). The ratio 
of phosphorylated ERK1/2 to the total ERK1/2 was around 2-3 fold higher in EDMD 
patients compared to controls which was quantified with ImageJ through three 
individual experiments (Figure 3.7B). 
In addition, we investigated if there were any changes in ERK pathway 
signalling when one of the major components of the LINK complex, SUN2 was 
depleted. IF showed endogenous nesprin-1 was mis-localised from the NE upon SUN2 
siRNA knock down in human lung fibroblasts (HLFs), indicating SUN2 is 
indispensable for nesprin-1 to target to the NE. Meanwhile, IF staining also showed 
both nesprin-1 and SUN2 were present in mitochondria like organelle in cytoplasm, 
whereas depletion of SUN2 showed some changes of SUN2 and nesprin-1 staining on 
this structure (Figure 3.8A). Moreover, our preliminary WB data showed the SUN2 
depletion was able to induce an increased trend of ERK1/2 phosphorylation (Figure 
3.8B). However, further experiments are required to confirm the aberrant ERK 
pathway caused by SUN2 interference. 
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In summary, these data showed the aberrant activation of ERK1/2 could be 
caused by mutations in genes encoding NE-LINC complex components. 














Figure 3.7 Nesprin-1/Lamin/Emerin mutants identified in EDMD-DCM patients 
showed aberrant activation of ERK pathway 
WB showed that aberrant activation of pERK was observed in human dermal fibroblasts 
derived from EDMD-DCM patients carrying nesprin-1 (V8387L), lamin A/C (R249Q and 
R401C) and emerin (329del59) mutations. Three independent experiments were performed 













Figure 3.8 SUN2 RNA interference caused aberrant activation of ERK pathway 
in human lung fibroblasts 
IF showed knocking down SUN2 led to mis-localised endogenous nesprin-1 at the NE in HLFs 
(A). WB demonstrated SUN2 was efficiently depleted and ERK pathway was preliminarily 
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3.2.6 Aberrant activation of ERK was induced in heart 
tissue derived from nesprin-1 KASH KO mice 
 
The nesprin-1 KASH KO mouse model was generated by Prof. Elizabeth 
McNally in Northwestern University [221].  Litters exhibited EDMD phenotypes at 
the early stage (<32 weeks), and cardiomyopathy associated with CD at late stage (>52 
weeks). Isolated CMs showed elongated nuclear shape with large invaginations of the 
NE, and reduced total amount of heterochromatin. The LINC complex components 
lamin A/C, emerin and SUN2 still localised at the NE, while IP revealed interaction 
between nesprin-1 and SUN2 were abolished, suggesting the SUN-KASH LINC 
complex was disrupted in this model [4, 221]. To further investigate if nesprin-1 
defects lead to an aberrant activation of ERK in nesprin-1 KASH KO mice, heart tissue 
from WT and KASH1 KO mice at early stage (17 week) and late stage (81 week) were 
subjected to WB. The protein lysates demonstrated ERK signalling was significantly 
increased in nesprin-1 KASH KO mouse hearts compared to WT in both early stage 
(<32 weeks) and late stage (>52 weeks) (Figure 3.9A). Quantification by densitometry 
of the ratio of pERK to tERK revealed the KO group raised 2.5- and 3-fold higher than 
WT in early and late group respectively (Figure 3.9B). Of note, ERK activation was 
exacerbated over time, especially in the KO group (Figure 3.9). The findings in KASH 
KO mouse hearts further enhanced the hypothesis that the aberrant activation of ERK 
involved in cardiomyopathy and was induced by nesprin-1 mutants.















Figure 3.9 Nesprin-1 KASH knockout mice showed aberrant activation of ERK 
pathway 
WB showed that augmented pERK activity in the nesprin-1 KASH KO mouse hearts 
compared to WT mouse hearts that were both collected at 17 and 81 weeks. Three independent 
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3.2.7 Nesprin-1 mutants led to abnormal activation of 
ERK1/2 pathway 
 
To determine whether these three novel nesprin-1 mutants could also induce 
aberrant activation of ERK1/2 pathway, GFP-nesprin-1α2 WT and mutants, as well as 
a dominant negative nesprin-1 KASH (DN KASH1), which has previously been shown 
to localise to the NE and displace endogenous nesprin-1 and cause NE defects, were 
transiently transfected into C2C12 [2, 112]. 
Firstly, ERK activation was investigated in the C2C12 cells transfected with DN 
KASH1. IF showed more intense and predominant nuclear fluorescence signal of 
phosphorylated ERK1/2 in myoblasts that overexpressed DN KASH1 than the GFP 
only (Figure 3.10A). The augmented activation of ERK was further confirmed by the 
immunoblotting (Figure 3.10B). 
Next, WT and nesprin-1α2 mutants were all transfected in the C2C12 cells. 
Immunoblotting against the pERK and tERK demonstrated that the ERK activation 
was not altered in cells transfected with nesprin-1α2 WT compared with GFP only, 
suggesting the nesprin-1α2 WT does not perturb the ERK pathway in muscle cells. 
However, the activation of ERK was detected from the cells expressing exogenous DN 
KASH1 or three mutants when compared with nesprin-1α2 WT (Figure 3.11). 
Furthermore, phosphorylated Ets-like transcription factor 1 (pELK1), a 
downstream target of ERK1/2, was examined in H9C2 cardiac myoblasts. 
Consistently, overexpression of the GFP tagged-nesprin-1 mutants and DN KASH1 
increased the expression of pERK1/2 and pELK1 compared with GFP alone or WT 
nesprin-1α2, revealing that the MAPK cascades including ERK and downstream ELK 
were activated by these three novel nesprin-1α2 mutations (Figure 3.12).









Figure 3.10 Nesprin-1 KASH augmented the ERK activities in C2C12 
IF showed more intense pERK staining was presented inside of the nucleus in the C2C12 
myoblasts transfected with DN KASH1 compared with the cells transfected with GFP only, 
suggesting the hyperactivation of pERK (A). The increased protein level of pERK was also 
substantiated by WB (B). Three independent experiments were performed shown as 
mean±SEM, *P<0.05 using Student’s t-tests. (This experiment was done by Chen Li, King’s 
College London.). Scale bar=25µm.














Figure 3.11 Nesprin-1 mutants caused aberrant activation of ERK pathway in 
C2C12 myoblasts 
WB showed overexpression of all three nesprin-1 mutants and dominant negative KASH1 led 
to augmented pERK activity compared with WT nesprin-1. GFP empty vector was used for 
negative control and a dominant negative KASH1 construct as a positive control. Three 
independent experiments were performed shown as mean±SEM, *P<0.05 using one-way 
ANOVA analysis. 




































Figure 3.12 Nesprin-1 mutants caused aberrant activation of ELK pathway in 
H9C2 cells 
Overexpression of three nesprin-1 mutants led to increased pERK1/2 and pELK1 activities in 
H9C2 cells (n=1). (This experiment was done by Chen Li, King’s College London.)
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3.3 Discussion 
 
In this study, three novel SYNE-1 missense mutations (R8272Q, S8381C and 
N8406K) were identified in DCM patients. Overexpression of the GFP tagged nesprin-
1α2 WT and mutants, the nuclear morphology was perturbed in the cells transfected 
with the nesprin-1α2 mutant. Binding partners lamin A/C and SUN2 were also mis-
localised from the NE, and GST pull-down indicated the binding affinity between 
nesprin-1α2 and lamin A/C, SUN2 was reduced by nesprin-1 mutants. This part of data 
suggested the nesprin-1α2 mutations (R8272Q, S8381C and N8406K) caused NE-
LINC complex disruption. In addition, the disrupted LINC complex induced by the 
three novel nesprin-1α2 mutations also caused hyperactivation of MAPK cascades 
(ERK1/2), indicating perturbed mechanotransduction. 
3.3.1 Nesprin-1 mutations compromised structural and 
functional integrity of nesprin proteins 
 
The three novel missense mutations (R8272Q, S8381C and N8406K) identified 
in DCM patients in this study resided within the unique adaptive domain (AD) region 
and the SR72 at the C-terminus of the nesprin-1 protein [22, 23] (Figure 3.1A). The 
SR72 and AD are extremely well conserved [23, 29]. It would therefore be reasonable 
to postulate that changes in these regions would not only impact the local structure, 
but also the function of the region. 
3.3.1.1 Mutants S8381C and N8406K 
 
The S8381C and N8406K mutations localised within SR72 on nesprin-1 giant, 
both are regions where uniform structure is not only critical but also conserved [23]. 
A serine was replaced with a cysteine in S8381C at the loop of α-helix structure (Figure 
3.13). Serine is a hydroxyl-containing neutral polar residue, while cysteine is sulphur-
containing non-polar hydrophobic residue [248]. Thus the cysteine may form the new 
hydrophobic core of the SR [6], leading to a completely disrupted secondary α-helix 
structure. 
In N8406K, an asparagine was replaced with a lysine at the α-helix (Figure 3.13). 
Asparagine is a neutral polar residue and uncharged, whereas lysine is a basic polar  
















Figure 3.13 Computer models showed the structure of nesprin-1 giant SR72 
and the localisations of mutations within this region 
Two nesprin-1α2 mutations localised at the SR72 of nesprin-1 giant, equivalent to the SR4 in 
the nesprin-1α2 isoform. The S8381C localised at the loop at the adjacent of the two α-helices, 
while the N8406K localised at the α-helix (The Ribbon representation of nesprin-1 giant SR72 
was generated using Modeller 9v2 and nesprin-1 mutations were labelled according to their 
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residue with positive charge [248]. They are functionally similar as polar residues, but 
charged lysine is more likely to participate in hydrogen bonding, thus changing the 
conformation of secondary α-helix structure. 
These exchanges of amino acids may lead to a severe disruption of secondary 
structure, and ultimately tertiary structure in nesprin proteins. Another alternate 
possibility is that the mutations, ultimately disrupting SR structure, have a knock-on 
effect on AD structure. As the AD can adapt its conformation to suit adjacent 
structures, the convolution of SR72 in nesprin-1 may lead to an altered AD structure 
[23]. This may affect the ability of nesprin-1 to maintain structural integrity to the 
nucleus via both ONM and INM isoforms and impact the ability of nesprin-1 to bind 
either emerin or lamin A/C. Comparing the S8381C and N8406K mutations, the serine 
to cysteine mutant (S8381C) has more dramatic changes in amino acid properties 
compared to the asparagine to lysine mutant (N8406K). This may help to explain the 
more convoluted nuclear morphology and severe impacts on their binding partners 
lamin A/C, as well as augmented ERK pathway observed in S8381C mutation. 
3.3.1.2 Mutant R8272Q 
 
The R8272Q mutation localised within an AD region [22, 23, 29]. The central 
domain has relatively little secondary structure, but strongly stabilised SRs within 
and/or among nesprin isoforms by increasing their overall helicity, stability and 
cooperativity of folding [23]. In R8272Q, an arginine was replaced with a glutamine. 
Arginine is a strongly basic polar residue and suitable for binding to molecules with 
many negative charges on its surface, while the glutamine is a neutral polar residue 
[248]. The mutations in the AD region may not have the same structural implications 
as if they were in an SR. However, the AD is able to stabilise the SRs and the whole 
nesprin-1 structure. Therefore, the R8272Q mutation may disrupt the AD regulation 
of nesprin-1 structural conformation and dimerization, and impact the function of this 
protein.
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The R8272Q mutation may have a more direct consequence on a nesprin binding 
partner KLC-1/2 [114]. Nesprin-2 has shown to bind with microtubule motor protein 
KLC-1/2 though a ‘LEWD’ at the AD region [114]. As nesprin-1 and -2 are highly 
homologous at this region, R8272Q localises just several amino acids upstream this 
binding motif [114]. Therefore, KLC-1/2 binding is likely to be negatively affected by 
nesprin-1 mutations especially R8272Q. We will further discuss the impact of the 
interaction between nesprin-1 mutations and KLC-1/2, as well as their functions in 
regulating nuclear migration and positioning in next chapter. 
3.3.2 Disrupted NE-LINC complex was caused by the 
nesprin-1 mutants 
 
Mutations in the LMNA gene, encoding A-type lamins, cause a number of 
different tissue specific laminopathies, including the muscle specific disorder: DCM 
and EDMD [249]. The molecular pathogenesis of these diseases is unknown but in 
some cases, may be related to disruption of the NE-LINC complex. Mice lacking A-
type lamins display phenotypes that are reminiscent of human muscular dystrophies 
and cardiomyopathies [250]. CMs derived from homozygous LMNA KO mice are 
characterised with grossly misshapen cell nuclei with clumping of peripheral 
heterochromatin, disorganised nesprin-1α and actin filaments, suggested a structurally 
weakened NE [250, 251]. MEFs from LMNA null mice were subjected to mechanical 
strain, and showed the increased nuclear deformation, defective mechanotransduction, 
and impaired viability due to lose of the intact NE-LINC complex [214]. Mutations in 
both nesprins and SUN1/2 have also been implicated in EDMD-DCM, whereby 
mutants cause abnormal localisation of the LINC complex proteins including lamin, 
emerin and SUN, and disrupted nesprin/lamin/emerin/SUN interactions, leading to 
defects in nuclear morphology and nuclear-cytoskeletal coupling [3, 4, 86, 87]. 
Furthermore, the disruption of endogenous LINC complexes by recombinant DN 
KASH constructs of nesprins -1, -2 and -3 also causes a significant loss of mechanical 
stiffness [2, 112, 178]. 
The three nesprin-1 mutations (R8272Q, S8381C and N8406K) identified in this 
study has altered protein structural properties, changed the associations between 
nesprin SRs and lamin A/C at the INM (for nesprin-1α2) or SUN proteins at the ONM 
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(for nesprin-1α2 and -1 giant isoforms), leading to nuclear deformation and uncoupled 
NE-LINC complex. 
Interestingly, the R8272Q mutant was able to bind lamin A at comparable levels 
to the WT nesprin-1, in contrast to weak binding to lamin C. Our current understanding 
of the interactions between nesprins and lamin A and lamin C remains incomplete. 
HDFs from limb-girdle muscular dystrophy patients carrying homozygous LMNA 
mutants Y259X which led to absence of both lamin A and lamin C. In those cells, 
nesprin-1α exhibited aberrant localisation in the ER, however it can be restored to the 
NE by transfection either lamin A or lamin C [252]. Another study showed in normal 
skin where lamin A/C is differentially expressed, strong nesprin-2 expression was 
found in all epidermal layers, including the basal layer where only lamin C is present, 
indicating that nesprin was able to localise properly dependent on lamin C protein only 
[253]. Altered ratios of lamin A to lamin C has been shown in some types of 
laminopathies [254], the dynamic and aberrant binding of nesprin-1 with lamin A or 
lamin C requires further investigation. 
We did not observe a defect in binding between nesprin-1 mutants and emerin, 
which is consistent with the notion that mutations in emerin are primarily associated 
with EDMD rather than DCM. Moreover, the nesprin-1α can bind tightly the emerin, 
and the binding affinity is relatively much higher than the binding with lamin A/C 
[61]. Overexpression exogenous nesprin-1α2, including WT, may dislodge 
endogenous nesprin from the NE with tightly bounded emerin together or the excessive 
overexpression of nesprin in the cytoplasm may compete for binding with the emerin 
[35]. Therefore, either exogenous nesprin-1α2 WT or mutants, will result in mis-
localisation of emerin. 
The data above support possible involvement of LINC complex disruption in the 
pathogenesis of DCM. Future studies on structure/flexibility of the SRs that are 
predominantly present in the muscle-specific nesprin isoforms will be required to 
confirm this hypothesis. 
3.3.3 Augmented activation of MAPK cascade was 
associated with disrupted NE-LINC complex 
 
Several studies on LMNAH222P knock-in mice have indicated activation of 
MAPKs in the development of DCM and EDMD [224]. In LMNAH222P mice, pERK1/2 
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and pJNK are induced and activate a series of downstream target genes, including bcl-
2, Elk1, junD and c-Jun in CMs from the mouse hearts as well as skeletal muscle tissue 
[194]. Transcription factors encoded by these genes can in turn regulate the expression 
of additional genes, including those encoding proteins involved in sarcomere structure, 
cardiomyofibre organisation and other aspects of heart function [194, 204, 205]. The 
aberrant ERK activity is further proved in other cell lines such as COS7 and HeLa 
which were transfected with LMNAH222P, or depletion of lamin A/C in C2C12 and Hela 
cells, as well as in ex vivo fibroblasts from EDMD/DCM patients carrying lamin A/C 
mutations [194, 206, 255]. Using MAPKs inhibitor, fibrosis can be reduced, heart 
function restored, increased the skeletal strength, and successfully rescue the DCM 
and EDMD phenotypes in LMNAH222P mice [207-209]. Those findings indicate that 
the activation of MAPK signalling could be a cornerstone in the development of DCM. 
Our data showed that enhanced pERK activity is also observed from fibroblasts 
derived from EDMD-DCM patients, the heart tissue derived from nesprin-1 KASH 
KO mice, and nesprin-1 mutants transfected C2C12 and H9C2 cells, suggesting that 
nesprin and lamin A/C function through a similar pathway and trigger up-regulation 
of ERK. Moreover, the hyperactivation of pERK was exacerbated with the increased 
age in nesprin-1 KASH KO mouse hearts, while the clinical cardiomyopathies 
symptoms were deteriorating [4], indicating the dynamic changes of the ERK pathway 
is associated with the severity of cardiomyopathies.  
In addition, there is evidence highlighting that nesprin-2 directly interacts with 
ERK1/2 via their SRs and recruit them to PML NBs to regulate the cell cycle and DNA 
damage response in VSMCs [42, 210]. Evidence also suggests that lamin A/C have an 
altered biochemical interaction with ERK1/2 to regulate the activator protein 1 (AP-
1), which is a transcription factor that regulates gene expression and key cellular 
processes [109, 256]. Thus, future work will examine how NE proteins regulate ERK 
activity potentially via influencing interactions between A-type lamins, NE proteins 
and components of MAPK cascades, as well as nuclear translocation of activated 
MAPKs.  
Of note, there is an interesting finding in addition to augmented ERK activities 
in HLFs with deletion of SUN2: IF staining showed endogenous nesprin-1 and SUN2 
localise at mitochondria like organelle in cytoplasm and deletion of SUN2 may led to 
perturbed structure of this organelle. However, it still need to be further investigated 
by using Mito Tracker to show if the structural integrity of mitochondria is affected. 
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Moreover, this finding is in agreement with previous studies that ANC-1 (the ortholog 
of nesprin in C. elegans) and Uth1p and Sun4p (the ortholog of SUN protein in 
Saccharomyces cerevisiae) both localise at mitochondria whereas ANC-1 mutants 
display defective mitochondrial positioning [182, 257]. Further experiments are 
needed to characterise: 1) if endogenous SUN2 also localise at mitochondria in 
mammalian cells similar to endogenous nesprin-1 [3]; 2) the dysfunction of LINC 
complex on the structure and function of mitochondria, especially in muscle cells. 
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3.3.4 Summary 
 
Novel nesprin-1 mutations identified from the DCM patients have a significant 
impact on nuclear structural integrity and lead to augmented cell signalling: 
1) Structural disruption: alteration of nuclear morphology, mis-localisation of 
its NE-LINC complex binding partners lamin A/C and SUN2 and reduction 
of their interactions, leading to disrupted NE-LINC complex in vitro; 
2) Aberrant cell signalling: augmented ERK activation caused by nesprin-1 
mutants in vitro and ex vivo which may be cause by the direct impact of NE 
structural disruption or impaired mechanotransduction; 
3) Nesprin-1 was previously identified as a VSMCs differentiation marker 
[15], and evidence has shown it participates in muscle cell differentiation 
[35, 37, 190]. Therefore, the effects of nesprin-1 mutations on nuclear 
migration/position and gene regulation during myogenesis will be further 
characterised in the next chapter. 
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Nesprin-1 was first identified as a VSMC differentiation maker. A 2.1kb cDNA 
clone, (1RA1) was identified from the differentiated rat aortic VSMCs, which further 
helped to identify the human ortholog of 1RA1, which was renamed as nesprin-1 [1]. 
The identification of nesprins indicated that they are tightly related to the 
differentiation process. 
Nesprins generate multiple isoforms by extensive alternative initiation, 
termination and splicing. Those isoforms contain different numbers of SRs, vary in 
size and are with or without KASH domains and CH domains. They exhibit tissue 
specific expression profiles [34]. For example, in muscles, nesprin-1α2 and nesprin-
2α1 are highly expressed in both heart and skeletal muscle, nesprin-2β is only highly 
expressed in skeletal muscle, whilst nesprin-2Ɛ2 is heart specific [34]. Nesprin-1 is 
shown to be concentrated in synaptic nuclei postnatally in the NMJ. It remains 
synaptically enriched following muscle fibre degeneration and/or regeneration, and 
presents at high levels in the central nuclei of dystrophic myotubes [13]. In addition, 
nesprin-1α can bind to muscle A-kinase anchoring protein (mAKAP) to control the 
Ca2+ release channel of the sarcoplasmic reticulum within CMs [258]. The data 
suggests essential roles of nesprins in muscle differentiation and function. 
4.1.1 Nesprin and myoblast differentiation 
 
In normal conditions, muscle cell differentiation involves a series of steps: 
myoblasts enter a quiescent phase where myoblast fusion starts; myotubes are created 
by fused myoblasts, in which nuclei are positioned at regular intervals; then, the 
myotubes undergo a phenotypic change, characterised by myofibril assembly [259, 
260]. The differentiation process also requires the sequential activation of myogenic 
regulatory factors (MRFs), such as Myogenic factor 5 (Myf5), Myoblast determination 
protein (MyoD), myogenin and MRF4. During development, up-regulation of MyoD 
and/or Myf5 drives myogenic cells to become myoblasts. Proliferating myoblasts 
withdraw from the cell cycle to become terminally differentiated myocytes that 
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express myogenin and MRF4, and subsequently muscle-specific genes such as myosin 
heavy chain (MHC) and the muscle creatine kinase (MCK) [260-262]. 
The dynamic change of small and giant nesprin isoforms has been shown to be 
involved in muscle differentiation. In human myoblasts, the expression of giant 
nesprin-1 is present and nesprin-1α2 is relatively very low. During myogenesis, 
nesprin-1α2 is massively upregulated and this is accompanied with a two-fold increase 
in nesprin-1 giant [37]. In vitro differentiation models, nesprin-2 isoforms have been 
shown to re-localise from the NE of C2C12 myoblasts to the sarcomere of myotubes 
[35]. Knocking down nesprin-1 prevents the mouse embryonic stem cells from 
differentiating into CMs [158]. In vivo, during the transition from immature to mature 
muscle fibres, nesprin-2 giant partly replaces nesprin-1 giant at the NE and short 
isoform nesprin-1α2 becomes dominant [38]. 
The LINC complex associated EDMD and DCM disorders have been implicated 
with the defects of myogenesis. The LMNA R453W mutation from EDMD patients is 
shown to severely impair C2C12 myoblast differentiation with a reduction of 
myogenin expression [263, 264]. Myoblasts from EDMD carrying compound 
heterozygous SUN1 mutations exhibit accelerated differentiation, both in terms of the 
total numbers of myotubes and the numbers of nuclei per myotube [87]. In another 
case, myoblasts from the EDMD patients carrying nesprin-1 or -2 mutations show the 
impaired differentiation with less well defined sarcomeric structures and diffusely 
distributed nesprin-1 and -2 [3]. In summary, those mutations from EDMD carrying 
either nesprin, lamin A/C or SUN perturb muscle differentiation, indicating the NE-
LINC complex plays an important role in myogenesis. Malfunction in the NE-LINC 
complex caused by overexpressed DN KASH2 or DN SUN1 perturbed C2C12 
differentiation with dysregulated the MRFs such as MyoD, myogenin and MHC [190]. 
Those data further support that the NE-LINC complex participates in 
mechanotransduction and gene regulation during muscle differentiation. More studies 
regarding to the underlying mechanism are required to help us to understand the 
pathogenesis of muscular dystrophies. 
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4.1.2 Nesprin interacts with microtubule motor protein 
kinesin-1 at the NE 
 
Mis-positioned myonuclei are not only a symptom of muscle disease but also are 
a direct cause. In healthy and mature muscle fibres, myonuclei are spaced throughout 
the periphery of the muscle fibre with even distance between nuclei. However, in 
diseased muscles, the nuclei are often clustered within the centre of the muscle cell 
[265]. NE-LINC complex has been discovered to participate in nuclear movement via 
connecting the NE to the microtubule to maintain the position of the nucleus and to 
move it during cell activities such as the cell migration and differentiation [180, 181]. 
Indeed, recent data have shown that the C-terminal region of nesprin-2 mediates 
myonuclear positioning by attaching the microtubule network to the NE during 
embryonic muscle development and cell migration [114]. These interactions occur via 
the microtubule motor proteins, dynein and kinesin, the latter being a heterotetramer 
of two KHC subunits -Kif5A, Kif5B, or Kif5C- and two KLC-1/2 subunits. Nesprin-
2 is shown to interact with KLC-1/2 at the ONM via a newly identified four-residue 
tryptophan-acidic (W-acidic) “LEWD” binding motif within an adaptive domain (AD) 
at its C-terminus, which is present in all muscle-specific isoforms [22, 23, 114]. 
Disruption of the LINC complex with a dominant-negative nesprin-2 KASH impairs 
the recruitment of kinesin-1 to the NE and induces nuclear aggregation in myotubes 
[188]. As both nesprin-1 and -2 are highly conserved in this C-terminal region, it is 
likely that nesprin-1 may also mediate the nesprin/KLC interaction via the “LEWD” 
binding motif but so far this has not been tested. The three novel nesprin-1 mutations 
localised near the “LEWD” binding region, notably R8272Q which was only 11 amino 
acids upstream of the binding motif (Figure 4.1)



















Figure 4.1 Nesprin-1 mutations were identified and localised at the binding 
region with microtubule motor protein KLC-1/2 
Nesprin-1 and -2 are highly homologous at the “LEWD” binding motif, which suggests that 
nesprin-1 may interact with microtubule motor protein kinesin-1 through the same binding 
region as shown in nesprin-2 (A). All three mutants were close to the KLC binding motif 
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In this chapter, I will set up to investigate: 
1) If nesprin-1 mutants perturb the nuclear migration and compromise the 
differentiation process in C2C12 mouse myoblast differentiation model 
in vitro; 
2) The mechanism of nesprin-1 in regulating nuclear distribution: If 
nesprin-1α2 WT binds with microtubule motor protein KLC-1/2 and if 
novel nesprin-1 mutations perturb their binding; 
3) Investigate the effect of nesprin-1 mutants during cardiac development 
in zebrafish embryos in vivo. 
 
4.2 Results 
4.2.1 Expression levels of endogenous nesprin-1α and 
MRFs were upregulated during myogenesis 
 
The C2C12 mouse myoblast cell line is a reliable immortal one, which has the 
capacity to form myotubes and has been widely used as a model of skeletal muscle 
development [266]. C2C12 myoblasts were cultured in the flask until they reached 
90% confluency, then were induced to differentiate with low serum differentiation 
medium. Small and short myotubes can be seen by day 2 and the number and size of 
myotubes quickly increased during the process. By day 6, the multi-nucleated 
myotubes were well formed over the whole culture dish (Figure 4.2). 
Using this model, firstly, the expression level of endogenous nesprin-1, MRFs 
(MyoD and myogenin), as well as the skeletal muscle marker MHC during the 
myoblast differentiation were examined. The differentiated muscle cells were 
collected from days 0, 2, 4 and 6 and extracted cell lysates were subjected to 
immunoblotting. WB showed that endogenous expression levels of nesprin-1α 
(including both 1α1 and 1α2) increased from day 2, followed by a rapid increase from 
day 2 to day 4, then gradually reached the highest level at day 6 (Figure 4.3). 
Myogenin, which was upregulated in differentiated myocytes, peaked at day 2 and 
then decreased when myocytes started to fuse together (Figure 4.3). MHC, a typical 
marker of terminally differentiated muscle cells, initially increased at day 2, and 
reached a 7-fold high at day 6 (Figure 4.3). 





















Figure 4.2 C2C12 myoblasts formed the myotubes within 6 days 
Myoblasts were grown on the uncoated flask with the normal culture medium until they reach 
90% confluency. Then they were stimulated with a low serum medium to initialise the 
differentiation. The myotubes started to form from day 2 and were well formed at day 6. Scale 
bar=200µm.
















Figure 4.3 Protein expression levels of nesprin-1α and MRFs were upregulated 
during C2C12 myoblast differentiation 
Protein lysates were collected at different differentiation time points. WB showed endogenous 
expression levels of nesprin-1, myogenin and MHC increased during myotube formation (A, 
B). The nesprin-1α protein level was highest at day 6, whereas myogenin was highest at day 
2, and MHC was detected from day 2 and increased until day 6. Three independent 
experiments were performed shown as mean±SEM, *P<0.05 using Student’s t-tests.
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RNA levels of MRFs were evaluated by qPCR. MyoD level was highest at day 
2, and reduced to basal level at day 6 (Figure 4.4); Myogenin rapidly increased at the 
day 2, then reduced until day 6 (Figure 4.4); MHC kept increasing from day 2, and 
was massively upregulated until the termination time point day 6 (Figure 4.4). 
Both WB and qPCR indicated the C2C12 muscle differentiation model was 
successfully generated under these experiment conditions. The myogenesis process 
can be monitored through the individual MRF such as MyoD, myogenin and MHC at 
each time points. In order to investigate whether the nesprin-1 mutants affect 
myogenesis, the optimised time points were chosen as following: day 2 for MyoD and 
myogenin, and day 6 for MHC at early and late differentiation respectively for 
investigation in further experiments. 
4.2.2 Generating retroviral constructs of nesprin-1α2 WT, 
mutants and KASH 
 
To investigate whether the novel nesprin-1 mutants could disrupt muscle cell 
differentiation, we generated retroviral constructs of nesprin-1α2 WT, mutants and DN 
KASH1 to achieve the high transduction efficiency and stable expression of nesprin-1 
in C2C12 cells. The strategy of generating retroviral constructs was following three 
major steps. 
First, V5-tagged nesprin-1α2 WT was amplified from the previously generated 
‘GFP-nesprin-1α2 WT’ construct, by using a V5 tagged forward primer containing 
NotI site from 5’ end of nesprin-1α2 and a reverse primer containing EcoRI site 
targeted to 3’ end of nesprin-1α2 (Figure 4.5A); V5-nesprin-1 KASH was amplified 
by using another V5 tagged forward primer containing NotI site that started from the 




























Figure 4.4 mRNA expression levels of MRFs were upregulated during C2C12 
myoblast differentiation 
qPCR showed endogenous expression levels of MyoD, myogenin and myosin increased during 
myotube formation. MyoD and myogenin peaked at day 2; MHC was detected from day 2 and 
increased until day 6. Three independent experiments were performed shown as mean±SEM, 






















































Figure 4.5 V5-tagged nesprin-1α2 and KASH1 were amplified by PCR 
V5-tagged nesprin-1α2 WT was amplified from the previously generated ‘GFP-nesprin-1α2 
WT’ construct, via using V5 tagged forward primer from 5’ end of nesprin-1α2 and a reverse 
primer targeted to 3’ end of nesprin-1α2 (A); V5-tagged nesprin-1 KASH was amplified by 
using another V5 tagged forward primer that started from the KASH domain and the same 
reverse primer as WT (B).
Spectrin repeat KASH Calponin homology domain 
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Following this, the amplified PCR products were inserted into pGEM T-easy 
vectors (Figure 4.6 A-C). The T-easy vector has ‘A’ and ‘T’ overhangs, which is the 
best backbone to readily ligate with PCR products with an extra ‘T’ or ‘A’. Mutants 
R8272Q, S8381C and N8406K were generated by site directed mutagenesis using the 
V5-nesprin-1α2 WT as a template. The successful ligations and colony growth were 
confirmed by unique restriction enzyme digestion. There were three clear bands 
present on the agarose gel representing V5-nesprin-1α2 WT and mutants (digested by 
NotI, EcoRI and XmnI) (Figure 4.7A). Two clear bands that estimated sizes indicated 
V5-nesprin-1 KASH and T-easy vector on the gel (digested by NotI and EcoRI) 
(Figure 4.7B). All the constructs in T-easy vectors were subjected to DNA sequencing 
for confirmation. 
Finally, V5-tagged nesprin-1α2 WT, mutants (R8272Q, S8381C and N8406K) 
and KASH in T-easy vector were digested using the restriction enzyme (Figure 4.6D). 
The right size bands corresponding to nesprin-1α2 WT, mutants and KASH were 
extracted from the agarose gel, then ligated with retroviral MIG vectors (A gift from 
Prof. Peter Zammit’s lab, King’s College London [237]) (Figure 4.6E). The MIG 
vector was modified from the retroviral backbone pMSCV-puro (Clontech, Mountain 
View, CA), in which the puromycin selection gene was replaced with eGFP to create 
pMSCV–IRES–eGFP. This served as the retroviral control vector and eGFP as a 
reporter for retroviral infection. The insertion site of nesprin-1 fragments was just 
before IRES, to form pMSCV-nesprin-IRES-eGFP, thus V5-tagged nesprin-1α2 
WT/mutants/KASH and GFP would be expressed under the same promotor as 
independent proteins due to the ‘IRES’ sequence. The successful insertions were 
confirmed by restriction enzyme digestion using unique enzymes NotI and EcoRI. 
MIG vector was shown on the gel with 6000bp size, while V5-nesprin-1α2 and mutants 
were shown with the 3000bp (Figure 4.8A & 4.8B) and KASH was around 300bp 















Figure 4.6 Strategy of generating retroviral nesprin-1α2 WT and mutants’ 
constructs 
V5-tagged nesprin-1α2 WT and KASH domain were amplified (A), then inserted into pGEM 
T-easy vectors by A/T overhang (B, C). Mutants were generated by the site directed 
mutagenesis using the V5-nesprin-1α2 as a template. The V5-nesprin-1α2 WT/mutants/KASH 
were extracted from the T-easy vectors by restriction enzyme digestion (NotI, EcoRI and 
XmnI for V5-nesprin-1α2 WT/mutants, NotI & EcoRI for V5-nesprin-1α2 KASH) (D), then 

































Figure 4.7 Generation of V5-tagged nesprin-1α2 WT, mutants and KASH 
constructs using pGEM T-easy vectors 
V5-tagged nesprin-1α2 WT was amplified from the previously generated ‘GFP-nesprin-1α2 
WT’ construct, by using V5 tagged forward primer containing NotI site from 5’ end of nesprin-
1α2 and a reverse primer containing EcoRI site targeted to the 3’ end of nesprin-1α2; V5-
nesprin-1 KASH was amplified, by using another V5 tagged forward primer containing NotI 
site which started from the KASH domain and a reverse primer same as the one for WT, then 
were inserted into pGEM T-easy vectors. Mutants were generated by site directed mutagenesis 
using the V5-nesprin-1α2 WT as a template. Successful ligations were confirmed by unique 
restriction enzyme digestion (NotI, EcoRI and XmnI for V5-nesprin-1α2 WT/mutants, NotI & 
EcoRI for V5-nesprin-1α2 KASH). There were three clear bands present on the agarose gel, in 
which the 3000bp band represented the V5-nesprin-1α2 WT and mutants (A). Two clear bands 
in which the 300bp represented the V5-nesprin-1 KASH (B). All the constructs were subjected 







































Figure 4.8 Generation of V5-tagged nesprin-1α2 WT, mutants and KASH 
constructs using retroviral vectors 
V5-tagged nesprin-1α2 WT, mutants and KASH were extracted from the pGEM T-easy 
vectors, then ligated with retroviral MIG vector digested by NotI and EcoRI. The successful 
insertions and colonies were confirmed by the restriction enzyme digestions using NotI and 
EcoRI. MIG vector was shown on the gel with 6000bp size, while V5-nesprin-1α2 and mutants 
were shown as the 3000bp and KASH was around 300bp. All the constructs were subjected to 








4.2.3 Infection of C2C12 myoblasts with retroviral nesprin-
1α2 WT, mutants and KASH 
 
The retroviral constructs of V5-nesprin-1α2 WT, mutants and KASH, together 
with an ecotropic packaging plasmid (RV helper), were transiently co-transfected into 
HEK 293T cells to produce non-replicating retroviruses (RVs), and the supernatants 
were collected 48, 60 and 72 hours after infecting the C2C12 myoblasts [237]. The 
infected cells were purified by Fluorescence-Activated Cell Sorting (FACS) machine. 
The uninfected cells served as a negative control, and the cells infected with MIG only 
(GFP only) served as the selective marker. As the infection efficiency could be various 
among different cells, we chose the highest fluorescence intensity range from the MIG 
only populations as the threshold to select the cells infected with nesprin-1 RVs. The 
RVs transduction efficiency was as high as 90%, but only the cells expressed similar 
intensity of GFP were selected and used in subsequent muscle cell differentiation 
experiments (Figure 4.9). 
IF showed V5-tagged WT nesprin-1α2, three mutants (R8272Q, S8381C, 
N8406K) and KASH1 were present at the NE of the infected myoblasts. GFP localised 
throughout the whole cell, and served as a reporter for retroviral infection (Figure 
4.10). 
4.2.4 Nesprin-1 mutants led to defects in myotube 
formation 
 
Efficient differentiation of C2C12 cells transduced with GFP alone (MIG only) 
or nesprin-1α2 WT was observed, with many multinucleated myotubes formed within 
6 days. However, more single myoblasts and fewer myotubes were observed in the 
cells transduced with either nesprin-1α mutants or KASH1 (Figure 4.11). 
The fusion index that represent the percentage of nuclei incorporated into MHC 
positive multinucleated cells vs. the total number of nuclei, was used to quantify 
myotube fusion. In cells overexpressing nesprin-1α2 WT or MIG only, the fusion index 
was similar at around 50%. However, a significant reduction of fusion index was 
observed in cells transduced with the mutants, in particular, R8272Q and N8406K, as 
well as KASH1 when compared to WT and MIG only (Figure 4.12A). Further analysis 
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to assess the size of myofibers by dividing the MHC positive populations into 4 groups 
(1-5 nuclei, 6-10 nuclei, 11-15 nuclei and >15 nuclei) was performed[263]. 
Small sized myotubes (1-5 nuclei/each myotube) were increased in all mutants 
and KASH1, accompanied with a reduction of larger size myotubes (6-10 nuclei/each 
myotube) compared to WT (Figure 4.12B). These findings revealed that myotubes 
expressing nesprin-1 mutants had a reduced capacity to form myotubes, the majority 























Figure 4.9 C2C12 myoblasts were highly infected with retroviral nesprin-1α2 
WT, mutants and KASH1 
C2C12 myoblasts were infected with retroviral nesprin-1α2 WT/mutants/DN KASH1 
respectively. Fluorescence-Activated Cell Sorting (FACS) was performed to purify the 






Figure 4.10 Exogenous nesprin-1 WT/mutants/KASH1 localised at the NE in 
C2C12 myoblasts. 
IF showed that exogenously expressed V5-tagged WT-1α2, mutants and DN KASH1 were 
localised at the NE. V5 staining (red) indicated the localisation of nesprin-1α2 WT, mutants 
(R8272Q, S8381C, N8406K), as well as KASH1. GFP (green) was expressed as a reporter for 











Figure 4.11 Nesprin-1 mutants led to fewer myotube formation 
Upon differentiation, fewer multinucleated myotubes (red) were observed in the cells infected 
with three mutants and DN KASH1 compared with the C2C12 cells infected with GFP alone 



















Figure 4.12 Nesprin-1 mutants caused defects in myoblast differentiation 
The fusion index was reduced in cells infected with the mutant R8272Q and DN KASH1 
compared with 1α2 WT (A), more than 600 nuclei for each clone were counted under 
microscopy (63x objective) at day 6, three independent experiments were performed for each 
clone. Further analysis of the MHC positive multinucleated populations revealed that 
myotubes expressing nesprin-1 mutants contained more population of myotubes with fewer 
nuclei compared to the controls (B). Three independent experiments were performed shown 


















































4.2.5 Nesprin-1 mutants led to dysregulation of MRFs 
 
Cell lysates were extracted every two days the during differentiation process for 
analysis of protein and RNA levels of MRFs. The levels of myogenin and MHC were 
dramatically reduced in cells transduced with the three mutants, particularly R8272Q 
and KASH1 when compared with nesprin-1α2 WT at day 2 and 6 respectively (Figure 
4.13A-C). qPCR also demonstrated that MyoD was significantly reduced in cells 
transduced with KASH1 at Day 2 (Figure 4.13A). It is noteworthy that RNA 
expression levels of myogenin and MHC and protein level of MHC was elevated in 
the WT compared with MIG, indicating nesprin-1α2 WT promoted myoblast 
differentiation during the process of myotube formation, whereas the mutants reduced 
these effects. 
4.2.6 Nesprin-1α WT interacted with KLC-1/2 and nesprin-1 
mutants disrupted this binding 
 
Recent data showed that nesprin-2 interacts with KLC-1/2 via a conserved 
“LEWD” motif at the C-terminus of nesprin-2 [114]. This motif is also present in 
nesprin-1 (Figure 4.1) [22, 23, 114], suggesting nesprin-1 may also bind to KLC-1/2 
and be involved in connecting the nucleus to the microtubule network and therefore 
plays a role in myonuclear positioning. 
Previous data has shown small nesprin isoforms including nesprin-1α, localise 
at the INM to bind with lamin A/C and emerin at the NE [35, 61]. However, there was 
no direct evidence showing if small nesprin-1 isoforms, particularly nesprin-1α2 
localise only at the INM or at both INM and ONM. C2C12 cells expressing the V5-
tagged nesprin-1α2 WT were permeabilized with either digitonin (only breaking down 















Figure 4.13 Nesprin-1 mutants caused dysregulation of MRFs during 
differentiation. 
qPCR and WB showed that nesprin-1 mutant R8272Q and dominant negative-KASH1 caused 
significant reduction of myogenin (A, B) and MHC (A, C) levels at DM day 2 and day 6 
respectively, qPCR also showed that dominant negative KASH1 caused significant reduction 
of MyoD (A) levels at DM day 2. All were normalised to GFP, three independent experiments 
were performed shown as mean±SEM. *P<0.05:compared with WT; #P<0.05: compared with 
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Upon digitonin treatment, IFs showed nesprin-1α2 can be detected at the NE, whereas 
INM protein SUN2 was unable to be detected (Figure 4.14A). When permeabilized 
with NP40, both nesprin-1α2 and SUN2 could be detected at the NE (Figure 4.14B), 
suggesting nesprin-1α2 localises at the ONM in addition to its previously identified 
INM localisation.  
Then, we tested the binding of nesprin-1α2 and KLC-1/2 in vitro. GFP-1α2 WT 
or nesprin-1α2 LEAA (mutated WD/AA within the LEWD motif, generated by our 
collaborator Dr. Sue Shackleton’s lab in University of Leicester) were co-expressed 
with Flag-tagged KLC-2 WT (a dominant light chain isoform in muscle) or the KLC-
2 N287L mutant, previously shown to disrupt nesprin-2/KLC binding [114] in U2OS 
cells. IP and WB showed that nesprin-1α2 could efficiently bind to KLC-2, and this 
binding was disrupted by either nesprin-1 LEAA (mutated WD/AA within the LEWD 
motif) or the KLC-2 N287L mutant [114] (Figure 4.15). We then tested the nesprin-1 
mutants using this system and found that the R8272Q mutant which contains the 
closest mutation to the binding motif, had significantly reduced binding to KLC-2 
compared with nesprin-1α2 WT, while the S8381C mutant appeared to enhance KLC-
2 binding (Figure 4.15). 
4.2.7 Nesprin-1 mutants affected the binding between 
nesprin-1 and KLC in both myoblasts and myotubes 
 
Next, I tested whether these mutants affected nesprin-1/KLC-1/2 binding during 
muscle cell differentiation. Firstly, WB showed that, similar to nesprin-1α, the 
endogenous expression level of KLC-1/2 increased during myoblast differentiation 
(Figure 4.16). In C2C12 myoblasts, GST pull-down assays further confirmed that 
nesprin-1α2 WT efficiently binds to KLC-1/2, and this binding was disrupted by the 
mutated LEWD motif-LEAA. In addition, the R8272Q mutant had significantly 
reduced binding to KLC-1/2 compared with WT in C2C12 cells, while the S8381C 
showed increased binding with KLC-1/2 (Figure 4.17A). This reduced interaction was 
especially evident in myotubes where expression of both nesprin-1 and KLC-1/2 was 
highest (Figure 4.17B). This part of the data was consistent with IP results and showed 
the interaction between nesprin-1α2 WT and KLC-1/2 existed in both myoblasts and 
myotubes, whereas this binding was perturbed by the three novel nesprin-1α2 mutants 

































Figure 4.14 Nesprin-1α2 localised at the ONM 
IF staining showed that V5-nesprin-1α2 was present at the ONM (A: digitonin treatment, only 
breaking down the ONM; B: NP-40 treatment, breaking down both INM and ONM). SUN2, 






























Figure 4.15 Nesprin-1α WT interacted with KLC-1/2 and nesprin-1 mutants 
disrupted this binding 
Overexpression and IP showed the binding between nesprin-1 WT/mutants and KLC 
WT/mutants in U2OS cells. HA-KLC2-N287L co-expressed with GFP-nesprin-1α2 WT and 
HA-KLC2 WT co-expressed with GFP-nesprin-1α2 LEAA (mutated WD/AA within the 
LEWD motif) served as positive controls. GFP empty vector with HA-KLC-2 WT was a 
negative control. IP showed that nesprin-1α2 could efficiently bind to KLC-2, and this binding 
was disrupted by either nesprin-1α2 LEAA or the KLC-2 N287L mutant. The R8272Q mutant 
showed significantly reduced binding with KLC-2, while the S8381C mutant appeared to 
enhance KLC-2 binding (A, C). Three independent experiments were performed shown as 






















Figure 4.16 Endogenous KLC-1/2 increased during differentiation process 
WB showed endogenous expression levels of KLC-1/2 increased during myotube formation, 
similar to the changes of endogenous nesprin-1α.	 Three independent experiments were 




























Figure 4.17 Defects in nesprin-1 and KLC-1/2 interaction 
GST pull-down showed the binding between nesprin-1 and KLC-1/2 using either GST-WT or 
mutant nesprin-1 beads in myoblasts (A) and myotubes (B) respectively. The binding for each 
mutant was quantified by densitometry, and expressed as a ratio of the value obtained for WT 
protein. Three independent experiments were performed shown as mean±SEM, *P<0.05 using 






















































4.2.8 Depletion of KLC-1/2 affected myoblast differentiation 
 
The KLC-1/2 was predominately localised at the NE, but was also present in the 
cytoplasm in myotubes formed with uninfected C2C12 or cells infected with the 
nesprin-1α2 WT (Figure 4.18). However, KLC-1/2 staining was reduced at the NE in 
myotubes infected with DN KASH1, indicating the mis-localised endogenous nesprin-
1 may lead to defects in recruiting KLC to the NE during the differentiation (Figure 
4.18). 
To further investigate the functional roles of nesprin-1α2 and KLC-1/2, we tested 
whether depletion of KLC-1/2 using multiple siRNA oligos would affect fusion of 
myoblasts and differentiation in a similar manner to that observed in the cells infected 
by the R8272Q mutant. Three different oligos (named as A, B and C) were used to 
individually target different regions of mouse KLC-1 and KLC-2 genes thus excluding 
off-target effects (Figure 4.19). siRNA oligos KLC-1A and KLC-2A were used in the 
first group (group 1), KLC-1B&C and KLC-2B&C were combined and used in the 
second group (group 2). WB showed the expression levels of both KLC-1 and -2 were 
reduced in myoblasts upon the KLC-1/2 depletion using oligos group 1 and 2 
respectively (Figure 4.20A & 4.20C). The KLC-1/2 siRNA also worked efficiently in 
the myotubes (Figure 4.20B & 4.20D). IF further confirmed a reduced KLC-1/2 
staining at NE in myotubes (Figure 4.21B), and a weaker cytoplasmic staining in both 
myoblasts and myotubes (Figure 4.21A & 4.21B). However, the localisation of 
endogenous nesprin-1 still remained at the NE, irrespective of KLC-1/2 depletion 
(Figure 4.22). Moreover, MHC levels and the fusion index were significantly reduced 
in myotubes upon KLC-2 knockdown (Figure 4.23A-B & 4.24A-B). Further analysis 
of MHC positive multinucleated cells (myotubes) revealed that KLC-2 depletion 
resulted in significantly fewer nuclei per myotube (majority myotubes with 1-5 nuclei, 
and fewer myotubes containing more than 6 nuclei) (Figure 4.23C, 4.24C & 4.25), 
indicating a defect in myoblast fusion. In contrast, KLC-1 depletion led to significantly 
more clustered nuclei per myotube (reduced number of myotube with 1-5 nuclei, 












Figure 4.18 Overexpression of DN KASH1 mis-localised KLC-1/2 from the NE 
C2C12 myoblasts infected with retroviral V5 tagged nesprin-1α2 WT and DN KASH1 
respectively and induced to differentiate. In myotubes formed with uninfected myoblasts 
(negative control) or exogenous nesprin-1α2 WT, the KLC-1/2 was concentrated at the NE and 
cytoplasm (dotted rectangle), while in the cells infected with DN KASH1, the staining of KLC-
1/2 (arrow) was reduced at the NE. Notably, GFP was stained with anti-rabbit Alexa Fluor 546 
























Figure 4.19 The localisation of siRNA oligos targeted to different regions of 
KLC-1/2 genes 
KLC-1 and -2 genes are homologous, and consist of a coiled-coil region (interacting with 
kinesin heavy chain) and tetratrico-peptide repeats (mediating protein-protein interaction), 
with divergent C-terminus. Three different siRNA oligos (named as A, B and C) were used to 
individually target different regions of mouse KLC-1 and KLC-2 genes. The targeted regions 
are labelled on the schematic. (Gene bank accession number for mouse KLC-1 and KLC-2 are 
NM_001025361 and BC014845 respectively)
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Figure 4.20 WB showed KLC-1/2 was knocked down in myoblasts and 
myotubes by using multiple siRNA oligos 
Multi-oligos were used to knock down the KLC-1/2. A, B was using the single oligo that 
targeted to KLC-1/2; C, D were using anther double oligos that targeted to KLC-1/2. WB 
showed the expression levels of both KLC-1 and -2 were reduced in myoblasts (A, C) and 
myotubes (B, D) upon KLC-1/2 depletion using different siRNA oligos. Three independent 

























Figure 4.21 IF showed KLC-1/2 was knocked down in myoblasts and myotubes 
by using siRNA oligos 
IF showed KLC-1/2 staining at the NE (arrowed) was reduced in myotubes upon KLC-1/2 
siRNA knock down (B), the cytoplasmic staining of KLC-1/2 was reduced in both myoblasts 
and myotubes (A, B). A: Scale bar=25µm, B: Scale bar=12.5µm.
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Figure 4.22 Endogenous nesprin-1α remained at the NE upon KLC-1/2 
knockdown in myoblasts  
IF showed endogenous nesprin-1α staining remained at the NE upon KLC-1/2 siRNA 















Figure 4.23 Knockdown of KLC-1/2 caused defects in myoblast fusion and 
differentiation (I) 
The expression level of MHC (A) and the fusion index (B) were significantly reduced in 
myotubes especially upon KLC-2 depletion (using KLC-2A oligo). More than 800 nuclei for 
each clone were counted by microscopy (63x objective) at day 6, three independent 
experiments were performed for each clone. Further analysis of MHC positive multinucleated 
cells revealed that KLC-2 depletion resulted in fewer nuclei per myotube. In contrast, KLC-1 
depletion (using KLC-1A oligo) led to significantly more clustered nuclei per myotube when 
compared with controls (C). Three independent experiments were performed shown as 













































Figure 4.24 Knockdown of KLC-1/2 caused defects in myoblast fusion and 
differentiation (II) 
The expression level of MHC (A) and the fusion index (B) were significantly reduced in 
myotubes especially upon KLC-2 depletion (using KLC-2B&C oligos). More than 800 nuclei 
for each clone were counted under microscopy (63x objective). Further analysis of MHC 
positive multinucleated cells revealed that KLC-2 depletion resulted in fewer nuclei per 
myotube (C). Three independent experiments were performed shown as mean±SEM or mean, 
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Figure 4.25 IF showed knockdown of KLC-1/2 caused defects in myoblast 
fusion and differentiation 
IF showed the nuclei aggregation and clustering (arrow-headed) were observed upon KLC-1 
and -1/2 knockdown via using different KLC-1/2 siRNA oligos. The smaller size of myotubes 
(with fewer nuclei in each myotube) were observed upon KLC-2 and KLC-1/2 knockdown via 
using different KLC-1/2 siRNA oligos. Scale bar=12.5µm.
MHC
Mock Control KLC-1A KLC-2A KLC-1A/2A
MHC
Mock Control KLC-1B & C KLC-2B & C KLC-1B & C/2B & C
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4.2.9 Generation of flag-tagged nesprin-1α2 WT and mutant 
constructs for investigating the roles of nesprin-1 in 
cardiac cell function in zebrafish embryos 
 
We have shown that nesprin-1 mutants affected muscle cell differentiation in 
vitro. To investigate whether the nesprin mutants affected cardiac structure or function 
in vivo, we set out to generate a zebrafish model by expressing nesprin-1α2 WT and 
mutants (R8272Q, S8381C and N8406K) in zebrafish embryos. The constructs were 
generated following the similar strategy as retroviral constructs described in 4.2.2. 
First, flag-tagged nesprin-1α2 WT was amplified from the previously generated ‘GFP-
nesprin-1α2 WT’, by using flag tagged forward primer containing NotI site from the 
5’ end of nesprin-1α2 of and a reverse primer targeted to the 3’ end of nesprin-1α2. 
Following the strategy, the amplified PCR product was inserted into the pGEM T-easy 
vector. Mutants R8272Q, S8381C and N8406K were generated by the site directed 
mutagenesis using the ‘flag-nesprin-1α2 WT’ as a template. Lastly, flag-tagged 
nesprin-1α2 WT, mutants (R8272Q, S8381C and N8406K) in T-easy vectors were 
extracted from the agarose gel after the NotI and EcoRI digestion and ligated with 
mammalian vector pcDNA3.1(-) (Figure 4.26A). The sequence of nesprin-1α2 WT and 
mutants were verified using two methods: the first was that restriction enzyme 
digestion using NotI and EcoRI. pcDNA3.1(-) vector was shown on the gel with 
5600bp size, while flag-nesprin-1α2 and mutants were shown with the 3000bp (Figure 















Figure 4.26 Generation of flag-tagged nesprin-1α2 WT and mutants constructs 
using pcDNA3.1(-) vectors 
(A) Flag-tagged nesprin-1α2 WT was amplified from the previously generated ‘GFP-nesprin-
1α2 WT’ construct, then inserted into pGEM T-easy vectors. Mutants were generated by site 
directed mutagenesis using the flag-nesprin-1α2 WT as a template. The Flag-nesprin-1α2 
WT/mutants were digested and extracted from the T-easy vectors by restriction enzyme 


















Figure 4.26 Generation of flag-tagged nesprin-1α2 WT and mutants constructs 
using pcDNA3.1(-) vectors 
(B) The sequences of nesprin-1α2 WT and mutants were verified by the restriction enzyme 
digestion using NotI and EcoRI. pcDNA3.1(-) vector was shown on the gel with 5600bp size, 
while flag-nesprin-1α2 and mutants were shown around 3000bp (B). All the constructs were 
subjected to DNA sequencing for further confirmation. 
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4.2.10 Human nesprin-1α2 WT causes heart developmental 
and conduction defects in zebrafish embryos while 
mutants induce a less severe heart phenotype 
 
Plasmid DNAs of human nesprin-1α2 WT and mutants (R8272Q, S8381C and 
N8406K) were transcribed into capped mRNAs, then injected in zebrafish embryos at 
the one-cell stage. At 48 hours post-fertilization (hpf), zebrafish embryos expressing 
human nesprin-1α2 WT showed heart defects including dilated atrial chambers with 
reduced heart rate (Figure 4.27). Furthermore, whole-mount in situ hybridization 
(WISH) demonstrated that the expression of myosin light chain polypeptide 7 
(MYL7), the ortholog of the human regulatory myosin light chain (RLC) gene [267, 
268], was reduced in 30% of the embryos expressing human nesprin-1α2 WT. The 
MLY7 staining also highlighted the dilated atrial chambers and heart developmental 
defects such as abnormal looping (Figure 4.28A-B & 4.29A-B). In contrast, expression 
of the human nesprin-1α2 mutants induced some heart developmental defects, such as 
abnormal heart looping and malpositioning of heart chambers (Figure 4.29A & 4.29B), 
but without heart enlargement or heart rate defects. There was also evidence of 
abnormal anterior-posterior axis development in all the embryos, when compared with 
uninjected and GFP expressed embryos (Figure 4.29C & 4.29D). Taken together this 
zebrafish larvae data suggests that overexpression of human nesprin-1α2 WT leads to 


















Figure 4.27 Human nesprin-1α2 WT induced dilated atrial chamber and 
reduced heart rate 
Lateral views of zebrafish live embryos at 48 hpf. The pericardium (A, arrowed) and heart rate 
were shown for each corresponding mRNA injected (B), zebrafish embryos with nesprin-1α2 
WT mRNA showed slow heart rate and dilated atrial chambers. About 4-7 embryos for each 
injection were measured. Means and SEM were obtained from three independent experiments 
for each treatment. #P˂0.05 using Student’s t-tests. (This experiment was done by our 




























Figure 4.28 Expression of MYL7 indicated the dilated heart in zebrafish 
overexpressing human nesprin-1α2 WT 
Whole-mount in situ hybridization (WISH) monitored the expression of cardiac fetal gene 
MYL7 at 48 hpf (A), the numbers (left in brackets) indicated the percentage of embryos 
displaying the phenotype represented in the picture shown, the numbers (right in brackets) was 
the total numbers counted of observed embryos. The relative atrium area of embryos for the 
corresponding mRNA injection was measured and calculated by the area of MYL7 expression 
using ImageJ (B), which was normalised to the atrium area of the embryos injected with GFP 
mRNA. Embryos were in ventral views with the anterior at the top.  About 4-7 embryos for 
each injection were measured. Mean±SEM were obtained from three independent experiments 
for each treatment. #P˂0.05 using Student’s t-tests. a: atrium, v: ventricle. (This experiment 






















































Figure 4.29 Human nesprin-1α2 WT induced heart development defects while 
mutants induced a less severe heart phenotype in zebrafish embryos 
WISH monitored the expression of MYL7 gene at 48 hpf (A), the numbers (left in brackets) 
indicated the percentage of embryos displaying the phenotype represented in the picture 
shown, the numbers (right in brackets) were the total numbers counted of observed embryos. 
Human nesprin-1α2 WT caused a dilated heart phenotype (B-D), and both WT and mutants 
caused defects in heart looping when compared with uninjected shown (A, B) and abnormal 
anterior-posterior axis development (C, D) in the injected embryos when compared with 
uninjected and GFP expressing embryos. Approximately 36 to 62 embryos for each injection 
were counted; the representative picture (D) showed abnormal anterior-posterior axis 
development (black arrowhead) and dilated heart (red arrow) for the affected embryos. (This 





In this chapter of thesis, we infected C2C12 myoblasts with retroviral V5-tagged 
nesprin-1α2 WT and mutants to investigate their effects on myogenesis in vitro. The 
C2C12 overexpressed nesprin-1 mutants or DN KASH1 showed significantly reduced 
fusion index, with increased population of multinucleated myotubes with fewer nuclei 
and dysregulated MRFs. Those changes suggested the nesprin-1α2 mutants resulted in 
a compromised differentiation of these cells. Interestingly, we showed for the first time 
the interaction between nesprin-1α2 and microtubule motor proteins KLC-1/2 and 
found the mutant nesprins affected their binding. 
Depletion of KLC-1/2 exhibited the similar differentiation defects which caused 
by nesrin-1 mutants. In vivo, human nesprin-1α2 WT causes heart developmental and 
conduction defects in zebrafish embryos while mutants induce a less severe heart 
phenotype due to disrupted LINC complex. These data further strengthened that an 
intact NE-LINC complex is critical for nuclear distribution, muscle cell differentiation 
and heart development. 
4.3.1 Generation of retroviral nesprin-1 WT and mutant 
constructs 
 
To investigate the effects of nesprin-1 mutants in a C2C12 differentiation model 
in vitro, retroviral constructs were generated. The initial aim was to generate flag-
tagged nesprin-1α2 WT and mutant versions of nesprin-1 retroviral constructs. 
Following the strategy described in 4.2.2, we successfully generated these constructs. 
Then the expression levels of nesprin-1α2 and mutants were checked via transfecting 
the plasmids in C2C12 cells. Unfortunately, WB showed the exogenous flag-nesprin 
could not be detected by the flag antibody while it could be detected by anti-nesprin-
1α antibody (Figure 4.30A). After optimisation of the experimental conditions, we still 
could not resolve this issue. Thus, the flag-tag was replaced by V5-tag, and the 
exogenous protein level was successfully detected by both anti-V5 and anti-nesprin-
1α antibodies (Figure 4.30B). 
Another challenge for retroviral experiments was how to choose the proper 
internal control to analyse data. The V5-tag was the best candidate as it was fused to 
the nesprin-1α, which would directly indicate how much proteins was overexpressed 
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after RVs infection. However, V5-KASH was only 10kDa and too small to be detected 









Figure 4.30 Overexpression of flag/V5-tagged nesprin-1α2 in C2C12 cells 
The exogenous flag tagged nesprin-1α could be detected via anti-nesprin-1 antibody, but not 
the anti-flag antibody in C2C12 cells transfected with flag-tagged nesprin-1α2 WT and MIG 
only (A). While the exogenous V5 tagged nesprin-1α could be detected via both anti-nesprn-
1 and V5 antibodies in the cells transfected with V5-tagged nesprin-1α2 WT and MIG only 




















after RVs infection. However, V5-KASH was only 10kDa and too small to be detected 
by immunoblotting; additionally, V5 was not present in the MIG-only vector. GFP was 
the other candidate as it was expressed under the same promotor with V5 fused 
nesprin-1α, but independently. GFP was contained in all the constructs as well as MIG 
only, and could easily be detected by WB. qPCR showed a very positive correlation 
of the expression levels (CT value) between GFP and V5-nesprin-1α2 (Figure 4.31). 
Therefore, GFP was chosen as the standard to measure the expression level of 
exogenous nesprin-1 for further experiments. 
4.3.2 Nesprin-1 mutations caused dysregulation of MTFs in 
myoblast differentiation 
 
Nesprin-1α2 is highly expressed in both skeletal and cardiac muscles as 
previously shown [1, 37, 38]. Although there were no obvious muscle phenotypes 
recorded in these DCM patients harbouring these mutations, it is plausible that in the 
patients presenting with the SYNE-1 mutations, the skeletal muscle dysfunction was 
too subtle or underestimated at clinical examination. Alternatively, in addition to these 
SYNE-1 mutations, another cardiac disease gene is potentially mutated thus enhancing 
the phenotype. Therefore, due to restricted accessibility to patient samples, we focused 
on investigating if these three novel mutants cause muscle dysfunctions by using the 
C2C12 mouse myoblast differentiation model. 
Myogenesis involves a series of sequential steps. Myoblasts originating from the 
mesoderm are converted to skeletal muscle lineage myoblasts after MyoD expression, 
enter the cell cycle and proliferate, then withdraw from the cell cycle and initiate 
differentiation with expression of MTFs such as myogenin.  Next cell fusion occurs to 
form multinucleated myotubes and expression of the muscle specific protein MHC 
[259-262]. Increasing evidence indicates that multiple cell signalling pathways play 
critical roles in myoblast fusion, including those involved in cytoskeleton organisation, 
cell adhesion and migration [262] as well as extracellular signalling molecules and 
components of extracellular matrix [259, 269]. Recent literature shows that LINC 
complex components, including nesprins and SUN1/2, mechanically couple the 
nucleus to the extracellular matrix and play an important role in differentiating muscle. 
In addition, these proteins have been implicated in regulating chromatin structure and 
gene expression. For example, C2C12 cells expressing a LMNA R453W mutant have 
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reduced capacity to differentiate, yet retain an unaltered morphology [263, 264], 
suggesting that subtle abnormal changes in lamina structure or composition may 
impair the anchoring of chromatin to the NE, affecting gene activities and regulation 
















Figure 4.31 Expression level of V5-tagged nesprin-1α2 and GFP was positively 
correlated  
C2C12 myoblasts were infected with retroviral nesprin-1α2 WT/mutants respectively. qPCR 
showed a positive correlation of the expression levels (CT value) between GFP and V5-
nesprin-1α2.




















reduced capacity to differentiate, yet retain an unaltered morphology [263, 264], 
suggesting that subtle abnormal changes in lamina structure or composition may 
impair the anchoring of chromatin to the NE, affecting gene activities and regulation 
which are indispensable for muscle differentiation, thus perturbing myogenesis. 
Using retroviral transduction in mouse C2C12 myoblasts in the current study, 
our data showed myoblasts expressing mutant nesprin-1α2 R8272Q or dominant 
negative-KASH1 had a significantly lower capacity to differentiate, and form 
multinucleated cells than those expressing 1α2 WT, although exogenously expressed 
1α2 WT and mutants were observed to be properly localised at the NE. Importantly, 
the inhibition of multi-nucleation by dominant negative-KASH1 and 1α2 mutants, 
especially R8272Q, is potentially linked to the inhibition of myogenin and MHC 
expression in transduced C2C12 cells. Our data also showed that nesprin-1α2 was 
expressed in the initial stage crucial for converting C2C12 myoblasts into myotubes, 
and promoted myoblast differentiation during the process of myotube formation, 
whereas the mutants reduced or abolished the effects, suggesting that expression of 
nesprin-1α2 mutants does not alter the proliferation of myoblasts, but rather impairs 
their capacity to express muscle-specific genes (myogenin and MHC). This results in 
an inability to fuse, especially observed in the R8272Q mutant, which also explains 
why nesprin-1 mutants affect the expression levels of myogenin more severely than 
MyoD, because MyoD is already expressed prior to initiation of differentiation at a 
stage when the expression level of nesprin-1 is still low. Therefore, we propose the 
following mechanisms whereby nesprin mutants may affect muscle differentiation: 
regulation of myogenin and expression of MHC are influenced by the LINC complex; 
nesprin mutants may fail to build a functional scaffold and/or to maintain chromatin 
compartmentalisation with lamin A/C, leading to an alteration in the amount of 
heterochromatin formed and/or its localisation. Potentially this causes defects in 
initiation of the terminal differentiation process resulting in decreased or delayed 
expression of myogenin and MHC, thus causing a delayed differentiation. This effect 
may be similar to that observed in C2C12 cells expressing an LMNA R453W mutant 
[263, 264] that showed a reduced capacity to differentiate. However, further 
experimentation on how nesprin-1 mutants affect regulation of MTFs is required to 
elucidate the precise function of nesprin in muscle cell differentiation.
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4.3.3 Nesprin-1 mutations disrupted nesprin-1/KLC 
interaction and myoblast fusion  
 
Proper nuclear positioning and movement is critical in muscle cell differentiation 
and development. In the nucleus, changes in gene activity that occur during terminal 
cell differentiation correlate with gene migration and relocation [270, 271]. Nuclear 
movement and positioning are driven by cytoskeletal networks of microtubules, actin 
and/or IFs and involve a connection between the cytoskeleton and the NE, mediated 
by the LINC complex [181, 191]. KO mouse studies have shown that nesprin-1 and 
SUN1/SUN2 play critical roles in anchoring nuclei in skeletal muscle [81, 135, 138]. 
Similarly, mutations identified in SUN1 and SUN2 genes associated with EDMD like 
phenotypes cause defective nuclear positioning when expressed in mouse fibroblasts 
[87]. The microtubule-based kinesin motor, kinesin-1, consisting of two KHCs and 
two KLCs, is localised at the NE. Binding of the dominant light chain isoform in 
muscle, KLC-2 [272], to nesprin-2 has been shown to be responsible for nuclear 
rotations and movement along microtubules [114]. There is evidence that nuclear 
position can influence gene expression. For example, nuclei at the neuromuscular 
junction (NMJ) have a unique transcriptional profile relative to the non-synaptic nuclei 
[271]. Nesprin-1 (SYNE-1) levels are much higher in synaptic nuclei than extrasynaptic 
nuclei, and also higher in myotubes than myoblasts in culture and central nuclei during 
regeneration [13, 38]. In addition, maintaining proper nuclear positioning is thought to 
ensure sufficient transcriptional capacity and minimise transport distances between the 
nuclei and the cytoplasm in highly organised long muscle cells [181, 273]. Our data 
confirmed that nesprin-1 binds to KLC-1/2, and nesprin-1 mutants, particularly 
R8272Q, disrupted this interaction. Overexpression of the DN KASH1 protein 
prevented recruitment of the kinesin to the NE in myotubes which were consistent with 
the findings in the nesprin-1α2 KO mouse model [124]. Furthermore, depletion of 
KLC-1 resulted in nuclear clustering, whereas depletion of KLC-2, a dominant muscle 
isoform, caused a reduction of MHC levels and the fusion index in myotubes that was 
consistent with those observed in the R8272Q mutant. This disruption of nesprin-
1/KLC interaction in C2C12 myoblasts may result in defects in nuclear movement 
along microtubules, leading to abnormal nuclear positioning. Further investigations 
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are required to elucidate the precise roles of nesprin-1 and KLC-1 and -2 in myonuclear 
positioning in muscle cell differentiation. 
4.3.4 Expression of nesprin-1α2 mutants induced less 
severe heart defects during zebrafish heart development 
compared to 1α2 WT 
 
To investigate whether the nesprin mutants affect cardiac structure or function 
in vivo, we generated a zebrafish model by expressing human nesprin-1α2 WT and 
mutants (R8272Q, S8381C and N8406K) in zebrafish embryos via injection of the 
corresponding human SYNE-1α2 (nesprin-1α2) mRNAs. The nesprin-1α2 in zebrafish 
is 50% homologous to human nesprin-1α2 (protein sequence was from [22] and 
compared with BLAST sequence analysis tool). Our data showed that human nesprin-
1α2 WT causes heart developmental and conduction defects in zebrafish embryos, and 
all three 1α2 mutants caused less severe heart developmental defects. Although these 
results are unexpected, there are some potential explanations. The literature shows that 
myoblasts originating from the mesoderm are converted to skeletal muscle lineage 
myoblasts after MyoD expression, enter the cell cycle and proliferate, then withdraw 
from the cell cycle and initiate differentiation with expression of MTFs such as 
myogenin [259-262]. So far, there is no direct evidence showing the expression profile 
of nesprin-1 and -2 during the embryos development either in murine or human 
species. However, there is evidence that the expression of nesprin-1α2 is relatively low 
in human myoblasts, while massively upregulated in human myotubes [37]. Analysis 
of expression profile of nesprins during human muscle development revealed an 
increase in nesprin-1 giant during early myogenesis in vitro [38]. Our data also showed 
there is very limited amount of nesprin-1α2 expression in the initial stage of muscle 
cell differentiation. Therefore, it is plausible to suggest there is no nesprin-1α2 
expression in the zebrafish egg given there is no muscle cell differentiation at this 
stage. Forced expression of human nesprin-1α2 mRNA in the injected zebrafish larvae 
at the one-cell stage when there was no expression of endogenous nesprin-1α2 led to 
ectopic expression of nesprin-1α2, potentially causing differentiation defects in heart 
development. All three nesprin-1α2 mutants showed much less dilated heart phenotype 
compared to nesprin-1α2 WT, suggesting that the altered binding interactions of these 
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mutants with binding partners caused less severe disruption to heart development, 
consistent with the in vitro binding data in Chapter 3. 
4.3.5 Summary 
 
In this chapter, we focused on the roles of nesprin-1 in myogenesis and heart 
development, and identified: 
I) In vitro: 
1. Nesprin-1α2 mutants delayed myoblast fusion and dysregulated MRFs, 
resulting in myogenesis defects in C2C12 differentiation models; 
2. Nesprin-1α2 interacted with microtubule motor proteins KLC-1/2 and 
regulated nuclear migration and positioning during muscle cell 
differentiation, while the mutants caused defects in myogenesis via 
perturbing their interaction; 
II) In vivo: 
Expression of nesprin-1α2 mutants induced less severe heart defects during 
zebrafish heart development compared to 1α2 WT. This indicated the 
current zebrafish model is not an ideal in vivo model as forced expression 
of nesprin-1α2 caused ectopic expression of nesprin-1 before expression of 
the endogenous isoform. Future studies utilising the zebrafish model with 
either cardiac (tissue specific) [274] / heat shock protein (timing dependent) 
promotors [275] or CRISPR/Cas9-mediated knock-in [276] is required to 
physiologically expressed nesprin-1 and characterised the impact of 
nesprin-1 mutants during zebrafish heart development. 
The literature and the data I have presented showed the NE-LINC complex 
disruption caused by nesprin mutants is the key step that leads to muscular dystrophy. 
Therefore, I am going to target the NE and multiple nesprin KASH containing 
isoforms, and generate cardiac specific nesprin-2 KASH transgenic mice and further 
characterise the roles of nesprin in heart in Chapter 5.
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Chapter 5: Generation and characterisation of 





In Chapters 3 and 4, the data I have shown suggest that nesprin-1 plays multi-
functional roles at the NE. These nesprin-1 mutants and DN KASH1 compromised the 
NE-LINC complex, leading to defects in NE organisation and myogenesis, and 
reinforcing the importance of an intact NE-LINC complex in linking the nucleus to the 
cytoskeleton and maintaining normal physiology and homeostasis. However, the roles 
of nesprins-1/-2 in heart have not been properly investigated in vivo, and there are a 
number of issues that still need to be resolved, in particular the lack of specific mouse 
models. 
Existing nesprin-1 and/or -2 mouse models provide valuable information 
regarding nesprin functions in maintaining nuclear morphology and regulating nuclear 
migration and positioning [4, 83, 85, 123, 124, 135-138, 221, 273]. However, two of 
the existing nesprin-1 KO mice exhibited cardiac phenotypes, but the origin of the 
phenotype may not even be directly due to nesprin-1 depletion. In one model, an 
aberrant 61 amino acid substitution of the KASH domain was generated upon global 
ablation of nesprin-1 KASH [4, 221]. In the other, cardiac specific nesprin-1 depletion 
was performed in addition to nesprin-2 global KO model [85]. It is plausible the 
cardiac defects observed in these two mouse models resulted from the aberrant 61 
amino acid substitution of KASH in the first mouse model and partly due to the global 
effect of nesprin-2 KO in the second model [4, 85, 221]. Of note, most of the mouse 
models do not recapitulate the human disease, as these models require homozygous 
expression of the mutant alleles to show the disease phenotype. These strategies ignore 
the potential role of the presence of the WT allele in disease pathogenesis as most of 
human diseases, especially EDMD and DCM, are autosomal dominant [3, 4, 122]. 
To further investigate the roles of nesprin-1/-2 via NE-LINC complex disruption 
in regulating pathogenesis in hearts, I aimed to target the NE and multiple nesprin 
KASH containing isoforms using a DN-KASH strategy, by taking advantage of the 
existing KASH2 Tg mouse strain [238, 239] and MLC2V Cre mice [277] to establish 
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a novel cardiac specific nesprin KASH2 Tg (csKASH-Tg) mouse line. In the csKASH-
Tg mice, the multiple nesprin KASH containing isoforms were dislodged from the NE 
by overexpressing KASH2 and generating the specific NE-LINC complex disruption 
model in the cardiomyocytes (CMs) (Figure 5.1). 
The Tg KASH mouse strain (CAG-LacZ-V5/EGFP-KASH2) was generated by 
our collaborator Dr. Didier Hodzic in Washington University [238, 239]. This mouse 
harbours a genetic construct consisting of an open reading frame (ORF) encoding 
mouse nesprin-2 KASH domain fused to EGFP (EGFP-KASH2), cloned downstream 
of a Lox-flanked ORF encoding β-galactosidase fused to a V5 epitope (LacZ-V5) with 
a flanked STOP codon at the end [238] (Figure 5.2A). This model has been 
successfully used to investigate the functions of nesprin in cerebellum and retina 
development, and exhibits efficient KASH2 overexpression, mis-localisation of the 
endogenous nesprin to the endoplasmic reticulum (ER) and NE-LINC complex 
disruption in a tissue specific manner [238, 239] (Figure 5.1). 
Myosin light chain 2 ventricular (MLC2V) Cre mice were originally generated 
by Prof. Ju Chen in San Diego University [277]. These mice carry the Cre-recombinase 
gene under control of endogenous MLC2V. MLC2V encoded by MYL2 gene, as a 
ventricular-restricted marker, presents as early as E8.75 during mammalian 
cardiogenesis [278], and is involved in maintaining cardiac contractility and 
ventricular chamber morphogenesis [279, 280]. The MLC2V Cre mice have been 
widely used for generating cardiac specific mouse models for over 20 years (Figure 
5.2B). 
In this chapter, I aimed to: 
1. Generate a cardiac specific NE-LINC complex disruption mouse model 
by overexpressing the DN KASH2 under the cardiac specific promotor 
MLC2V; 
2. Characterise the phenotypes of this csKASH-Tg mouse model at the 
basal line; 
3. Further characterise the heart phenotypes of the csKASH-Tg mice after 




















Figure 5.1 Overexpression of EGFP-KASH2 result in NE-LINC complex 
disruption 
SUN domain containing proteins interact with KASH domain containing proteins to form the 
‘hub’ of LINC complex, linking the nucleus to the cytoskeleton(A). Overexpression of EGFP-
KASH2 displaces endogenous nesprin-1 and -2 from the NE to the endoplasmic reticulum 
(ER), in a dominant negative fashion, thus uncoupling the nucleoskeleton from the 
































Figure 5.2 Breeding strategy of cardiac specific KASH2 Tg mice 
Breeding of Tg KASH (CAG-LacZ/EGFP-KASH2) with Tg (MLC2V Cre) mice produced Tg 
(MLC2VCreCAG-EGFP-KASH2) offspring in which Cre recombinase was expressed 








5.2.1 Establishment of a novel cardiac specific KASH2 Tg 
mouse model 
 
By breeding MLC2V Cre mice with Tg KASH mice, Crerecombinase mediated 
somatic excision of the LacZ/V5 ORF and STOP codon, allowed activation of 
transcription of EGFP-KASH2 specifically in CMs under the MLC2V promotor 
(Figure 5.2). 
All mice used in this study are of C57/BL6 strain. Offspring were genotyped 
after birth using primers designed to identify the ‘GFP-KASH2’ and ‘MLC2V Cre’ 
simultaneously. The control group was Tg KASH2 mice that were referred to as floxed 
control (FLctrl). Mice with both EGFP-KASH2 and Cre expression were named as 
cardiac specific Tg KASH2 (csKASH-Tg). MLC2V Cre only mice were referred as 
Cre. Mice containing neither the GFP-KASH2 nor Cre were named as WT (Figure 
5.3A). Genotypic analysis of total 193 pups showed that the expression of the GFP-
KASH2 gene did not affect Mendelian birth ratios (Figure 5.3B). 
WB showed EGFP-KASH2 was specifically expressed in csKASH-Tg heart 
when compared with the FLctrl heart (Figure 5.4A). qPCR further showed the 
expression level of exogenous KASH2 in csKASH-Tg was 12-fold high when 
compared with FLctrl, which only had endogenous KASH2 expression (Figure 5.4B). 
There was no expression of GFP-KASH2 in other tissues including skeletal muscle, 
lung, aorta, liver and kidney in both csKASH-Tg and FLctrl (Figure 5.4A). IF showed 
the subcellular localisation of GFP-KASH2 only present at the NE of CMs in 
csKASH-Tg mice compared with FLctrl mice (Figure 5.4C). There was no staining of 
GFP-KASH2 in other organs including skeletal muscle, lung, aorta, liver and kidney 
in both csKASH-Tg and FLctrl groups (Figure 5.4C). These data validated the success 












Figure 5.3 Transgenic mice were born at the expected Mendelian ratios 
PCR genotyping of DNA extracted from the ear biopsy was performed with primers targeted 
to the ‘GFP-KASH2’ (~280bp) or ‘Cre’ (~200bp) sequence. GAPDH (~300bp) served as an 
internal control. The ‘GFP-KASH2’ only mice were referred to as floxed control (FLctrl). 
Mice with both ‘EGFP-KASH2’ and ‘Cre’ expression were named as cardiac specific Tg 
KASH2 (csKASH-Tg). Cre mice were the MLC2V Cre only. WT mice were the original 
C57/BL6 strain mice neither containing the GFP-KASH2 nor Cre. (B) Genotype ratios were 
present as a percentage of the total number of mice, which were born at the expected 





































Figure 5.4 GFP-KASH was cardiac specifically expressed 
(A) Using an antibody targeted to GFP protein, WB showed GFP-KASH2 was specifically 
expressed in csKASH-Tg heart compared with FLctrl. There was no expression of GFP-KASH 
in other tissues including skeletal muscle, lung, aorta, liver and kidney in both csKASH-Tg 
and FLctrl mice. (B) qPCR showed the expression level of exogenous KASH2 in csKASH-Tg 
was 12-fold high when compared with FLctrl, which only had endogenous KASH2 expression. 





























Figure 5.4 GFP-KASH was cardiac specifically expressed 
(C) IF showed GFP-KASH2 wasmainly present at the NE of cardiomyocytes in csKASH-Tg 
mice compared with FLctrl mice. There was no observed GFP-KASH staining at the NE in 
other tissues including skeletal muscle, lung, aorta, liver and kidney in both csKASH-Tg and 



































5.2.2 Characterisation of cardiac specific KASH2 Tg mouse 
model at basal line 
5.2.2.1 Cardiac specific KASH2 Tg mice developed normally up to 
one year 
 
csKASH-Tg offspring developed normally up to 1 year after birth (Figure 5.5A). 
There was no observed gender difference and all mice survived during the first year of 
observation. Male pups were used for this study. There was no difference in body 
weight (BW), heart weight (HW), tibia length (TL) (Figure 5.5B), as well as the ratios 
of HW/BW and HW/TL (Figure 5.5C) between csKASH-Tg and FLctrl groups when 
observed at week 52. 
5.2.2.2 Echocardiography showed the cardiac hypertrophic response 
was induced in csKASH-Tg mice 
 
To evaluate cardiac structure and functions, non-invasive transthoracic 
echocardiography was performed on the csKASH-Tg and FLctrl mice at week 15, 
week 30 and week 52 respectively (Figure 5.6A). There was no difference in heart rate 
between the csKASH-Tg and FLctrl mice during echocardiographic assessment 
(Figure 5.6B) 
However, the cardiac structure showed significant changes at week 52. Firstly, 
structural parameters were analysed by comparing csKASH-Tg with FLctrl groups. In 
csKASH-Tg: echocardiography showed thickness of left ventricle (LV) wall including 
LV posterior wall during diastole and systole (LVPWd and LVPWs), was significantly 
increased (Figure 5.6C & 5.7A). The interventricular septum (IVS) showed a trend of 
mild increase, but no statistical significance (Figure 5.7B). The LV internal diameter 
at the end of diastole and systole (LVIDd and LVIDs) was significantly decreased 
(Figure 5.7C), and both LV end-systolic (ESV) and -diastolic volume (EDV) were 
reduced (Figure 5.7D). There was a reduction of stroke volume (SV) (SV=EDV-ESV) 
(the volume of blood pumped from the LV per beat) in csKASH-Tg compared with 
FLctrl (Figure 5.7E). 
Following this, the functional parameters were then analysed. Heart function was 
evaluated by measuring ejection fraction (EF=SV/EDV) or fractional shortening 
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(FS=(LVIDd-LVIDs)/LVIDd), which are the important index of heart systolic 
function [240]. Echocardiography showed there was no difference in either EF or FS 
between csKASH-Tg and FLctrl mice (Figure 5.7F). 
In summary (Table 5.1), the echocardiographic data indicated a hypertrophic 
















Figure 5.5 csKASH-Tg mice developed normally up to 1 year 
csKASH-Tg offspring developed normally up to 1 year after birth.  There were no observed 
gender difference and all mice survived during the first year of observation (A). Male pups 
were used for this study. There was no difference in body weight (BW), heart weight (HW), 
tibia length (TL) (B), as well as the ratios of HW/BW and HW/TL (C) between csKASH-Tg 
and FLctrl groups when observed at week 52. FLctrl n=11; csKASH-Tg n=15. Data was 





















































































































Figure 5.6 Echocardiography showed an increased LV wall thickness in 
csKASH-Tg mice 
Cardiac structure and function were measured by echocardiography when mice were under 
anaesthesia (A). There was no difference in heart rate between the csKASH-Tg and FLctrl 
mice during echocardiographic assessment (B). LV parasternal long axis showed an increased 
LV wall thickness, especially the left ventricular posterior wall (LVPW) (yellow arrow) at the 
end-diastole in csKASH-Tg compared with FLctrl (C). FLctrl n=11; csKASH-Tg n=15. Data 
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Figure 5.7 Echocardiography showed the cardiac hypertrophic response was 
induced in csKASH-Tg mice 
Echocardiography were analysed by comparing csKASH-Tg with FLctrl groups. In csKASH-
Tg mice, there was a significant increased thickness of the left ventricular posterior wall during 
diastole and systole (A: LVPWd and LVPWs); a trend of increased interventricular septum 
(IVS) (B); decreased left ventricular internal diameter at the end of diastole and systole 


















































































































Figure 5.7 Echocardiography showed the cardiac hypertrophic response was 
induced in csKASH-Tg mice 
There was a reduced left ventricular end-systolic (ESV) and -diastolic volume (EDV) (D) as 
well as stroke volume (SV) (E). There was no difference in either ejection fraction (EF) or 
fractional shortening (FS) between csKASH-Tg and FLctrl mice (F). FLctrl n=11; csKASH-







































































Table 5.1 Echocardiographic analysis showed a cardiac hypertrophic response 
was induced in csKASH-Tg mice at 52 weeks 
 
 Parameter Units FLctrl csKASH-Tg P value Significant 
 Heart rate bpm 521.6±6.9  503.9±5.4 0.0544 ns 
LV wall LVPWd mm 0.74±0.02 0.87±0.04 0.0196 * 
LVPWs mm 0.93±0.03 1.06±0.04 0.0358 * 
IVSd mm 0.83±0.02 0.88±0.03 0.3645 ns 
IVSs mm 1.14±0.04 1.19±0.04 0.4370 ns 
LV internal 
diameter 
LVIDd mm 4.33±0.04 4.04±0.10 0.0214 * 
LVIDs mm 3.36±0.04 3.11±0.09 0.0345 * 
LV volume EDV µl 84.48±1.64 72.58±3.97 0.0221 * 
ESV µl 46.22±1.27 38.90±2.84 0.0476 * 
SV µl 38.80±1.49 33.68±1.66 0.0372 * 
Heart function EF % 45.95±1.63 46.89±1.34 0.6571 ns 
FS % 22.80±0.97 23.20±0.77 0.7451 ns 
ns: not significant; * P<0.05 
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5.2.2.3 Histological examination showed thicker LV wall and fibrosis 
in csKASH-Tg mouse hearts 
 
To evaluate the morphological feature of hearts in csKASH-Tg mice, 
Haematoxylin and Eosin (H&E) staining was performed on frozen heart sections (long 
axis). Analysing the four heart chambers under the light microscopy with low power, 
there was an increased thickness of LV wall in csKASH-Tg mice compared with 
FLctrl mice at 1-year time point (Figure 5.8). 
To investigate if there was any interstitial collagen deposition in csKASH-Tg 
mouse hearts, Masson's trichrome staining was performed on the frozen heart sections 
(short axis). There was some fibrosis staining present in csKASH Tg mouse hearts at 
1 year old, but no fibrosis was detected in FLctrl mouse hearts (Figure 5.9). 
5.2.2.4 Size of cardiomyocytes was increased in csKASH-Tg mice 
 
To determine if there were differences in cardiomyocyte size caused by DN 
KASH2 expression, wheat germ agglutinin (WGA) staining was performed to stain 
the cell membranes on frozen heart sections (short axis) [281, 282]. Quantitation 
indicated there was a significant increased CM size in csKASH-Tg mice compared 
with FLctrl at 1-year-old (Figure 5.10). 
5.2.2.5 Cardiomyocyte nuclear morphology was changed in csKASH-
Tg hearts 
 
To investigate if there were any changes of cardiomyocyte nuclear morphology 
in csKASH-Tg mice, nuclei were stained with DAPI and overexpressed GFP-KASH2 
in CMs was detected by GFP staining. IF showed the exogenous GFP-KASH2 was 
only localised at the NE in the CMs in csKASH-Tg mice when compared with FLctrl 
mice (Figure 5.11A). The GFP-KASH2 positive CMs in csKASH-Tg exhibited an 
elongated nuclear shape compared with CMs in FLctrl mice (Figure 5.11A). 
Computational morphometric analyses showed dramatically increased nuclear length 
(long axis), perimeter and area in csKASH-Tg CMs when compared with the FLctrl 
mice (Figure 5.11B), however, no observed change of nuclear width (short axis). These 
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changes indicated there was enlarged nuclear size and altered nuclear morphology in 
CMs in csKASH-Tg mice. 
5.2.2.6 Hypertrophic and fibrotic genes were expressed in csKASH-
Tg mouse hearts 
 
At the molecular level, the hypertrophic response or development of heart failure 
(HF) can be evaluated via reliable markers such as αMHC, βMHC, atrial natriuretic 
peptide (ANP) and brain natriuretic peptide (BNP) [283-286]. Gene expression of 
these fetal genes in our mouse model was analysed: βMHC, a marker for the major 
thick filaments in ventricles [284] was significantly increased in csKASH-Tg mice 
compared with FLctrl (Figure 5.12A). ANP, a hypertrophic marker [287], was 3-fold 
higher than FLctrl (Figure 5.12B). The fibrosis markers, pro-fibrotic genes 
procollagen1α1 and procollagen3α1 [288, 289] both showed an upregulation in 
csKASH-Tg mice compared with FLctrl (Figure 5.12C). There was no significant 
changes of other fetal genes including αMHC (the major isoforms expressed 
predominantly in cardiac atria [283]) and BNP (heart failure marker [286]) (Figure 
5.12A & 5.12B). Those data further implied the LV was under the hypertrophic 
response, with modulation of expression of cardiac fetal genes and fibrotic genes. 
5.2.2.7 Endogenous NE-LINC components were mis-localised from 
NE in csKASH-Tg mice 
 
Our data in Chapter 3 and previous literatures suggest that nesprin mutants and DN 
KASH lead to mis-localisation of endogenous nesprin from the NE and also affect the 
localisation of its binding partners such as lamin A/C, emerin and SUN at the NE [3, 
35, 178]. Therefore, the localisation of endogenous nesprin and its binding partners at 
the NE were further examined in the CMs of csKASH-Tg mice. 
IF showed GFP-KASH2 accumulated at the NE of csKASH-Tg CMs, however, 
the staining of endogenous nesprin-1α was reduced at the NE in these CMs when 
compared with FLctrl mice (Figure 5.13A). IF also showed the mis-localisation of 
endogenous lamin A/C and emerin in the CMs upon overexpression of DN KASH2 










Figure 5.8 HE staining showed an increased LV wall thickness in csKASH-Tg 
mouse hearts 
Haematoxylin and Eosin (H&E) staining was performed on frozen heart sections (long axis) 
to evaluate the morphological feature of hearts. The LV wall was thicker in csKASH-Tg (B, 
blue double-headed arrow) compared with FLctrl mice (A, black double-headed arrow) at 1 
















Figure 5.9 Myocardial fibrosis was observed in csKASH-Tg mice 
Masson's trichrome was performed on frozen heart sections (short axis). There was some 
fibrosis staining present in csKASH Tg mouse hearts (B, blue arrow) at 1 year old, but no 












Figure 5.10 Size of cardiomyocytes was increased in csKASH-Tg mice 
The sarcolemma of CMs from the heart cross section was labelled by the wheat germ 
agglutinin (WGA) staining (green staining) in both FLctrl and csKASH-Tg mice at 1 year old 
(A). Quantitation indicated there was a significant increased CM size in csKASH-Tg mice 
compared with FLctrl at 1-year-old (B). n=10 individual hearts/group; around 250 CMs/heart 
were quantified. Data was analysed by performed Student’s t-tests, shown as mean±SEM. 





































Figure 5.11 Cardiomyocyte nuclear morphology was altered in csKASH-Tg 
mice 
(A) Representative of the cardiomyocyte nuclei in both FLctrl and csKASH-Tg at 1 year old 
(Blue was DAPI staining, Green was the GFP-KASH2 stained by GFP antibody). The 
exogenous GFP-KASH2 was only present at the NE in the CMs in csKASH-Tg heart 
compared with FLctrl. The GFP-KASH positive nuclei (A, bottom two panels) exhibited an 
















Figure 5.11 Cardiomyocyte nuclear morphology was altered in csKASH-Tg 
mice 
 (B) Nuclear morphology parameters further revealed the irregular shape of nuclei in csKASH-
Tg mouse hearts including increased nuclear length (long axis), perimeter/area compared with 
the FLctrl, however, no observed change of nuclear width (short axis). n=3 hearts/each group, 
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Figure 5.12 Hypertrophic and fibrotic genes were expressed in csKASH-Tg 
mouse hearts 
Evaluating the expression of fetal genes in csKASH-Tg and FLctrl hearts at 1-year time point. 
Fetal genes βMHC (A) and ANP (B), as well as fibrotic genes procollagen1α1 and 3α1 (C) 
were upregulated in csKASH-Tg compared with FLctrl. There were no significant changes of 
other fetal genes including αMHC and BNP in csKASH-Tg compared with FLctrl (A, B). 

























































































































Figure 5.13 Endogenous NE-LINC complex components were mis-localised 
from NE in csKASH-Tg mice 
IF showed mis-localisation of endogenous nesprin-1α (A, dashed boxes), lamin A/C and 
emerin (B & C, arrow) while GFP-KASH2 accumulated at the NE of CMs in csKASH-Tg 




 5.2.2.8 Subtle changes of expression levels of NE-LINC complex 
components in csKASH-Tg mice 
 
To investigate if overexpression of DN KASH2 cause defects in expression 
levels of various nesprin-1/-2 isoforms and NE-LINC complex components, qPCR and 
WB were performed. qPCR showed there was no difference of expression of nesprin 
endogenous isoforms containing nesprin-2 CH domain or nesprin-1 KASH domain 
between csKASH-Tg and FLctrl groups (Figure 5.14A). The expression level of SUN1 
was increased in csKASH-Tg compared with FLctrl (Figure 5.14B). Other NE-LINC 
complex components such as lamin A/C, emerin, SUN2 and nesprin-1α were 
unchanged at both RNA and protein levels in csKASH-Tg compared with FLctrl 
(Figure 5.14 B & 5.15). 
Taken together, the data at the basal line showed: overexpression of DN-KASH 
in CMs of csKASH-Tg mice disrupted the NE-LINC complex, induced a hypertrophic 
response with activated fetal gene expression. 
5.2.3 Characterisation of cardiac specific KASH2 Tg mouse 
model under pressure overload 
5.2.3.1 The csKASH-Tg mice was subjected to pressure overload 
 
To further validate any increased susceptibility to mechanical stress resulted 
from disrupted NE-LINC complex in CMs and its accompanied cardiac structure and 
function changes, transverse aortic constriction (TAC) were performed on both FLctrl 
and csKASH-Tg mice. 
11-week old, male mice around 25g were subjected to severe pressure overload 
surgery in collaboration with Prof. Ajay Shah’s lab (King’s College London). 
Echocardiographic images were collected for all the mice before and after surgery. 
The bound descending aorta showed restricted forward flow and 4-fold increase in 
flow velocity (Figure 5.16). The hemodynamic changes resulted in overloaded 
pressure for the LV. The heart function was assessed 2 weeks post-operation prior to 
harvesting due to the severe TAC procedure which accelerated the LV remodelling 
and heart failure process [241]. All the mice were divided into four groups including 
FLctrl Sham (n=5), FLctrl TAC (n=4), csKASH-Tg Sham (n=1) and csKASH-Tg TAC 
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(n=3). As the mouse experiments were performed in the last year of my research, we 
were not able to acquire enough mice for the csKASH-Tg Sham group due to limited 
time. Therefore, we only compared the FLctrl Sham vs. FLctrl TAC and FLctrl TAC 
vs csKASH-Tg TAC in further experiments. 
5.2.3.2 LV hypertrophy was induced by pressure overload in both 
FLctrl and csKASH-Tg 
 
The body weight (BW) was measured before and after surgery and there was no 
difference among each group (Figure 5.17A). The ratio of HW/BW and HW/TL were 
used to assess the changes in heart mass. Both HW/BW and HW/TL were significantly 
increased in FLctrl TAC group compared with FLctrl Sham, suggesting that LV 
hypertrophy was induced by acute pressure overload in two weeks (Figure 5.17B). In 
the csKASH-Tg and FLctrl TAC groups, there was an increased trend in csKASH-Tg 
compared with FLctrl, indicating the csKASH-Tg TAC may have a more severe LV 
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Figure 5.14 qPCR showed SUN1 was increased in csKASH-Tg mice 
The RNA levels of NE-LINC complex components were examined from both FLctrl and 
csKASH-Tg hearts at 1 year old. There was no difference of expression of nesprin isoforms 
containing nesprin-2 CH domain or nesprin-1 KASH domain between csKASH-Tg and FLctrl 
groups (A). The expression level of SUN1 was increased and other NE-LINC complex 
proteins lamin A/C, emerin, SUN2 and nesprin-1α2 were unchanged in csKASH-Tg compared 
with FLctrl (B). FLctrl n=17; csKASH-Tg n=21. Data was analysed by Student’s t-tests, 
shown as mean±SEM. *P<0.05. 




































Figure 5.15 WB showed unchanged protein levels of NE-LINC complex 
components 
(A) The protein levels of NE-LINC complex components including lamin A/C, emerin, 






















Figure 5.15 WB showed unchanged protein levels of NE-LINC complex 
components 
(B) Statistical analysis showed there were no significant differences in protein levels of lamin 
A/C, emerin, SUN1, SUN2 and nesprin-1α between csKASH-Tg and FLctrl mice (B). FLctrl 














































































































Figure 5.16 Echocardiographic images of the aorta in TAC mice 
Aortic images were acquired before and after TAC surgery by echocardiography. Images of 
the aorta before TAC were shown in group A. B-mode of aorta arch was well shown (green 
arrow). The velocity of forward flow (white arrow) in the descending aorta was around 
1000mm/s (yellow labelling). B group represented the aortic images two weeks post-
operation. The descending aorta was bound (green arrow), with restricted forward flow (white 
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Figure 5.17 Heart mass was increased by pressure overload in both FLctrl and 
csKASH-Tg mice 
The BW in csKASH-Tg and FLctrl groups were measured before and after surgery 
respectively. There was no significant difference among four groups (A). The ratios of 
HW/BW and HW/TL were significantly increased in FLctrl TAC compared with FLctrl Sham, 
however only showed an increased trend in csKASH-Tg TAC compared with FLctrl TAC (B). 
FLctrl Sham n=5, FLctrl TAC n=4, csKASH-Tg Sham n=1 and csKASH-Tg TAC n=3. Data 
was analysed by Student’s t-tests, shown as mean±SEM. *P<0.05, BW-body weight, HW-



































































































































5.2.3.3 Echocardiography showed severe defects in cardiac 
structure and function in csKASH-Tg TAC mice 
 
Echocardiography monitored the changes of heart structure and functions in both 
csKASH-Tg and FLctrl groups before and after surgeries. Using 1D M-Mode, the 
flattened LV wall motion in FLctrl and csKASH-Tg after TAC indicated the reduced 
LV contraction and compromised systolic function when compared to the same group 
before surgery (Figure 5.18B & 5.18D). There was no observed difference of LV wall 
movement in csKASH-Tg Sham and FLctrl Sham before and after surgery (Figure 
5.18A & 5.18C). 
Then the echocardiographic data was analysed within the three groups 
(csKASH-Tg Sham was excluded due to the data collected from only 1 mouse): I) In 
the FLctrl Sham, there were no changes in heart structure and functions after Sham 
surgery compared with the same mice before surgery, excluding any changes caused 
by surgical intervention (Figure 5.19A-G). II) In the FLctrl TAC group, there were 
significant increases in LVPW (LVPWd, LVPWs) (Figure 5.19A), LV diameter and 
LV volume (LVIDs, ESV) (Figure 5.19C, 5.19D), as well as decreased EF (Figure 
5.19G) in FLctrl mice after TAC compared with same mice before TAC. III) In the 
csKASH-Tg TAC group, these mice displayed similar changes to those observed in 
FLctrl TAC group before and after surgery (Figure 5.19A-G). 
Next, echocardiographic data were further analysed between two groups after 
surgery (csKASH-Tg Sham was excluded due to the data collected from only 1 
mouse): I) There was an enlarged LV volume (ESV) (Figure 5.19D) and reduced EF 
(Figure 5.19F & Figure 5.19G) in FLctrl TAC compared with FLctrl Sham. II) There 
was a trend towards thicker LV wall (Figure 5.19A & 5.19B), larger LV chamber 
diameter and volume (Figure 5.19C & 5.19D) and more reduced EF (Figure 5.19F & 
5.19G) in csKASH-Tg TAC compared with FLctrl TAC. 
Those changes suggested LV hypertrophy and heart failure were induced in 
FLctrl mice due to the acute pressure overload, and may potentially be exacerbated in 


























Figure 5.18 Echocardiography showed reduced heart contraction after TAC 
surgery 
M-mode images were acquired by echocardiography before and after surgery to monitor the 
dynamic changes of heart structure and functions in each individual mouse (A-D). This 1-D 
view recorded the LV wall movement, which reflected the LV systolic function. Green double 
arrow line represented the LV internal diameter at the end of diastole, while the yellow double 
arrow line represented the LV internal diameter at the end of systole. The flattened LV wall 
motion in FLctrl and csKASH-Tg after TAC indicated the reduced LV contraction and 
compromised systolic function when compared to the same group before surgery (B, D). There 
was no observed difference of LV wall movement in csKASH-Tg Sham and FLctrl Sham 
before and after surgery respectively (A, C). 
FLctrl Sham
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Figure 5.19 Echocardiography showed severe cardiac structural and 
functional changes in csKASH-Tg TAC mice 
Echocardiography monitored the LV structural and functional parameters. Within each group 
I) FLctrl Sham:  there was no changes in heart structure and functions after Sham surgery 
compared with the same mice before surgery (A-G). II) FLctrl TAC: there were significant 
increases in LVPW (LVPWd, LVPWs) (A), LV diameter and LV volume (LVIDs, ESV) (C 
& D), as well as decreased EF (G) in mice after TAC compared with same mice before TAC. 
III) csKASH-Tg TAC: these mice displayed similar changes to those observed in FLctrl TAC 
group before and after surgery (A-G). 
Between two groups I) There was an enlarged LV volume (ESV) (D) and recued EF (F & G) 
in FLctrl TAC compared with FLctrl Sham. II) There was a trend towards thicker LV wall (A 
& B), larger LV chamber diameter and volume (C & D) and decreased EF (F & G) in csKASH-
Tg TAC compared with FLctrl TAC. 
FLctrl Sham n=5, FLctrl TAC n=4, csKASH-Tg Sham n=1 and csKASH-Tg TAC n=3. Data 
was analysed by Student’s t-tests or Two-way ANOVA Turkey’s test, shown as mean±SEM. 
*P<0.05 compared within the group; # P<0.05 compared between two groups. 

















































































5.2.3.4 Histological examination showed massive myocardial fibrosis 
in csKASH-Tg TAC mice 
 
Myocardial fibrosis was assessed in Masson's trichrome stained LV sections 
(short axis) at 2 weeks after surgery. In the Sham group, there was no visible difference 
in the extents of fibrosis in both FLctrl and csKASH-Tg hearts (Figure 5.20A & 
5.20C). However, there was massive fibrosis across the whole LV cross sections in the 
csKASH-Tg TAC mice (Figure 5.20D), when compared with FLctrl TAC mice that 
only showed limited area of fibrosis (Figure 5.20B). 
5.2.3.5 Up-regulated expression of hypertrophic and fibrotic genes in 
csKASH-Tg TAC mouse hearts 
 
The mRNA levels of fetal and fibrotic genes were evaluated by qPCR. In the 
FLctrl group: there were down-regulated βMHC and αMHC expression (Figure 
5.21A), up-regulated ANP and BNP expression (Figure 5.21B), as well as increased 
expression of fibrotic genes Procol1α1 and Procol3α1 (Figure 5.21C) in the FLctrl 
TAC mice when compared with the FLctrl Sham. 
Comparing the two TAC groups, the ANP, Procol1α1 and Procol3α1 in 
csKASH-Tg TAC group was significantly increased, with 3-fold higher in csKASH-
Tg TAC hearts compared with FLctrl TAC (Figure 5.21B & 5.21C). There were no 
significant changes in other fetal genes including α/βMHC and BNP in csKASH-Tg 
TAC when compared with FLctrl TAC (Figure 5.21A & 5.21B). 
These results were consistent with the echocardiographic and histological 
staining data, indicating overexpression of the DN KASH promoted pressure overload-
induced LV dysfunction. 
5.2.3.6 Disruption of NE-LINC complex was induced by pressure 
overload in csKASH-Tg mice 
 
To investigate whether the expression levels of endogenous NE-LINC complex 
associated proteins were altered in csKASH-Tg TAC mice, WB and qPCR were used. 
Nesprin-2 KASH domain containing isoforms were 7-fold high than endogenous 
KASH2 isoforms in FLctrl group due to overexpression of EGFP-KASH2 in the 
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csKASH-Tg mouse hearts. KASH2 isoform expression was not altered by the TAC 
procedure in both csKASH-Tg and FLctrl groups (Figure 5.22A). Other nesprin 
isoforms that contained nesprin-2 CH or nesprin-1 KASH domains were also 
unchanged in all groups before and after surgery (Figure 5.22A). 
SUN2 was significantly down-regulated in the FLctrl TAC compared to the 
FLctrl Sham (Figure 5.22B). Moreover, lamin A/C showed an upregulated trend in 
FLctrl TAC when compared with FLctrl Sham, but significantly increased in the 
csKASH-Tg TAC compared with FLctrl TAC (Figure 5.22B). Other NE-LINC 
complex components including emerin, SUN1 and nessprin-1α were unchanged in 
FLctrl and csKASH-Tg before and after TAC (Figure 5.22B & 5.23). These results 
suggested that pressure overload alone was enough to alter the expression level of 
SUN2, whilst increased lamin A/C was induced by both overexpression of KASH and 
pressure overload. 
5.2.3.7 Biomechanical response was altered in csKASH-Tg mice 
under the pressure overload 
 
The cells response to mechanical strain can be measured by the expression of the 
mechanosensitive genes [211, 212]. Literatures showed attenuated mechanical 
induction of egr-1, iex-1, c-fos and c-jun under mechanical strain in MEFs derived 
from LMNA or EMD null mice, and the CMs derived from nesprin-1/-2 KO mice [85, 
153, 213, 214], suggesting the critical role of the integral NE-LINC complex in 
mechanotransduction and gene regulation. 
We examined the changes of mechanosensitive genes in the csKASH-Tg and 
FLctrl mice. In the FLctrl group, qPCR data showed significant upregulated egr-1 after 
TAC procedure compared with the Sham group (Figure 5.24). Next, two TAC groups 
were compared: egr-1 and c-myc were significantly elevated in csKASH-Tg TAC 
compared with FLctrl TAC (Figure 5.24). These data indicated that the 
mechanosensitive gene such as egr-1 responded to the abnormal hemodynamic 































Figure 5.20 Massive myocardial fibrosis was present in csKASH-Tg TAC mice 
Masson’s trichrome were performed on the frozen heart sections (short axis). In the Sham 
group, there was no visible difference in the extents of fibrosis in both FLctrl and csKASH-
Tg heart (A, C). In TAC group, there was massive fibrosis across the whole LV cross sections 
in the csKASH-Tg TAC mice (D, blue arrow), when compared with FLctrl TAC mice that 

























Figure 5.21 Upregulated expression of hypertrophic and fibrotic genes in 
csKASH-Tg TAC mouse hearts 
qPCR analyses showed: in the FLctrl group, there were down-regulated βMHC and αMHC 
expression (A), up-regulated ANP and BNP expression (B), as well as increased expression of 
fibrotic genes Procol1α1 and Procol3α1 (C) in the FLctrl TAC mice when compared with the 
FLctrl Sham. 
Comparing the two TAC groups, the ANP, Procol1α1 and Procol3α1 in csKASH-Tg TAC 
group was significantly increased in csKASH-Tg TAC hearts compared with FLctrl TAC (B, 
C). There were no significant changes in other fetal genes including α/βMHC and BNP in 
csKASH-Tg TAC when compared with FLctrl TAC (A, B). FLctrl Sham n=5, FLctrl TAC 
n=4, csKASH-Tg Sham n=1 and csKASH-Tg TAC n=3. Data was analysed by Student’s t-





























































































































































































































Figure 5.22 qPCR showed SUN2 was reduced in FLctrl TAC mice and lamin 
A/C was increased in csKASH-Tg TAC mice 
(A) Changes in nesprin isoforms: nesprin-2 KASH domain containing isoforms were 7-fold 
high than endogenous KASH2 isoforms in FLctrl group due to overexpression of EGFP-
KASH2 in the csKASH-Tg mouse hearts. KASH2 isoform expression was not altered by the 
TAC procedure in both csKASH-Tg and FLctrl groups. Other nesprin isoforms that contained 


















































































































Figure 5.22 qPCR showed SUN2 was reduced in FLctrl TAC mice and lamin 
A/C was increased in csKASH-Tg TAC mice 
(B) Changes in NE-LINC complex components: SUN2 was significantly down-regulated in 
the FLctrl TAC compared to the FLctrl Sham. Lamin A/C showed an upregulated trend in 
FLctrl TAC when compared with FLctrl Sham, but significantly increased in the csKASH-Tg 
TAC compared with FLctrl TAC. Other NE-LINC complex components including emerin, 
SUN1 and nesprin-1α2 were not altered in all groups. FLctrl Sham n=5, FLctrl TAC n=4, 
csKASH-Tg Sham n=1 and csKASH-Tg TAC n=3. Data was analysed by Student’s t-tests, 















































































































































































Figure 5.23 WB showed no significant changes of expression levels of NE-
LINC complex components in csKASH-Tg after TAC 
(A) Protein levels of NE-LINC complex components including lamin A/C, emerin, SUN1/2 
and nesprin-1α were analysed by WB using the heart tissue derived from FLctrl and csKASH-

















Figure 5.23 WB showed no significant changes of protein levels of NE-LINC 
complex components in csKASH-Tg after TAC 
(B) Statistical analysis showed there were no significant differences in protein levels of lamin 
A/C, emerin, SUN1/2 and nesprin-1α in csKASH-Tg and FLctrl groups before and after 
surgery. FLctrl Sham n=5, FLctrl TAC n=4, csKASH-Tg Sham n=1 and csKASH-Tg TAC 














































































































































































Figure 5.24 Mechanosensitive genes were altered in csKASH-Tg mice under 
the pressure overload 
The changes of mechanosensitive genes in the csKASH-Tg and FLctrl mice before and after 
TAC were investigated. In the FLctrl group, qPCR data showed significant upregulated egr-1 
after TAC procedure compared with the Sham group. Next, two TAC groups were compared. 
egr-1 and c-myc were significantly elevated in csKASH-Tg TAC compared with FLctrl TAC. 
Other mechanosensitive genes including c-jun, iex-1 and c-fos were unchanged in all groups. 
FLctrl Sham n=5, FLctrl TAC n=4, csKASH-Tg Sham n=1 and csKASH-Tg TAC n=3. Data 









































































































































































In this chapter, we successfully generated a cardiac specific KASH2 
overexpression mouse model which exhibited the NE-LINC complex disruption in 
CMs under the MLC2V promotor. The cardiac phenotype and cellular changes of 
csKASH-Tg mice are summarised in Table 5.2. At the basal line, csKASH-Tg mice 
developed normally up to 1 year, and showed a cardiac hypertrophy response with re-
expression of fetal gene βMHC, ANP and fibrotic gene procollagen1α1/3α1 in the 
heart. The mis-localisation of lamin A/C, emerin and endogenous nesprin-1α, 
indicated a disrupted NE-LINC complex in csKASH-Tg mice, which also contributed 
to irregular nuclear morphology in CMs. Under pathological hemodynamic stress, the 
csKASH-Tg TAC mouse hearts showed more severe LV hypertrophic response and 
systolic dysfunction compared to the FLctrl, with increased expression of fetal gene 
ANP and fibrotic genes procollagen1α1/3α1 in hearts. The fibrotic heart in csKASH-
Tg also showed abnormal expression of mechanosensitive genes egr-1 and c-myc, 
indicating that uncoupling of the NE-LINC complex impaired the transduction of 




Table 5.2 Characterisation of cardiac phenotype and cellular changes in csKASH-Tg mice 
 csKASH-Tg 
 Basal line (compared with FLctrl) Under TAC (compared with FLctrl TAC) 
Echocardiography Thicker LV wall, 
reduced LV chamber size, 
unchanged systolic function 
Increased trends: thicker LV wall, enlarged LV 
chamber size, 
exacerbated systolic function 
Histology Thicker LV wall, minor fibrosis Massive fibrosis 
CMs  Enlarged CMs area, irregular nuclear morphology - 
Cardiac fetal genes and 
fibrotic genes 
Increased βMHC, ANP and fibrotic genes 
procollagen1α1/3α1 
Increased ANP and fibrotic genes 
procollagen1α1/3α1 
NE-LINC complex Expression level: increased SUN1 
Localisation: mis-localised lamin A/C, emerin and 
nesprin-1α 
Expression level: increased lamin A/C 
Localisation: - 
Mechanosensitive genes - Upregulated egr-1 and c-myc 




5.3.1 Rationale for generation of cardiac specific nesprin-2 
KASH overexpression mice 
 
Recent studies focused on the NE-LINC complex have shown this structure is 
not only the physical linker between nucleoskeleton and cytoskeleton, but also 
responsible for mechanical force transduction and gene regulation [2, 111, 112, 176, 
178, 190]. The mutations identified in the genes encoding NE-LINC complex 
associated proteins nesprin, SUN, lamin A/C and emerin have all been found to 
associate with the muscle specific diseases DCM and EDMD [3, 4, 53, 86, 87, 145, 
221]. Various animal models have been generated via different strategies to mimic the 
physiological and pathophysiological functions of the NE-LINC complex in muscle 
disease [223, 290]. In particular, the nesprins form the SUN-KASH interaction which 
is a fundamental part of the NE-LINC complex [111, 115]. To date, 13 nesprin murine 
models have been established and have highlighted the critical roles of nesprin-1 and 
-2 in nuclear positioning, mechanotransduction and cardiac or skeletal muscle 
functions [290]. Interestingly, two of these models have shown cardiac related 
phenotypes [4, 85, 221]. Based on the strategy utilised in those mouse models, nesprin-
1 KASH domain or nesprin-2 were globally deleted from the double alleles [85, 221], 
which ignore the potential role of the presence of the WT allele in human disease. 
In our mouse model, the nesprin-2 KASH domain specifically overexpressed in 
the hearts using a DN strategy and driven by the cardiac specific MLC2V promotor. 
The rationales behind using cardiac specific Tg strategy include: 1) Nesprin KASH is 
a well-documented experimental tool that leads to LINC complex disruption, as it is 
the key element in the interaction between nesprin-1/-2 and their NE-LINC complex 
partners [2]. Thus, disruption of the KASH and SUN interaction at NE-LINC complex 
will disrupt endogenous nesprin functions [238, 291], and provide a better model to 
examine the role of the LINC itself rather than individual proteins. 2) Both nesprin-1 
and -2 share a high degree of homology and are highly conserved in this C-terminal 
region, especially the KASH domain. Overexpression the recombinant DN-KASH 
constructs of nesprins-1, -2 and -3 saturates endogenous nesprins from the NE to ER, 
leading to a significant loss of mechanical stiffness and myogenesis defects, similar to 
the effects caused by nesprin-1/-2 mutants as reported [112]. 3) The zebrafish embryo 
data in Chapter 4 showed the expression of nesprin-1α2 WT had the biggest effect in 
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causing heart developmental and conduction defects while the mutations caused less 
severe phenotypes via compromised the binding with other NE-LINC complex 
components. The limitation of this in vivo zebrafish model was the forced expression 
of muscle specific isoform nesprin-1α2 at the one egg stage earlier before myogenesis 
initiation, leading to an ectopic expression effect. In our KASH2 Tg mouse model, the 
expression of DN KASH was initialled from E8.75 under the MLC2V promoter in 
CMs [278]. At this time point, three cardiac regions can be distinguished by the 
bulging morphology: bulbus cordis (future right ventricle), primitive left ventricle, and 
common atrial chamber behind the primitive left ventricle [292, 293]. Therefore, the 
expression of DN-KASH in csKASH-Tg followed the physiological heart 
developmental time point in vivo. 
5.3.2 Cardiac specific nesprin-2 KASH Tg mice induced a 
hypertrophic response especially under the mechanical 
stress 
 
Under basal conditions, csKASH-Tg mice developed a cardiac hypertrophic 
response from 30 weeks up to 1 year. Echocardiography showed increased LV wall 
thickness with unchanged heart systolic function. In addition, the CMs size had 
increased significantly in the csKASH-Tg with deformation of nuclear morphology. 
The fetal genes βMHC and ANP were re-expressed, along with upregulated fibrotic 
gene procollagen1α1/3α1. Those findings indicated that there was a cardiac 
hypertrophic response due to the overexpression of DN KASH in hearts. 
There is widespread agreement that the hypertrophic response is a transition 
phenotype to heart failure (HF). It initially compensates to the physiology or 
pathological changes, but this is then followed by progression of worsening of 
symptoms that lead to HF [294, 295]. LV hypertrophy is a complex phenotype that 
may be influenced by hemodynamic overload and non-hemodynamic variables such 
as ethnicity, gender, neurohumoral, environment etc. [295, 296]. The main factor 
hemodynamic changes can be either physiological (exercise) or pathological. In our 
studies, the mice were not subjected to exercise, and no hypertrophic symptom from 
the original founders (FLctrl) was reported [238, 239]. Therefore, physiology 
hemodynamic changes such as exercise capacity induced hypertrophic hearts in 
athletes can be excluded from the hypertrophy observed in the csKASH-Tg hearts 
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[297]. In addition, when the csKASH-Tg mouse hearts were subjected to pressure 
overload, the LV exhibited an enlarged internal diameter and volume at the end of 
diastole, with massive fibrosis and altered biomechanical gene expression profile 
compared with FLctrl TAC. The deteriorated cardiac response to the hemodynamic 
stress further confirmed that the pathological process induced by DN KASH would 
lead to a more fragile heart. 
LV hypertrophy as the intermediate phenotype of heart failure, can lead to this 
final outcome with reduced EF (HFrEF) or preserved EF (HFpEF) [298]. The latter 
HF accounts for 50% HF, and is characterised with the prolonged isovolumic LV 
relaxation, slow LV filling and increased diastolic LV stiffness [299]. The subcellular 
changes of HFpEF include an increase in the size of CMs, alteration in the ECM with 
accumulation of fibrosis. In our csKASH-Tg mice, the increased LV wall, with 
maintained EF, enlarged CMs, increased accumulation of collagen in ECM and 
fibrosis, indicated the hypertrophic cardiomyopathy (HFpEF) was induced by 
overexpression of DN KASH2. In further studies, the assessment of myocardial strain 
(LV segment movement and deformation) and diastolic functions by 
echocardiography [300] will be needed for the diagnostic evaluation and linking the 
cellular changes with clinical symptoms to elucidate the pathogenesis of the 
cardiomyopathy evident in csKASH-Tg mice. 
5.3.3 csKASH-Tg mice exhibited a late onset and mild 
cardiac phenotype 
 
In this study, csKASH-Tg mice exhibited a deleterious cardiac phenotype with 
a late-onset manner. There are several potential explanations. Firstly, the well 
characterised LMNA mice which showed early onset DCM and HF were due to the 
homozygous KO or mutants (H222P, N195K) knock-in strategy [224, 250, 301]. 
However, the heterozygous LMNA KO mice showed a milder phenotype, with slightly 
decreased EF only at one-year-old [229]. The different severity of DCM can be 
influenced by whether there is a functional WT allele. In our Tg mouse model, the 
expression level of nesprin WT alleles were preserved. Secondly, nesprin-1 and -2 
generate multiple isoforms can act in a compensatory role in cardiac tissue functions 
[34]. Studies indicated the heart phenotype would not have been induced when either 
SYNE-1 or SYNE-2 was knocked out, but required both to be absent [85, 135]. 
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Interestingly, the DCM phenotype did not show in other nesprin KO mouse models 
that targeted on either nesprin-1 or -2 isoforms [124, 136-138], further strengthening 
the compensation hypothesis. Nesprin-2 isoforms have been shown to dynamically 
switch between the nucleus and cytoplasm in CMs under the hypertrophic stimuli in 
vitro or TAC procedure in vivo (Catherine Shanahan lab, unpublished data). Nesprin-
1 showed these isoforms switch during the C2C12 differentiation (Catherine Shanahan 
lab, unpublished data). In csKASH-Tg mice, overexpression DN KASH2 would 
theoretically displace the endogenous nesprin-1 and -2 isoforms containing the KASH 
domain, but the efficiency also depended on the expressed amount/level of GFP-
KASH2. Notably the multiple unidentified nesprin isoforms generated by alternative 
initiation and splicing may contribute to the compensation of NE-LINC complex 
disruption and result in the late onset and milder cardiac phenotype in csKASH-Tg 
mice. 
5.3.4 NE-LINC complex was disrupted in csKASH-Tg mice 
 
The overexpressed DN KASH was shown to mis-localise endogenous nesprin 
from the NE, and disrupt the NE-LINC complex [178, 238, 239]. The fold changes of 
exogenous GFP-KASH2 relative to endogenous KASH2 containing isoform was only 
quantified by qPCR instead of combination of WB. It was due to two reasons: i) there 
are no specific nesprin antibodies generated specifically against the region of KASH2 
domain; ii) there are numerous nesprin-2 KASH containing isoforms which vary in 
size (nesprin-2 giant is around 800kDa whereas GFP-KASH2 is 31kDa). It is very 
challenging to detect all of them on one blotting and compare the intensity of multiple 
bands with GPF-KASH2. In our mouse model, the expression level of SUN1 was 
increased in csKASH-Tg compared with FLctrl in the basal line. The expression of 
SUN2 was upregulated under the TAC procedure in FLctrl TAC compared with FLctrl 
Sham, and lamin A/C was increased in conjunction with overexpressing KASH and 
pressure overload. Other NE-LINC complex components emerin and nesprin-1α were 
unchanged in csKASH-Tg and FLctrl before and after TAC. Those subtle changes in 
expression level of the NE-LINC complex components were consistent with other 
nesprin mouse models. In nesprin-1 KASH KO mice, lamin A/C level was unchanged 
in the heart [4]. Global nesprin-1 KO mice have only increased SUN1 in the heart 
lysate [135]. Even in the double SYNE-1 and SYNE-2 KO mice, both the protein and 
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RNA levels of those LINC complex components are more variable, but without 
statistical difference [85]. Combined with all the nesprin mouse models, it is 
reasonably to postulate that: loss of either nesprin-1 and/or -2 would not dramatically 
alter expression profiles of NE-LINC complex associated proteins; SUN1 may serve 
as the dominant SUN protein to form the SUN-KASH bridge in the heart; the minimal 
changes of expression levels of the NE-LINC complex components may be amplified 
by the pathological changes such as pressure overload and result in HF in csKASH-
Tg mice. 
In addition, with such minimal changes of the expression level, the localisation 
of those NE-LINC complex factors were surprisingly reduced at the NE in the 
csKASH-Tg heart. Overexpression of GFP-KASH2 reduced endogenous nesprin-1α, 
lamin A/C and emerin from the CMs, similar to the effect caused by nesprin-1 mutants 
from DCM patients in Chapter 3. In nesprin double KO mice, loss of both nesprin-1 
and -2 have a significant impact on the localisation of both lamin A/C and emerin in 
the CMs [85]. Those findings indicated that dysfunction of nesprin have more impact 
on changing the localisation of associated proteins rather than altering their expression 
levels. In addition to the reduced bindings between nesprin and lamin A/C and SUN2 
caused by nesprin-1α mutations in Chapter 3, it is plausible that the disrupted NE-
LINC complex in CMs was induced by the mis-localisation of NE-LINC complex 
components and their perturbed bindings. 
5.3.5 Functions of NE-LINC complex were perturbed in 
csKASH-Tg mice 
 
The force transmission from the ECM to the nucleus is dependent on the intact 
NE-LINC complex [112, 176, 215]. Components of NE-LINC complex such as lamin 
A/C, emerin and nesprin-1/-2 have been shown to participate in mechanotransduction 
and regulate the mechanosensitive genes (egr-1, iex-1, c-fos, c-myc and c-jun) [85, 
211, 213, 214]. MEFs derived from LMNA or EMD null mice had reduced expression 
of the mechanosensitive genes egr-1 and iex-1 [213, 214]. Isolated CMs lacking both 
nesprin-1 and -2 displayed attenuated biomechanical genes (egr-1, iex-1, c-fos, c-myc 
and c-jun) in response to stretching [85]. In vivo pressure overload models, egr-1 null 
mice had reduced LV hypertrophic response to the pressure overload [302], suggesting 
egr-1 was a crucial regulator in pathological cardiovascular processes. In addition, 
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heterozygous LMNA null mice exhibited attenuated hypertrophy with absent induction 
of egr-1 and iex-1 at 1-week post-surgery compared to the WT mice [229]. Thus, 
hyper-activation of mechanosensitive genes egr-1 and iex-1 might be positive 
correlated to the ventricular and CMs hypertrophy. In our csKASH-Tg mice, the LV 
remodelling was accelerated by pressure overload, and this was associated with an 
increased response of mechanosensitive genes egr-1 and c-myc, whereas other 
mechanosensitive genes iex-1, c-fos and c-myc were similar to the FLctrl TAC. These 
data further reinforce the hypothesis that the disrupted NE-LINC complex impairs 
mechanotransduction signalling and influences the eventual biochemical response. 
One explanation is that the nucleus as the mechanosensor is impaired and is made 
deficient by the disrupted NE-LINC complex. The changed nuclear morphology and 
stiffness increased the susceptibility of nuclei to the mechanical strain. Moreover, 
another intriguing explanation could be that the up-regulated lamin A/C in csKASH-
Tg mice contributed to the dysregulation of mechanical sensitive genes. Lamin A/C 
has been shown to directly interact with another biomechanical gene c-fos at the NE 
to suppress Activating Protein 1 (AP-1). Meanwhile, c-fos in the nucleus can down-
regulate egr-1 [303]. Increased lamin A/C with unchanged c-fos expression in our 
csKASH-Tg TAC mice may sequester more c-fos at the NE and result in fewer c-fos 
in the nuclear interior and cause increased gene expression of egr-1 in response to 
pressure overload. 
Of note, all those mechanosensitive genes showed a rapid response to 
mechanical stretch. In vitro, these genes show induction response within 1-2 hours and 
go back to basal line within 2 days [211, 304]; while in vivo, the rapid response can be 
detected at 1 week and returns to normal at 3 weeks [229, 305]. Due to the different 
experimental conditions and the various severity of the pressure overload models, it is 
necessary to examine the dynamic changes of mechanosensitive genes in the csKASH-
Tg mouse model and to choose the appropriate time point to investigate the impact of 
disrupted NE-LINC complex on transduction of mechanical stimuli into biochemical 






Taken together, the data from csKASH-Tg mice suggested that: 
1. Overexpression of DN-KASH in CMs disrupted the NE-LINC complex 
and induced a hypertrophic response with activated fetal gene re-
expression, which was likely a compensatory response at the early phase 
of developing DCM. 
2. The disrupted NE-LINC complex in csKASH-Tg mice led to a more 
susceptible heart under the mechanical stress, resulting in a decline in 
cardiac cell functions and defects in force transmission and 
mechanotransduction. This was consistent with the late-onset of DCM in 
general, which again validated the model compared to other existing 
nesprin KO models.  
3. In future work, we will focus on investigating the roles of nesprin-1/-2 
and NE-LINC complex in nuclear migration, sarcomeric structure and 
functions in CMs using this csKASH-Tg mouse model.
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Chapter 6: General discussion and future 
directions 
 
6.1 Thesis summary 
 
In this study, three novel rare variants (R8272Q, S8381C, and N8406K) in the 
C-terminus of the SYNE-1 gene (nesprin-1) were identified in 7 DCM patients by 
mutation screening. These nesprin-1 mutants caused increased NE fragility and NE-
LINC complex disruption, leading to defects in mechanotransduction and myogenesis 
in vitro, which was further investigated preliminarily in zebrafish embryos and a 
cardiac specific KASH2 Tg mouse model. These data suggest that nesprin-1 plays 
multi-functional roles at the NE. These nesprin-1 mutants and DN-KASH comprise 
NE-LINC complex, leading to defects in NE organisation, myogenesis, which may 
contribute to pathogenesis of DCM. 
 
6.2 Discussion and future direction 
6.2.1 Roles of nesprin-1/-2 in NE-LINC complex 
 
The multi-isometric scaffolding proteins nesprin-1/-2 play multiple functions at 
the NE-LINC complex (Figure 6.1). In general, large nesprin-1/-2 isoforms localise at 
the ONM, forming the SUN-KASH trimetric interaction at the perinuclear space, and 
linking the nucleus to the cytoskeleton via their CH domains binding to F-actin [111, 
183]. Meanwhile, small nesprin-1/-2 isoforms localise at the INM, interacting with NE 
proteins, emerin, SUN1/2 and the nuclear lamina to form the NE complex [35]. In 
addition, lamin A/C and emerin can directly bind with chromatin-associated proteins 
such as HP-1, BAF and H2A-H2B histone dimers, which is important for maintaining 
chromatin architecture, regulating cell signalling and gene expression during different 
cellular activities. This NE-LINC complex strengthen the connection from inside of 
the nucleus to the cytoskeleton and further to the ECM. 
In Chapter 4, it was shown for the first time that small nesprin isoforms lacking 
CH domains such as nesprin-1α2 also localise at the ONM. These isoforms interacted 
with microtubule motor proteins kinesin-1 to drive the nuclear distribution during 
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muscle cell differentiation. Nesprin-1 mutations perturbed myoblast fusion and 
differentiation in a similar manner to the depletion of KLC-1/2. The expanding 
interactions of nesprins with cytoskeleton elements at both the ONM and INM 





















Figure 6.1 Working model for the roles of nesprin-1/-2 
The schematic figure shows nesprin-1/-2 play multiple-functions at both INM and ONM. 
Large nesprin-1/-2 isoforms localise at the ONM, forming the SUN-KASH bridge at the 
perinuclear space, and linking the nucleus to the cytoskeleton via the CH domains binding to 
the F-actin. Small nesprin isoforms lacking the CH domains such as nesprin-1α2 also localise 
at the ONM, forming the microtubule LINC via the interaction with microtubule motor 
proteins kinesin-1. Meanwhile, small nesprin-1/-2 isoforms in the INM can interact with NE 
proteins, emerin, SUN1/2 and nuclear lamina to form NE complex. The NE complex at INM 
and LINC complex at ONM together form the NE-LINC architecture strengthen the 





































muscle cell differentiation. Nesprin-1 mutations perturbed myoblast fusion and 
differentiation in a similar manner to the depletion of KLC-1/2. The expanding 
interactions of nesprins with cytoskeleton elements at both the ONM and INM 
facilitate scaffolding of the overall cellular structure and maintain cellular 
homeostasis. 
6.2.2 Genotype and phenotype correlation of nesprin-1 
mutations 
 
Nesprins, especially nesprin-1, have been implicated in a wide range of diseases, 
including EDMD, DCM, AMC, CMD, ARCA1, ASD and bipolar disorder [3, 4, 122, 
155-157, 159, 161, 166-168]. Summarisation of all mutations in the SYNE-1 gene: the 
majority (around 85%) of known mutations associated with muscle disease such as 
EDMD and DCM are heterozygous missense mutations localised at the C-terminus of 
nesprin-1 giant, equivalent to muscle specific isoform nesprin-1α2. Mutated 
nucleotides in this region can cause amino acid substitution and loss/gain of protein 
functions [306]. Mutated nesprin-1 may increase the instability of the NE-LINC 
complex scaffolding in muscle cells, leading to structural disruption. In contrast, 
mutations affecting CNS development are homozygous and scatter along the whole 
SYNE-1 gene. The nonsense mutations cause amino acids substitution that introduce a 
stop codon [306]. This premature stop codon results in many truncated nesprin-1 
variants lacking SRs and KASH domain or absence of nesprin-1 due to nonsense-
mediated decay of mutant mRNA [162, 164]. The varied positions of mutations in the 
SYNE gene and their related diseases indicate: 1) The KASH domain and CH domain 
containing isoforms have tissue specific scaffolding functions in muscle and CNS 
respectively; 2) The mutations localised at the nesprin-1α2 region resulting in the 
EDMD and DCM further highlight that muscle specific isoforms are indispensable for 
maintaining normal heart and skeletal muscle function. 
In my studies, I utilised the novel nesprin-1 mutants identified in DCM patients 
and investigated their impacts on the NE-LINC complex in vitro and in vivo (zebrafish 
embryos development), and further characterised the effects of nesprin mutants in 
heart via generating the cardiac specific KASH2 Tg mouse model. The compromised 
functions of NE-LINC complex caused by nesprin-1/-2 mutants can be summarised 
into three major aspects: 1). Nesprin-1 mutations and DN KASH2 altered nuclear 
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morphology, mis-localised its binding partners lamin A/C and SUN2 from the NE, 
which have both been confirmed both in vitro and in vivo. Furthermore, the three novel 
nesprin-1 mutants perturbed interactions between nesprin-1 and NE-LINC complex 
associated proteins including lamin A/C and SUN2 at the INM, as well as the 
microtubule motor proteins KLC-1/2 at the ONM. These changes resulted in the 
disrupted NE-LINC complex, uncoupling the nucleoskeleton from the cytoskeleton 
(F-actin and microtubule), and compromised the functions of NE-LINC complex as a 
physical linker and force transmission propagator. 2) Nesprin-1 can recruit KCL-1/2 
to the NE through a highly conserved ‘LEWD’ motif and drive nuclei distribution 
during myotube formation. The altered interaction between nesprin-1 and KLC-1/2 in 
myoblasts and myotubes affected microtubule mediated nuclear migration and 
positioning, leading to defects in myogenesis. 3) The disrupted NE-LINC complex and 
irregular nuclear morphology is likely to influence chromatin structural integrity. Mis-
localised emerin and lamin A/C may also alter binding with chromatin-associated 
proteins such as HP-1 and BAF. Disruption of these interactions would affect cell 
signalling and gene regulation including : augmented cell signalling (hyperactivation 
of MAPK kinase induced by nesprin-1 mutants), dysregulated gene expression 
(perturbed myogenic regulatory factors by nesprin-1 mutants in muscle cell 
differentiation in vitro and upregulated cardiac fetal genes and fibrotic genes by 
overexpression of DN KASH2 in heart in vivo) and abnormal mechanotransduction 
(altered mechanosensitive genes in csKASH-Tg mice under pressure overload). The 
compromised NE-LINC complex functions shown in these three aspects (Figure 6.2) 






















Figure 6.2 Working model for nesprin-1/-2 mutants 
The schematic figure shows how nesprin-1/-2 mutants disrupt the NE-LINC complex, 
contributing the pathogenesis of muscle disease. * indicates where the nesprin-1 mutants are; 
GFP-KASH indicates the strategy of mouse model in Chapter 5; number 1-3 indicate the 
affected NE-LINC complex functions by nesprin-1 mutants or DN KASH2 (1. structural 

























































6.2.3 Further characterisation of csKASH-Tg mice 
6.2.3.1 Investigating the roles of NE-LINC complex in nuclear 
positioning in CMs 
 
NE-LINC complex plays a critical role in nuclear migration and positioning [69, 
118, 180, 185, 191]. In EDMD patients carrying SUN mutations or C2C12 myoblasts 
overexpressing SUN mutants, gross defects in myonuclear arrangement were detected 
which was caused by impaired microtubule nucleation [87]. In Chapter 4, the three 
novel nesprin-1α2 mutants perturbed the interaction with microtubule motor proteins 
and this resulted in defects of myonuclear fusion and positioning in C2C12 myoblasts. 
In contrast to skeletal muscle cells, it remains unknown if there is a nuclear migration 
defect in CMs in our csKASH-Tg mice. In murine animals, CMs stop proliferation and 
finish karyokinesis within several days after birth and then maintain a diploid nucleus 
for the rest of their lives [307, 308]. Studies show during this short period, centrosome 
integrity is disassembled and microtubule-organizing centre (MTOC) factors such as 
pericentrin and pericentriolar material 1 protein (PCM-1) are re-localised to the NE 
depending on the recruitment of microtubule motor proteins kinesin-1 and 
dynein/dynactin to achieve the post-mitotic state in CMs [309, 310]. PCM-1 [310] and 
pericentrin (personal communications with Dr. Sue Shackleton’s lab, University of 
Leicester, unpublished data) have been shown to interact with nesprin-1α2 at the ONM. 
In addition to that we have confirmed the interaction between nesprin-1α2 and 
microtubule motor proteins kinesin-1 in Chapter 4. Therefore, it will be interesting to 
investigate if there is any defect in microtubule organisation and how they are related 
to nuclear positioning in CMs in our csKASH-Tg model, and explore the role of the 
NE-LINC complex in the post-mitotic state of mammalian cardiomyocytes. 
6.2.3.2 Investigating the potential roles of nesprin-1 in nuclear Ca2+ 
transient in CMs 
 
The cardiomyopathy related LV remodelling is a complex process involving 
cardiac myocyte growth and death, vascular rarefaction, fibrosis, inflammation, and 
electrophysiological remodelling [311, 312]. The hypertrophic response in csKASH-
Tg at basal line and the more severe LV remodelling under pathological hemodynamic 
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stress is similar to the cardiomyopathy phenotypes developed in the late-onset DCM 
patients in our study. 
Literatures showed intracellular Ca2+ plays central roles in physiology and 
pathology of CMs, such as excitation-contraction coupling and secondary messengers, 
and alteration of the nuclear Ca2+ transient is an early event in cardiac remodelling 
[313, 314]. Recent data showed the NE protein emerin plays a role in nuclear transient 
in CMs, as EDMD induced pluripotent stem (iPS) cell-derived cardiomyocytes 
carrying emerin mutations were shown to have increased half decay time of nuclear 
Ca2+ transient [247]. However, the underlying mechanism regarding how emerin 
mutants cause defects in nuclear Ca2+ transient is unknown. In addition, literature 
showed nesprin-1α could anchor muscle A-kinase anchoring protein (mAKAP) at the 
NE to control the Ca2+ release channel of the sarcoplasmic reticulum in CMs [258]. 
We propose nesprin and emerin regulate the intracellular Ca2+ transients through the 
NE-LINC complex. Therefore, the Ca2+ transients in CMs will be investigated using 
our csKASH-Tg mouse model. This may provide us with additional information for 
the roles of NE-LINC complex in CM dysfunction and could be used as potential 
therapeutic targets in DCM/EDMD and cardiac remodelling. 
6.2.3.3 Gene expression profile analysis in hearts from csKASH-Tg 
mice 
 
NE-LINC complex disruption has been shown to alter the levels and distribution 
of heterochromatin and thus may have an effect on the epigenetic status of myocyte 
nuclei, in turn altering the transcriptome of the cell in response to normal contractile 
activity or mechanical stress [315-317]. In the published LINC complex mouse 
models, genome-wide expression analysis has shown MAPK activation is significantly 
elevated in LMNAH222P and EMD null mice [194, 195]. Using MAPK inhibitors prior 
to the onset of cardiomyopathy and muscular dystrophy can prevent the development 
of DCM and EDMD [207-209, 226, 227]. In this thesis, the augmentation of ERK 
activation was shown in HDFs carrying EDMD mutations and KASH1 KO mouse 
hearts, as well as C2C12 cells overexpressing nesprin-1α2 mutations. Thus, it will be 
interesting to examine csKASH-Tg and FLctrl mice after TAC via Affymetrix 
microarray analysis, to explore the expression profiles of dysregulated genes and 
associated signalling pathways in additional to the well characterised MAPK pathway. 
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This additional information would provide novel cues for further mechanistic 




In this thesis, I have characterised how nesprin-1/-2 mutants affect NE 
organisation, myogenesis and how this can contribute to DCM via the NE-LINC 
complex associated structural disruption and gene dysregulation. In future, improved 
knowledge of the diverse nesprin isoforms that exist, elucidation of the myriad of 
nesprin binding partners and their functions in NE-LINC complex in cardiomyocytes 
will help to uncover novel mechanisms whereby disruption of the NE-LINC complex 
contribute to development of cardiac cell dysfunction and pathogenesis of DCM, thus 
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Appendix I. Clinical features of research subjects 
 






Gender, % male 67.0 (158/218) 51.0 (117/210) 0.0007 
Age at diagnosis/inclusion, year 48.3±15.2 49.2±9.2 0.4565 
LVEDD, mm/m2 66.3 ±9.1 45.1 ± 5.9 <0.0001 
LVEF, % 33.2 ±13.3 59.3 ± 8.9 <0.0001 
 
Clinical features refer to the time of presentation. LVEDD, left ventricular end 
diastolic diameter;  
LVEF, left ventricular ejection fraction. 
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Appendix II. Rare (<1%) nesprin-1 variants identified in DCM 
patients 
 
Exon DNA variation Amino acid 
exchange 
Allele frequency in patients 
(%, n=436 alleles) 
Allele frequency in a reference 
population (%, n=420 alleles) 
136 c. 25417 G>A p. R8272Q 0.46 0 
139 c. 25743 A>T p. S8381C 0.46 0 
139 c. 25820 C>A p. N8406K 0.69 0 
133 c. 24299+12 G>A intron 0.69 0 
135 c.24308+3 A>G intron 0.46 0 
136 c.25463 C>T p.H8287H 0.92 0 
139 c.25730 G>C p.L8376L 0.69 0 
139 c.25748 C>T p.S8382S 0.46 0 
 
GenBank reference sequence: nesprin-1 giant (SYNE-1): AF495910.1; 1a2: 
AY184203.1. Nucleotide and amino acid numbers are based on nesprin-1 giant. n, 
number of alleles analysed.
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Appendix III: Clinical description of the patients harbouring 
the mutations identified in this study 
 
Patient No.1 was a male carrying the R8272Q mutation. He had no family history 
of cardiovascular diseases and suffered shortness of breath after exertion since his 
forties. He was diagnosed with DCM and started receiving drug therapy including 
diuretics and digoxin since the age of 59. His symptom exaggerated at the age of 68, 
echocardiography showed the LV diameter was 90mm with very thin interventricular 
septum (IVS) and left ventricular posterior wall (LVPW). LVEF was 26%. N-terminal 
pro-B-type Natriuretic Peptide (pro-BNP) was 2912pg/ml, significantly greater than 
normal reference value (0-227pg/ml). ICD was subsequently implanted. The patient 
died of progressive left-sided heart failure one year later. 
 
Patient No.2 was a male carrying the R8272Q mutation. He has no family history 
of cardiovascular diseases. He suffered shortness of breath after exertion since the age 
of 52, one year later he was diagnosed with DCM. Echocardiography showed the LV 
diameter was 72mm, LVEF was 37%. 
 
Patient No.3 was a male carrying the S8381C mutation. He has no family history 
of cardiovascular diseases. He suffered shortness of breath after exertion at the age of 
56, the LV diameter was 56 and LVEF was 34%. ECG showed sinus rhythm, the pro-
BNP level was 1847pg/ml, greater than the normal reference value. He was treated 
with beta-blocker, diuretics and digoxin and then free of symptom. At the age of 62, 
echocardiography showed the LVEF was 24%. ECG showed atrial fibrillation (AF), 
pro-BNP increased to 4140pg/ml. 
	
Patient No. 4 was a male carrying the N8406K mutation. He has no family 
history of cardiovascular diseases. His first symptom was repeated palpitation. At the 
age of 67, he began to feel fatigue after exertion. Ambulatory electrocardiogram 
revealed ventricular tachycardia. Echocardiography showed his LV diameter was 
67mm and LVEF was 42%. He refused ICD implantation and thus was treated with 




Patient No. 5 was a male carrying the N8406K mutation. He has no family 
history of cardiovascular disease. He suffered shortness of breath after exertion at the 
age of 68, ECG showed AF. He was treated with beta-blocker, diuretics and digoxin. 
He died of cardiac arrest at the age of 68. The diagnosis of DCM was further confirmed 
by autopsy. 
No clinical data was available for patient No. 6 (S8381C) and No.7 (N8406K).
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Appendix IV:  List of methods and results contributed by 
collaborators 
 




screening in DCM patients 
Result 3.1.1: Identification of three 
novel nesprin-1 mutants in DCM 
patients. 
Appendix I: Clinical features of 
research subjects; II: Rare (<1%) 
nesprin-1 variants identified in 
DCM patients; III: Clinical 
description of the patients 
harbouring the mutations identified 
in this study. 
Sichuan 
University 
The impact of nesprin-1α2 
WT and mutants during 
Zebrafish embryonic 
development  
Method 2.6.8: Zebrafish. 
Result 4.2.10 Human nesprin-1α2 
WT causes heart developmental and 
conduction defects in zebrafish 
embryos while mutants induce a 
less severe heart phenotype. 
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Appendix V: Novel nesprin-1 mutations associated with 
dilated cardiomyopathy cause nuclear envelope disruption 
and defects in myogenesis
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Abstract
Nesprins-1 and -2 are highly expressed in skeletal and cardiac muscle and together with SUN (Sad1p/UNC84)-domain
containing proteins and lamin A/C form the LInker of Nucleoskeleton-and-Cytoskeleton (LINC) bridging complex at the nu-
clear envelope (NE). Mutations in nesprin-1/2 have previously been found in patients with autosomal dominant Emery–
Dreifuss muscular dystrophy (EDMD) as well as dilated cardiomyopathy (DCM). In this study, three novel rare variants
(R8272Q, S8381C and N8406K) in the C-terminus of the SYNE1 gene (nesprin-1) were identified in seven DCM patients by muta-
tion screening. Expression of these mutants caused nuclear morphology defects and reduced lamin A/C and SUN2 staining at
the NE. GST pull-down indicated that nesprin-1/lamin/SUN interactions were disrupted. Nesprin-1 mutations were also asso-
ciated with augmented activation of the ERK pathway in vitro and in hearts in vivo. During C2C12 muscle cell differentiation,
nesprin-1 levels are increased concomitantly with kinesin light chain (KLC-1/2) and immunoprecipitation and GST pull-down
showed that these proteins interacted via a recently identified LEWD domain in the C-terminus of nesprin-1. Expression of
nesprin-1 mutants in C2C12 cells caused defects in myoblast differentiation and fusion associated with dysregulation of
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myogenic transcription factors and disruption of the nesprin-1 and KLC-1/2 interaction at the outer nuclear membrane.
Expression of nesprin-1a2 WT and mutants in zebrafish embryos caused heart developmental defects that varied in severity.
These findings support a role for nesprin-1 in myogenesis and muscle disease, and uncover a novel mechanism whereby dis-
ruption of the LINC complex may contribute to the pathogenesis of DCM.
Introduction
Dilated cardiomyopathy (DCM) is characterised by dilatation
and impaired contraction of the left ventricle or both ventricles,
and is an important cause of heart failure and sudden cardiac
death, particularly in the young. The genetic causes of DCM are
extremely complicated and over 50 genes have been implicated,
many of them encoding components of the cytoskeleton and
nuclear envelope (NE) (1,2).
Mutations in the LMNA gene, encoding the nuclear inter-
mediate filament proteins lamin A/C, account for 6% of familial
DCM patients in addition to causing a wide spectrum of dis-
eases, named laminopathies. The laminopathies include
Emery-Dreifuss muscular dystrophy (EDMD), which manifests
with skeletal muscle wasting, heart conduction defects (CD) and
DCM (3,4). Mutations in the EMD gene, encoding the inner nu-
clear membrane (INM) protein emerin, a binding partner of
lamin A/C, also cause EDMD with CD (5). How mutations in both
emerin and lamin A/C, which are ubiquitously expressed pro-
teins, can lead to muscle-specific diseases has been a subject of
debate for some time. However, evidence has shown that lamin
A/C and emerin are both associated with the LInker of
Nucleoskeleton and Cytoskeleton (LINC) bridge complex, which
links the nucleus to the actin cytoskeleton. The major compo-
nents of the LINC complex are: nesprins-1 and -2 (NE-spectrin
repeat proteins) and SUN (Sad1p/UNC84)-domain containing
proteins (SUN1/2) (6–8). Nesprin-1 and -2 can bind actin via a
paired N-terminal Calponin Homology (CH) actin binding do-
mains and the nuclear membrane via a C-terminal Klarsicht/
ANC-1/Syne Homology (KASH) domain (9,10). The KASH domain
also binds to SUN1/2 which span the INM and bind to lamin A/C
directly via their N-terminal nucleoplasmic domain, thus
providing a physical connection between the nucleus and the
cytoskeleton (6,11,12). Mutations in nesprin-1 and -2 have been
implicated in EDMD 4 (AD-EDMD 4, OMIM 612998) and 5 (AD-
EDMD5, OMIM 612999), and SUN1 and SUN2 have also been
implicated in EDMD (13–16). Thus, it has been suggested that
disruption of the LINC complex by LMNA and EMD mutations,
as well as SYNE (nesprin) and SUN mutations, may trigger ef-
fects on either chromatin structure causing deregulation of
gene expression, or disruption of structural organisation of the
cell, which is particularly important in muscle as it is subject to
mechanical strain.
Another mechanism that may explain tissue specific disease
is muscle-specific expression of LINC complex components.
Alternative transcription and splicing of SYNE1 and SYNE2, the
genes encoding nesprin-1 and -2, generate multiple isoforms
that vary greatly in size (17). The largest giant nesprin-1 and
-2 isoforms localise at the outer nuclear membrane (ONM) and
connect the nucleus to the actin cytoskeleton. However, smaller
nesprin-1 and -2 isoforms, with a truncated N-terminus but
sharing spectrin repeats (SRs) in common with the C-terminal
regions of the giant proteins, also localise at the INM
where they bind to emerin, lamin A/C and SUN1/2, forming a
complex at the INM (18). These smaller isoforms, in particular,
nesprin-1a2 and -2a1, are highly and specifically expressed in
cardiac and skeletal muscle (7,19). Thus, mutations in SYNE1/2
that disrupt these specific nesprin-1 and -2 isoforms, or muta-
tions in other components of the LINC complex that disrupt
their binding with nesprin-1 and -2, are likely to play a key role
in muscle-specific laminopathies.
In support of this notion, mutations in the C-terminal re-
gions of the nesprin-1 (SYNE1) and -2 (SYNE2) genes have been
identified in patients with muscle specific disorders. This is in
contrast to mutations located towards the N-terminus, which
are associated with ataxia (13,14,20). For example, several mis-
sense mutations in the C-terminus were identified in several
small family pedigrees, as well as in sporadic EDMD patients
with DCM (13). Studies in fibroblasts from these patients
showed abnormal localisation and binding of the LINC complex
proteins lamin, emerin and SUN2, as well as nuclear morph-
ology defects and loss of NE integrity. A missense mutation in
the same C-terminal region of the SYNE1 gene was identified in
a DCM patient, which resulted in increased expression of
nesprin-1 and lamin A/C, also indicating a perturbation of the
LINC complex (14). Furthermore, nesprin-1 KASH domain
knockout (KO) mice developed an EDMD-like phenotype and
DCM (21), displaying muscle degeneration with elongated nuclei
and reduced heterochromatin. Ablation of the C-terminal re-
gions of both nesprin-1 and -2 in cardiomyocytes resulted in
early onset cardiomyopathy (22). These mutant cardiomyocytes
exhibited altered nuclear positioning, shape, and chromatin
positioning, leading to impairment of gene expression in re-
sponse to biomechanical stimuli due to loss of either nesprin -1
or -2 or both (22). Finally, in studies in vitro, overexpressing
dominant-negative versions of nesprin KASH or SUN proteins in
mouse C2C12 myoblasts perturbed the mechanical control of
cell differentiation (23). In these studies, nuclear displacement
and defects in nuclear rotation were also noted, implicating the
LINC complex in myonuclear positioning.
Indeed, recent data have shown that the C-terminal region
of nesprin mediates myonuclear positioning by attaching the
microtubule (MT) network to the NE during embryonic muscle
development and cell migration (24). These interactions occur
via the MT motor proteins, dynein and kinesin, the latter being
a heterotetramer of two kinesin heavy chain (KHC) subunits -
Kif5A, Kif5B, or Kif5C- and two kinesin light chain (KLC)-1/2 sub-
units. Nesprin-2 was shown to interact with KLC-1/2 at the ONM
via a newly identified four-residue tryptophan-acidic (W-acidic)
‘LEWD’ binding motif within an adaptive domain (AD) at its
C-terminus, which is present in all muscle-specific isoforms
(25–27). Disruption of the LINC complex with a dominant-
negative nesprin-2 KASH impaired kinesin-1 association with
the NE and induced nuclear aggregation in myotubes (24). As
both nesprin-1 and -2 are highly conserved in this C-terminal
region, it is likely that nesprin-1 may also mediate the nesprin/
KLC interaction via the ‘LEWD’ binding motif but so far this has
not been tested.
In this study, we screened the SYNE1 and SYNE2 genes in 218
DCM patients. We identified three novel nesprin-1 variants
(R8272Q, S8381C, and N8406K) in seven patients and investi-
gated their roles in NE organisation and myogenesis.
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Results
Identification of three novel nesprin-1 mutants in
DCM patients
Mutation screening of both the SYNE1 and SYNE2 genes was
performed in 218 sporadic cases of DCM and 210 ethnically
matched controls (Supplementary Material, Table S1). 23 exons
for nesprin-1 corresponding to nesprin-1a1 and 1a2 and 16 exons
for nesprin-2 corresponding to isoforms nesprin-2a, 2b and 2e
were screened. This screening strategy was based on high and
specific expression of these isoforms in cardiac and skeletal
muscle as well as mapping of the lamin A/C, emerin, SUN and
KLC binding sites to domains within these isoforms (19,28–30).
Twelve single nucleotide polymorphisms (SNPs)/variants in
SYNE1 were identified, which included intronic sequence vari-
ations (n¼ 2), synonymous (n¼ 5) and non-synonymous, amino
acid exchanges (n¼ 5). Eight of the variants were not present in
420 control alleles of an ethnically matched reference popula-
tion (Supplementary Material, Table S2). No nesprin-2 SNPs/
variants were identified in the region screened. Interestingly,
three of the identified nesprin-1 mutations were unique DNA
variants, which resulted in R8272Q, S8381C, N8406K amino acid
exchanges in the C-terminus of the nesprin-1 giant as well as
within the muscle specific isoform nesprin-1a2, and identified in
seven unrelated DCM patients (Fig. 1A, Supplementary
Material). The amino acids changed by these missense muta-
tions were in regions that were evolutionarily well conserved
and within the mapped emerin and lamin A/C binding domains
(25) and also the proposed KLC-1/2 binding domain in nesprin-1
(24,27) (Fig. 1B). The rarity of these variants and their conserva-
tion and positioning suggest they may be causative for DCM in
the patients examined. ExAC database search revealed
that population frequencies for the R8272Q allele were
0.0002145 (26/121204). Further in silico functional analyses
showed that all three variants are predicted to cause significant
functional impairment for nesprin-1 (Polyphen-2: possibly dam-
aging, SIFT: damaging and Mutation Taster: disease causing).
Therefore, all three rare variants were included in further cell
biological investigations.
Over-expression of nesprin-1 mutants disrupted nuclear
morphology and reduced lamin A/C and SUN2 staining
at the NE
We generated GFP-tagged wild-type (WT) and mutant R8272Q,
S8381C, N8406K constructs in the context of the muscle specific
isoform nesprin-1a2 (Fig. 2A). When transfected into human
osteosarcoma (U2OS) cells, abnormalities of nuclear morph-
ology, measured by nuclei circularity, were induced by con-
structs harbouring the three novel nesprin-1 mutants when
compared with WT (Fig. 2B and E). Immunofluorescence (IF)
staining showed exogenous expression of the mutants, espe-
cially S8381C, caused weaker staining of lamin A/C at the NE
(Fig. 2C and E and Supplementary Material, Fig. S1A), while all
three mutants caused weaker staining of SUN2 at the NE, when
compared with WT nesprin-1a2 (Fig. 2D and E and
Supplementary Material, Fig. S1B). In addition, emerin was mis-
localised by both the WT and mutants when compared with
GFP alone (Fig. 2E). When the same constructs were transfected
into neonatal rat cardiomyocytes (NRCs), IF staining showed
that both lamin A/C and SUN2 staining was weaker at the NE
with all three mutants compared with WT nesprin-1a2 (Fig. 2F
and G and Supplementary Material, Fig S1C and D), indicating
nesprin-1 mutants differentially affect the localisation of NE
binding partners.
Figure 1. Identification of nesprin-1 variants in DCM patients. Mutation screening in SYNE1 and 2 genes was performed in 218 DCM patients and 210 healthy controls,
and identified seven patients harbouring three novel nesprin-1 mutations (R8272Q, S8381C, N8406K, shown in bold) in the C-terminus of nesprin-1 giant (A), equivalent
to nesprin-1a, within an evolutionally conserved region containing the lamin and emerin binding domains (A, B). Previously identified nesprin-1 mutants in DCM
(R8212H) and EDMD-CD patients (R8095H, V8387L and E8461K) were also shown (13,14). The KLC binding motif (LEWD) is shown in (B) (24,27).
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Figure 2. Overexpression of nesprin-1 mutants caused abnormal nuclear morphology and reduced NE staining of lamin A/C and SUN2. GFP-tagged nesprin-1a2 WT and
mutants are shown schematically (A). The full length of this isoform is 977 amino acids, equivalent to amino acids 7875–8796 in nesprin-1 Giant. U2OS cells were trans-
fected with either GFP-nesprin-1a2 WT or mutants. IF staining showed overexpression of mutants, especially S8381C, led to abnormalities in nuclear morphology (B),
reduced lamin A/C and SUN2 staining at the NE (C, D, arrowed). The mis-shapen nuclei were measured by circularity, and mislocalisation of lamin A/C, SUN2 and
emerin in the transfected cells was quantified by comparing the NE staining in non-transfected cells on the same slide. Graphical representation of the frequency of
misshaped nuclei and defects in lamin A/C, SUN2, and emerin at the NE caused by all three mutants (E). At least 100 transfected nuclei were counted in more than
three individual experiments and the results are presented as mean 6 SEM and also analysed by Student’s t-tests and one-way ANOVA. (*P < 0.05 compared with WT;
#: P < 0.05 compared with GFP only). In addition, IF showed both lamin A/C and SUN2 staining at the NE was reduced in the transfected NRCs using GFP-tagged
nesprin1a2 mutant S8381C compared with GFP-tagged WT nesprin-1a2 (F, G, arrowed).
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Nesprin-1 mutants disrupt the interactions between
nesprin-1, lamin A/C and SUN2 within the NE complex
To investigate whether the mutants affected the binding between
nesprin-1 and its NE binding partners, GST-taggedWT andmutant
nesprin-1a2 constructs lacking the KASH domain (equivalent to
nesprin-1 giant amino acids 7875–8662) were generated (Fig. 3A left
panel). Protein lysates from un-transfected U2OS cells and trans-
fected cells with Myc-SUN2 (full length) were subjected to GST
pull-down using either WT or mutant GST-nesprin-1a2. All three
mutants had significantly reduced binding to lamin A/C and SUN2,
but not emerin (Fig. 3A right panel, and B) when compared with
WT nesprin-1a2. A reverse GST pull-down was also performed.
Protein lysates from U2OS cells transfected with either GFP-
nesprin-1a2 WT or each of three mutants were subjected to pull-
down using either GST-lamin A (amino acids 356–665, containing
nesprin-1/2 binding domain) or GST-emerin (amino acids 1–176,
lacking the TM domain). The results confirmed all three mutants
had significantly reduced binding to lamin A (Fig. 3C), but not
Figure 3. Nesprin-1 mutants affect the interaction between nesprin-1a2 and lamin A/C or SUN2. GST-tagged WT nesprin-1a2 SR1-6 (equivalent to nesprin-1 giant SR
69–74) and mutants are generated and shown schematically (3A left panel, labelled with *), which constructs consisted of 837 amino acids, lacking KASH domain,
equivalent to amino acids 7875–8662 of nespin-1 giant. GST pull-down using either GST-WT or mutant nesprin-1 beads showed all three mutants affected binding be-
tween nesprin-1 and lamin A/C or SUN2, but not emerin (A, B), which was confirmed by reverse GST pull down by transfecting either GFP-nesprin-1a2WT or each mu-
tant and using either GST-lamin A (amino acids 356–665) (C) or GST-emerin (amino acids 1–176) beads (D). The binding for each mutant was quantified by densitometry
with respect to the input material and expressed as a ratio of the value obtained for WT protein. Three independent experiments were performed shown as mean 6
SEM, *P < 0.05 using one-way ANOVA analysis. Coomassie blue staining gel also showed equal amount of GST-nesprin 1a2, lamin or emerin beads used.
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emerin (Fig. 3D). Taken together, these data indicated that these
nesprin-1 mutations in the 1a2 region cause disruption of the
lamin A/C, SUN2 and nesprin-1 complex at the INM.
Nesprin-1 mutants augment activation of extracellular
signal-regulated kinase (ERK) pathway
Previous studies have shown that cells harbouring lamin and
emerin mutations have altered activation of ERK1/2 (31,32).
To investigate whether nesprin-1 defects lead to aberrant ERK1/
2 activation, protein lysates from human dermal fibroblasts
(HDFs) derived from EDMD and DCM patients carrying either
nesprin-1, lamin A/C or emerin mutations (13), and heart tissue
from WT and nesprin-1 KASH KO mice with EDMD-like pheno-
type and DCM (21) were examined. Western blot (WB) showed
significant up-regulation of ERK1/2 activity in patient fibroblasts
(Fig. 4A) and nesprin-1 KASH KO mouse hearts (Fig. 4B). To de-
termine whether the novel nesprin-1 mutants could also induce
activation of ERK1/2 signalling, GFP-nesprin-1a2 WT and mu-
tants, as well as a dominant-negative nesprin-1 KASH (1KASH),
which has previously been shown to displace endogenous
nesprin-1 and cause NE defects (6,33), were transiently trans-
fected into C2C12 and H9C2 myoblasts. Immunoblotting with
antibodies against phosphorylated ERK1/2 (pERK) and total
ERK1/2 (tERK) as well as phosphorylated ELK1 (pELK1), a down-
stream target of ERK1/2, demonstrated that overexpression of
the GFP tagged-nesprin-1 mutants and 1KASH increased the
amount of pERK1/2 and pELK1 compared with GFP alone or WT
nesprin-1a2, in both C2C12 cells (Fig. 4C) and H9C2 cells
(Supplementary Material, Fig. S2).
Figure 4. Nesprin-1 mutants cause aberrant activation of MAPKs. WB showed that aberrant activation of pERK was observed in human dermal fibroblasts from EDMD-
DCM patients carrying nesprin-1 mutation (V8387L), lamin A/C (R249Q and R401C) and emerin (g.329del59) mutations (A), as well as nesprin-1 KASH KO mice heart
collected at 17 and 81weeks, respectively (B). WB also showed overexpression of all three nesprin-1 mutants and dominant negative-1KASH led to augmented pERK ac-
tivity compared with WT nesprin-1 and GFP alone (C). GFP empty vector was used for negative control and a dominant negative-1KASH construct as a positive control.
Three independent experiments were performed shown as mean 6 SEM, *P < 0.05 using one-way ANOVA analysis.
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Nesprin-1 mutants lead to dysregulation of myogenic
transcription factors
To further investigate if these three novel mutants cause
muscle cell dysfunction, we next used the C2C12 mouse myo-
blast differentiation model. Previous studies showed that muta-
tions in LMNA and overexpression of 1KASH or SUN proteins in
C2C12 cells disrupt myoblast differentiation (23,34,35).
Myogenesis is driven by myogenic transcription factors (MTFs)
such as MyoD and myogenin (36,37). To determine the expres-
sion levels of endogenous nesprin-1a, MyoD and myogenin as
well as the skeletal muscle specific protein myosin heavy chain
(MHC) during the differentiation process, protein lysates were
collected at days 0, 2, 4 and 6 following induction (serum with-
drawal). WB and/or qPCR showed that endogenous expression
levels of nesprin-1a (including both 1a1 and 1a2), MyoD, myoge-
nin and MHC were increased along with myotube formation
(Fig. 5A–C, Supplementary Material, Fig. S3). Nesprin-1a levels
peaked at day 6, whereas MyoD and myogenin levels peaked at
day 2. MHC was detected from day 2 and increased until day 6.
Therefore, day 2 for MyoD and myogenin, and day 6 for MHC
were chosen as the optimised investigation time points for early
and late differentiation in further experiments.
To investigate whether the novel nesprin-1 mutants could
disrupt muscle cell differentiation, we used retroviral transduc-
tion to generate C2C12 cells stably expressing V5-tagged
nesprin-1a2 WT and mutant constructs as well as dominant
negative-1KASH, which were cloned into a MIG (IRES-GFP) retro-
viral vector. GFP protein was expressed independently as a re-
porter for retroviral infection. Fluorescence-activated cell
sorting (FACS) was performed to purify the infected GFP positive
populations and these were used in subsequent muscle cell dif-
ferentiation experiments (Supplementary Material, Fig. S4A, B).
IF staining showed that exogenously expressed V5-tagged WT
nesprin-1a2, mutants and 1KASH were observed at the NE in
myoblasts (Fig. 6A, Supplementary Material, Fig. S5A). Efficient
differentiation of C2C12 cells transduced with eGFP alone (MIG
only) or nesprin-1a2 WT was observed, with many multi-
nucleated myotubes formed within 5–6 days. However, fewer
myotubes were formed in the cells transduced with either
nesprin-1a mutants or 1KASH (Fig. 6B, Supplementary Material,
Fig. S5B). Quantification of the fusion index i.e. the percentage
of nuclei incorporated into MHC positive multinucleated cells
vs. the total number of nuclei, showed a significant reduction in
cells transduced with the mutants, in particular, R8272Q and
N8406K as well as 1KASH when compared to WT (Fig. 6C).
Further analysis of the MHC positive populations revealed that
myotubes expressing nesprin-1 mutants contained fewer nuclei
compared to the controls (Fig. 6D), indicating a defect in myo-
blast fusion. Both qPCR and WB showed that the levels of myo-
genin and MHC were dramatically reduced in cells transduced
with the mutants, particularly R8272Q and 1KASH when
compared with nesprin-1a2 WT at day 2 and 6 respectively
(Fig. 6E–G). qPCR also demonstrated that MyoD was significantly
reduced in the cells transduced with 1KASH at Day 2 (Fig. 6E).
Nesprin-1 mutants cause disruption of nesprin-1 and
KLC interaction
Recent data showed that nesprin-2 interacts with KLC-1/2 via a
conserved ‘LEWD’ motif at the C-terminus of nesprin-2 (27).
This motif is also present in nesprin-1 (Fig. 1B) (25–27), suggest-
ing nesprin-1 may also bind to KLC-1/2 and be involved in con-
necting the nucleus to the microtubule network and therefore
play a role in myonuclear positioning. By treatment of C2C12
Figure 5. Expression level of nesprin-1a increase during C2C12 myoblast differentiation. C2C12 myoblasts in regular medium (RM) were stimulated with a low serum
differentiation medium (DM), leading to myotube formation during the process (A). WB showed endogenous expression levels of nesprin-1, myogenin and myosin/
MHC increased during myotube formation (B, C). Nesprin-1a protein levels (detected by MANNES1E) were highest at day 6, whereas myogenin was highest at day 2,
and MHC was detected from day 2 and increased until day 6.
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cells expressing the plasmid containing V5-tagged nesprin-1a2
WT with digitonin or NP-40, we showed that nesprin-1a2 was
also localised at the ONM in addition to its previously identified
INM localisation where it co-localises and binds to lamin A/C
(Supplementary Material, Fig. S6). Therefore, we set out to in-
vestigate whether nesprin-1 could also bind to KLC-1/2. GFP-1a2
WT or nesprin-1a2-LEAA (mutated WD/AA within the LEWD
motif) were co-expressed with Flag-tagged KLC-2WT
Figure 6. Nesprin-1 mutants cause defects in myoblast differentiation. IF showed that exogenously expressed V5-tagged WT-1a2 or mutants and dominant genative-
1KASH were localized at the NE. GFP was expressed as a reporter for retroviral infection (A). Upon differentiation, fewer multinucleated myotubes were observed in
cells transduced with mutant R8272Q and dominant negative-1KASH compared with C2C12 cells transduced with eGFP alone (MIG only) or nesprin-1a2 WT (B). The fu-
sion index was reduced in cells transduced with the mutant R8272Q and dominant negative-1KASH compared with 1a2 WT (C), more than 600 nuclei for each clone
were counted by microscopy (63# objective) at day 6, three independent experiments were performed for each clone. Further analysis of the MHC positive multi-
nucleated populations revealed that myotubes expressing nesprin-1 mutants contained fewer nuclei compared to the controls (D). qPCR and WB showed that nesprin-
1 mutant R8272Q and dominant negative-1KASH caused significant reduction of myogenin (E, F) and MHC (E, G) levels at DM day 2 and day 6 respectively, qPCR also
showed that dominant negative-1KASH caused significant reduction of MyoD (E) levels at DM day 2. All were normalized to GFP, three independent experiments were
performed shown as mean6 SEM, *P < 0.05 using Student’s t-tests or two-way ANOVA analysis.
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(a dominant light chain isoform in muscle) or the KLC-2 N287L
mutant, previously shown to disrupt nesprin-2/KLC binding (27)
in U2OS cells. Immunoprecipitation (IP) and WB showed that
nesprin-1a2 could efficiently bind to KLC-2, and this binding was
disrupted by either mutation (LEAA) in the conserved nesprin-1
LEWD motif or the KLC-2 N287L mutant (27) (Fig. 7A). We then
tested the nesprin-1 mutants using this system and found that
the R8272Q mutant had significantly reduced binding to KLC-2
compared with nesprin-1a2 WT, while the S8381C mutant ap-
peared to enhance KLC-2 binding (Fig. 7A).
Next we tested whether these mutants affect nesprin-1/KLC-
1/2 binding during muscle cell differentiation. Firstly, WB
showed that, similar to nesprin-1a, the endogenous expression
level of KLC-1/2 increased during myoblast differentiation
(Figs. 5B and 7B). Using GST-nesprin-1a2 WT (lacking KASH do-
main), nesprin-1a2-LEAA and the three mutants, pull-down fur-
ther confirmed that nesprin-1a2 efficiently binds to KLC-1/2, and
this binding was disrupted by the mutated LEWD motif-LEAA.
In addition, the R8272Q mutant had significantly reduced bind-
ing to KLC-1/2 compared with WT in C2C12 cells. This reduced
interaction was especially evident in myotubes where expres-
sion of these two proteins is highest (Fig. 7C and D). Finally, we
tested whether depletion of KLC-1/2 using multiple siRNA oligos
would affect fusion of myoblasts and differentiation in a similar
manner to that observed in the R8272Q mutant. WB showed the
expression levels of both KLC-1 and -2 were reduced in both
myoblasts and myotubes after KLC-1/2 depletion (Fig. 8A and B,
Supplementary Material, Fig. S7C and D), and IF also showed a
reduced KLC-1/2 staining at the NE, however, nesprin-1 re-
mained at the NE (Supplementary Material, Fig. S7A). Moreover,
MHC levels and the fusion index were significantly reduced in
myotubes upon KLC-2 knockdown (Fig. 8C and D,
Supplementary Material, Fig. S7E and F). Further analysis of
MHC positive multinucleated cells (myotubes) revealed that
KLC-2 depletion resulted in fewer nuclei per myotube (Fig. 8E,
Supplementary Material, Fig. S7G), indicating a defect in myo-
blast fusion. In contrast, KLC-1 depletion led to significantly
more clustered nuclei per myotube when compared with con-
trols (Fig. 8E, Supplementary Material, Fig. S7B), indicating a de-
fect in nuclear positioning in addition to myoblast fusion.
Human nesprin-1a2WT causes heart developmental
and conduction defects in zebrafish embryos while
mutants induce a less severe heart phenotype
To investigate whether the nesprin mutants affect cardiac
structure or function in vivo, we generated a zebrafish model by
expressing nesprin-1a2 WT and mutants (R8272Q, S8381C and
N8406K) in zebrafish embryos via injection of the corresponding
human SYNE1a2 (nesprin-1a2) mRNAs at the one-cell stage. At
48h post-fertilization (hpf), zebrafish embryos expressing
Figure 6. Continued.
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human nesprin-1a2 WT showed heart defects including dilated
atrial chambers with reduced heart rate (Fig. 9A and B,
Supplementary Material, video). There was also evidence of ab-
normal anterior-posterior axis development and curved tails
(Supplementary Material, video). Furthermore, whole-mount in
situ hybridization (WISH) demonstrated that the expression of
myosin light chain polypeptide 7 (myl7), the ortholog of the
human regulatory myosin light chain (RLC) gene (38,39), was
reduced in 30% of the embryos expressing human nesprin-1a2
WT. The expression pattern of this gene also highlighted the
dilated atrial chambers and heart developmental defects such
as abnormal looping (Fig. 9C and D; Supplementary Material,
Figure 7. Defects in nesprin-1 and KLC-1/2 interaction. Overexpression and IP showed the binding between nesprin-1WT/mutants and KLC WT/mutants in U2OS cells,
HA-KLC2-N287L was co-expressed with GFP-nesprin-1a2 WT as a positive control, GFP empty vector with HA-KLC-2WT as a negative control (A). WB showed endogen-
ous expression levels of KLC-1/2 increased during myotube formation (B). GST pull-down showed the binding between nesprin-1 and KLC-1/2 using either GST-WT or
mutant nesprin-1 beads in myoblasts (C) and myotubes (D), respectively. The binding for each mutant was quantified by densitometry and expressed as a ratio of the
value obtained for WT protein. Three independent experiments were performed shown as mean6 SEM, *P < 0.05 using Student’s t-tests.
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Fig. S8A and B). In contrast, expression of the human nesprin-
1a2 mutants induced some heart developmental defects, such
as abnormal heart looping and malpositioning of heart cham-
bers (Supplementary Material, Fig. S8A and B), but without heart
enlargement or heart rate defects. There was also evidence of
abnormal anterior-posterior axis development in all the em-
bryos, when compared with uninjected and GFP expressed em-
bryos (Supplementary Material, Fig. S8C and D). Taken together
these zebrafish larvae data suggests that overexpression of
human nesprin-1a2 WT leads to cardiac developmental defects
while nesprin-1a2 mutants induced a less severe heart
phenotype.
Discussion
Mutations in lamin A/C and emerin, which form a complex at
the INM, can cause EDMD with conduction system defects, as
well as DCM. Similarly, missense mutations in the C-terminal
region of the nesprin-1 (SYNE1) and -2 (SYNE2) genes and SUN1/
2 genes were identified in EDMD-DCM patients, leading to
Figure 8. siRNA knockdown of KLC-1/2 cause defects in myoblast fusion and differentiation. WB showed the expression levels of both KLC-1 and -2 were reduced in
myoblasts (A) and myotubes (B) upon KLC-1/2 depletion. The expression level of MHC (C) and the fusion index (D) were significantly reduced in myotubes especially
upon KLC-2 depletion (using KLC-2A oligo), more than 800 nuclei for each clone were counted by microscopy (63# objective) at day 6, three independent experiments
were performed for each clone. Further analysis of MHC positive multinucleated cells revealed that KLC-2 depletion resulted in fewer nuclei per myotube. In contrast,
KLC-1 depletion (using KLC-1A oligo) led to significantly more clustered nuclei per myotube when compared with controls (E). Means and SEM were obtained from
three independent experiments for each clone. *P < 0.05 using Student’s t-tests or two-way ANOVA analysis.
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disrupted nesprin/lamin/emerin/SUN1/2 interactions and nu-
clear morphology defects (40,41). In the current study, three
novel missense mutations (R8272Q, S8381C and N8406K) were
identified in the same C-terminal region of nesprin-1 in DCM
patients, which affected nuclear morphology and impaired pro-
tein–protein interaction with lamin A/C and SUN2. The mutants
also augmented ERK activation in vitro. Importantly, these mu-
tations, especially mutant R8272Q, caused defects in myoblast
differentiation associated with dysregulation of MTFs and dis-
ruption of the nesprin-1/KLC-1/2 interaction at the ONM. These
findings provide new information on how nesprin-1 performs
multi-functional roles in muscle cell development and disease
via its connections at both INM and ONM, and also how these
mutations and disruption of the LINC complex contribute to
muscle dysfunction, and potentially the pathogenesis of DCM.
Nesprin-1 mutations interfere with NE organisation
Mutations in the LMNA gene, encoding A-type lamins, cause a
number of different tissue specific laminopathies, including
DCM (42). The molecular pathogenesis of these diseases is un-
known but in some cases may be related to disruption of the
LINC complex. Mice lacking A-type lamins display phenotypes
that are reminiscent of human muscular dystrophies and cardi-
omyopathies (43,44). Embryonic fibroblasts derived from LMNA
KO mice are characterised with grossly misshapen cell nuclei
and a structurally weakened NE, and mislocalization of
nesprins leading to reduced mechanical stiffness (45).
Mutations in both nesprins and SUN1/2 have also been impli-
cated in EDMD-DCM, whereby mutants cause abnormal local-
isation of the LINC complex proteins including lamin, emerin
and SUN, and disrupted nesprin/lamin/emerin/SUN inter-
actions, leading to defects in nuclear morphology and nuclear-
cytoskeletal coupling (13–16). Furthermore, the disruption of
endogenous LINC complexes by recombinant dominant
negative-KASH constructs of nesprins-1, -2 and -3 also causes a
significant loss of mechanical stiffness (6,33,46). Interestingly,
the three novel missense mutations (R8272Q, S8381C and
N8406K) identified in DCM patients in this study reside within
the unique AD region at the C-terminus of the nesprin-1 and -2
proteins (25,26). This region is evolutionally highly conserved
and overlaps with the lamin and emerin binding regions. It has
relatively little secondary structure and is likely to be flexible
(26), and potentially able to adapt its conformation to stabilise
the associations between nesprin SRs, lamin A/C and emerin at
the INM (for nesprin-1a2) or SUN proteins at the ONM (for
nesprin-1a2 and -1 giant isoforms). The three nesprin-1 muta-
tions (R8272Q, S8381C and N8406K) identified in this study cause
changes in the charge or hydrophilic/hydrophobic properties of
conserved amino acids and likely affect the structure/flexibility
of the AD region of nesprin-1, altering it interactions with lamin
A/C and SUN2. These binding changes were most likely due to
Figure 9. Human nesprin-1a2 WT induces heart development defects in zebrafish. Lateral views of zebrafish live embryos at 48 hpf. The pericardium (A, arrowed) and
heart rate are shown for each corresponding mRNA injected (B), zebrafish embryos with nesprin1a2 WT mRNA showed slow heart rate and dilated atrial chambers.
Whole-mount in situ hybridization (WISH) monitoring expression of the myl7 gene at 48 hpf (C), the numbers (left in brackets) indicate the percentage of embryos dis-
playing the phenotype represented in the picture shown, the numbers (right in brackets) is the total numbers counted of observed embryos. The relative atrium area of
embryos for the corresponding mRNA injection was measured and calculated by the area of myl7 expression using ImageJ (D), which was normalised to the atrium
area of the embryos injected with GFP mRNA. Embryos are in ventral views with the anterior at the top. About 4–7 embryos for each injection were measured. Means
and SEM were obtained from three independent experiments for each treatment. P < 0.001 using Student’s t-tests. a: atrium, v: ventricle.
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disruption of the functions of all the endogenous nesprin-1 iso-
forms containing the KASH domain in the transfected cells (19).
Interestingly, the R8272Q mutant was able to bind lamin A at
comparable levels to the WT nesprin-1, in contrast to weak
binding to lamin C. Our current understanding of the inter-
actions between nesprins and lamin A and lamin C remains in-
complete, so this apparent binding difference requires further
investigation. We did not observe a defect in binding between
nesprin-1 mutants and emerin, which is consistent with the no-
tion that mutations in emerin are primarily associated with
EDMD rather than DCM (28,47). The data above support possible
involvement of LINC complex disruption in the pathogenesis of
DCM. Future studies on structure/flexibility of the SRs that are
predominantly present in the muscle-specific nesprin isoforms
will be required to confirm this hypothesis.
Several studies on LMNA KO and H222P knock-in mice have
indicated activation of MAPKs in the development of DCM.
Inhibitors of MAPKs could partially rescue the DCM phenotype,
implicating ERK in the pathogenesis of lamin A/C cardiomyop-
athy (48,49). Our data showed that enhanced ERK activity is also
observed in heart tissue from the nesprin-1 KASH KO mice,
fibroblasts derived from EDMD-DCM patients and nesprin-1 mu-
tant transfected cells, suggesting that nesprin and lamin A/C
function through a similar pathway and trigger up-regulation of
ERK. Future work will examine how NE proteins regulate ERK
activity potentially via influencing interactions between A-type
lamins, NE proteins and components of MAPK cascades, as well
as nuclear translocation of activated MAPKs (50,51).
Nesprin-1 mutations and dysregulation of MTFs in
myoblast differentiation
Nesprin-1a2 is highly expressed in both skeletal and cardiac
muscles as previously shown (7,52,53). Although there were no
obvious muscle phenotypes recorded, it is plausible that in the
patients presenting with the SYNE1 mutations the skeletal
muscle dysfunction was too subtle or underestimated at clinical
examination. Alternatively, in addition to these SYNE1 muta-
tions, another cardiac disease gene is mutated thus enhancing
the phenotype. Therefore, due to restricted accessibility to pa-
tient samples, we focused on investigating if these three novel
mutants cause muscle dysfunctions by using the C2C12 mouse
myoblast differentiation model.
Myogenesis involves a series of sequential steps. Myoblasts
originating from the mesoderm are converted to skeletal muscle
lineage myoblasts after MyoD expression, enter the cell cycle
and proliferate, then withdraw from the cell cycle and initiate
differentiation with expression of MTFs such as myogenin (54).
Next cell fusion occurs to form multinucleated myotubes and
expression of the muscle specific protein MHC. Increasing evi-
dence indicates that multiple cell signalling pathways play crit-
ical roles in myoblast fusion, including those involved in
cytoskeleton organization, cell adhesion and migration (55) as
well as extracellular signalling molecules and components of
extracellular matrix (54,56). Recent literature shows that LINC
complex components, including nesprins and SUN1/2, mechan-
ically couple the nucleus to the extracellular matrix and play an
important role in differentiating muscle. In addition, these pro-
teins have been implicated in regulating chromatin structure
and gene expression. For example, C2C12 cells expressing a
LMNA R453Wmutant have reduced capacity to differentiate, yet
retain an unaltered morphology (57), suggesting that subtle ab-
normal changes in lamina structure or composition may impair
the anchoring of chromatin to the NE, affecting gene regulation
and perturbing myogenesis.
Using retroviral transduction in mouse C2C12 myoblasts in
the current study, our data showed myoblasts expressing mu-
tant nesprin-1a2 R8272Q or dominant negative-1KASH had a sig-
nificantly lower capacity to differentiate and form
multinucleated cells than those expressing 1a2 WT, although
exogenously expressed 1a2 WT and mutants were observed to
be properly localised at the NE. Importantly, the inhibition of
multinucleation by dominant negative-1KASH and 1a2 mutants,
especially R8272Q, is potentially linked to the inhibition of myo-
genin and MHC expression in the transduced C2C12 cells. Our
data also showed that nesprin-1a2 was expressed in the initial
stage crucial for converting C2C12 myoblasts into myotubes and
promoted myoblast differentiation during the process of myo-
tube formation, whereas the mutants reduced or abolished the
effects, suggesting that expression of nesprin-1a2 mutants does
not alter the proliferation of myoblasts, but rather impairs their
capacity to express muscle-specific genes (myogenin and MHC).
This results in an inability to fuse, especially observed in the
R8272Q mutant, which also explains why nesprin-1 mutants af-
fect the expression levels of myogenin more severely than
MyoD, because MyoD is already expressed prior to initiation of
differentiation at a stage when the expression level of nesprin-1
is still low. Therefore, we propose the following mechanisms
whereby nesprin mutants may affect muscle differentiation:
regulation of myogenin and expression of MHC are influenced
by the LINC complex; nesprin mutants may fail to build a func-
tional scaffold and/or to maintain chromatin compartmental-
isation with lamin A/C, leading to an alteration in the amount
of heterochromatin formed and/or its localisation. Potentially
this causes defects in initiation of the terminal differentiation
process resulting in decreased or delayed expression of myoge-
nin and MHC, thus causing a delayed differentiation. This effect
may be similar to that observed in C2C12 cells expressing an
LMNA R453Wmutant (57) that showed a reduced capacity to dif-
ferentiate. However, further experimentation on how the
nesprin-1 mutants affect regulation of MTFs is required to eluci-
date the precise function of nesprin in muscle cell
differentiation.
Nesprin-1 mutations disrupt nesprin-1/KLC interaction
and myoblast fusion
Proper nuclear positioning and movement is critical in muscle
cell differentiation and development. In the nucleus, changes in
gene activity that occur during terminal cell differentiation are
correlated with gene migration and relocation (58,59). Nuclear
movement and positioning are driven by cytoskeletal networks
of MTs, actin and/or intermediate filaments and involve a con-
nection between the cytoskeleton and the NE, mediated by the
LINC complex (60,61). KO mouse studies have shown that
nesprin-1 and SUN1/SUN2 play critical roles in anchoring nuclei
in skeletal muscle (62,63). Similarly, mutations identified in
SUN1 and SUN2 genes associated with EDMD like phenotypes
cause defective nuclear positioning when expressed in mouse
fibroblasts (15,16). The MT-based kinesin motor, kinesin-1, con-
sisting of two KHCs and two KLCs, is localised at the NE. Binding
of the dominant light chain isoform in muscle, KLC-2, to
nesprin-2 has been shown to be responsible for nuclear rota-
tions and movement along MTs (27). There is evidence that nu-
clear position can influence gene expression. For example,
nuclei at the neuromuscular junction (NMJ) have a unique
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transcriptional profile relative to the non-synaptic nuclei (59).
Nesprin-1 (SYNE1) levels are much higher in synaptic nuclei
than extrasynaptic nuclei, and also higher in myotubes than
myoblasts in culture and central nuclei during regeneration
(52,64). In addition, maintaining proper nuclear positioning is
thought to ensure sufficient transcriptional capacity and min-
imise transport distances between the nuclei and the cytoplasm
in highly organised long muscle cells (60,65). Our data con-
firmed that nesprin-1 binds to KLC-1/2, and nesprin-1 mutants,
particularly R8272Q, disrupted this interaction. Furthermore,
depletion of KLC-1 resulted in nuclear clustering, whereas de-
pletion of KLC-2, a dominant muscle isoform, caused reduction
of MHC levels and the fusion index in myotubes, that was con-
sistent with those observed in the R8272Q mutant. This disrup-
tion of nesprin-1/KLC interaction in C2C12 myoblasts may
result in defects in nuclear movement along MTs, leading to ab-
normal nuclear positioning. Further investigations are required
to elucidate the precise roles of nesprin-1 and KLC-1 and -2 in
myonuclear positioning in muscle cell differentiation.
Expression of nesprin-1a2 mutants induce less severe
heart defects during zebrafish heart development
compared to 1a2 WT
To investigate whether the nesprin mutants affect cardiac
structure or function in vivo, we generated a zebrafish model by
expressing human nesprin-1a2 WT and mutants (R8272Q,
S8381C and N8406K) in zebrafish embryos via injection of the
corresponding human SYNE1a2 (nesprin-1a2) mRNAs. Our data
showed that human nesprin-1a2 WT causes heart developmen-
tal and conduction defects in zebrafish embryos, and all three
1a2 mutants caused less severe heart developmental defects.
Although these results are unexpected, there are some potential
explanations. Human nesprin-1a2 is not expressed in the heart
and muscle until the initial stages of muscle cell differentiation
(7,52,53). Therefore, injection of human nesprin-1a2 mRNA into
zebrafish larvae at the one cell stage, when the expression level
of endogenous nesprin-1 was minimal, caused ectopic expres-
sion effects on heart development. The effect of the mutants
was less severe potentially because their binding interactions
are compromised leading to less disruption. Future studies uti-
lising the zebrafish model with either cardiac (tissue specific)/
heat shock protein (timing dependent) promotors or CRISPR/
Cas9-mediated knock-in is required to clarify underlying dis-
ease mechanism.
In summary, our data support the hypothesis that nesprin-1
plays multi-functional roles at both INM and ONM during
muscle cell development and disease (Fig. 10). Although the role
of nesprin-1 dysfunction in DCM requires further experimenta-
tion, we show that novel nesprin-1 mutants affect diverse func-
tions, including gene expression and myoblast fusion and
differentiation. Further investigation is now required to eluci-
date the complex mechanisms behind this dysregulation espe-
cially in the cardiac system.
Materials and Methods
Research subjects
The study cohort consisted of 218 unrelated individuals with
DCM and 210 healthy controls, collected from the West China
Hospital, Sichuan University, China. All blood materials of the
patients and controls included in this study were taken with in-
formed consent for DNA analysis and approval of the local eth-
ics board. The clinical characteristic of the patients and controls
were summarized in Supplementary Material, Table S1 and
Supplementary material. Most of DCM patients were men and
had significantly larger left ventricular (LV) chamber and lower
left ventricular ejection fraction (LVEF) when compared with
the ethnic and age-control samples.
Figure 10. Working model for the role nesprin-1. The schematic figure shows nesprin-1 plays multiple-functions at both INM and ONM, and how mutants can disrupt
the NE-LINC complex, contributing to the pathogenesis of muscle disease. *Indicates where the mutants are.
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Mutation analysis
Primer pairs were designed across the intron/exon boundaries
and untranslated regions of nesprin-1a1 and 1a2, nesprin-2a1,
2a2, 2b, 2e1 and 2e2, i.e. the smaller INM localised isoforms of
nesprin-1 and nesprin-2 shown to bind emerin and lamin and
be either highly or specifically expressed in muscle tissue. 180
oligonucleotide primers from intronic sequences for 88 exons
were designed using the program Primer3Input (primer3_www.
cgi v 0.2) and used previously (13). Mutation screening was per-
formed using the PCR-based mutation detection technique
DHPLC (WAVE 4500B system, Transgenomic). Appropriate
DHPLC conditions for running temperatures and buffer gradi-
ents were established for each individual exon.
Plasmid constructs/retroviral constructs/site-directed
mutagenesis
Human cDNA of nesprin-1a2 WT constructs (amino acids 1–977,
equivalent to nesprin-1 giant 7875–8796) were amplified using a
high-fidelity GC-rich PCR kit (Roche) and inserted respectively
in-frame into the EcoRI site of the pEGFP-C1 vector (Clontech)
for overexpression of GFP-nesprin, and the NotI and EcoRI sites
of pcDNA3.1(-) vector (Invitrogen) for in vitro synthesis of Flag-
tagged nesprin mRNA and microinjection. GST nesprin-1a2 SR1-
6 construct (amino acids 1–837, lacking KASH domain, equiva-
lent to nesprin-1 giant 7875–8662, SR 69–74) and V5-tagged
nesprin-1a2 construct (amino acids 1–977, equivalent to
nesprin-1 giant 7875–8796) were amplified from the established
pEGFP-C1-nesprin-1a2 WT construct and inserted into EcoRI
and SalI sites of the pGEX-4T-1 vector (Pharmacia) and EcoRI
and NotI sites of the MIGplus retroviral vector respectively. The
MIGplus vector was a kind gift from Prof. Peter Zammit (66),
which was modified from the retroviral (RV) backbone pMSCV-
puro (Clontech, Mountain View, CA), in which the puromycin
selection gene was replaced with eGFP to create pMSCV–IRES–
eGFP, served as the RV control vector and eGFP as a reporter for
retroviral infection. Retroviruses were then packaged into 293T
cells using standard methods as described previously (66). All
the constructs of nesprin-1 mutant constructs (R8272Q,
S83831C, N8406K) were generated using QuickChangeTM XL
site-directed mutagenesis kit (Stratagene). Primers for the con-
structs above are listed in Supplementary Material, Tables
S3–S5. Myc-SUN2 has been reported previously (67). CB6-HA-
KCL2WT and mutant N287L were kind gifts from Dr Mark
Dodding (King’s College London, UK). GST-lamin A (amino acids
356–665) and GST-emerin (amino acids 1–176) were kind gifts
from Dr Juliet Ellis (King’s College London, UK).
Cell nuclei circularity quantification
‘Analyse particles’ function in ImageJ was used to measure cir-
cularity of cell nuclei, with circularity values given between 0
and 1 (values closer to 1 being more circular in shape) (68).
Antibodies and immunofluorescence
Primary antibodies were sourced as follows: lamin A/C (N-18,
sc-6215, Santa Cruz), SUN2 [kind gifts from Dr Didier Hodzic,
University of Washington, US and (67)], emerin (NCL-EMERIN,
Novacastra), GFP (ab290, ab13970, Abcam), GAPDH (sc-25778,
Santa Cruz), b-actin (A5316, Sigma), a-tubulin (ab52866, Abcam),
phospho-p44/42 MAPK (pERK1/2) (4370, Cell Signalling
Technology), p44/42 MAPK (tERK1/2) (9102, Cell Signalling
Technology), V5 (R96025, Invitrogen), nesprin-1 (MANNES1A
and MANNES1E (52), generated against the C-terminus of the
nesprin-1 giant), myogenin (sc-576, Santa Cruz), myosin (clone
A4.1025, against all isoforms expressed by MYH1, Alexis
Corporation), HA (ab1424, Abcam), KLC-1/2 (63–90, a kind gift
from Prof Scott Brady, University of Illinois at Chicago, USA).
Alexa fluorophore (488/546/647)-conjugated secondary antibod-
ies were from Invitrogen. HRP-conjugated secondary antibodies
were from Amersham. IF staining was performed as described
previously (13). In particular, to further define the subcellular lo-
calisation for GFP-tagged nesprin-1a2, the transfected cells were
fixed by 4% paraformaldehyde/PBS, then permeabilized using
either 0.001% digitonin/PBS or 0.5% NP40/PBS.
Cell culture, transfection and RNAi
HDFs, U2OS, C2C12 myoblasts were cultured at 37 $C/5% CO2 in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal calf serum (FCS) and 1% Pen-Strep-Glutamine
(PSG). For myoblast differentiation, C2C12 were cultured in low-
mitogen medium (DMEM supplemented with 1% PSG and 2%
horse serum) as described previously (7). For transient transfec-
tion, cells were plated onto glass coverslips or T25 flask at ap-
proximately 1.2# 105 cells/ml and transfected using FuGENE
HDTM (Promega) according to the manufacturer’s instructions
and fixed for IF staining or harvested for Western blotting 24h
after transfection as described previously (7,13). siRNA transfec-
tions were also performed by using HiPerFect (Qiagen) according
to the manufacturer’s instructions. KLC-1/2 siRNA oligomers
targeting to the mouse KLC-1/2 were previously described (27)
and obtained from Dharmacon, named as KLC-1A and KLC-2A.
Additional four KLC-1/2 siRNA oligos obtained from Qiagen (Cat.
No: SI01085154, SI01085168, SI01083327 and SI01083341) were
renamed as KLC-1B and -1C, KLC-2B and -2C respectively.
Allstars negative control siRNA was also supplied from Qiagen.
Neonatal rat cardiomyocytes (NRCs) isolation, culture
and transfection
Primary cultures of NRCs were isolated from 1- or 2-day-old
neonatal Sprague–Dawley rats. Hearts were collected and atria
were removed. Hearts were then washed, excised, minced and
enzymatically digested at 37 $C with ADS buffer [116mmol/L
NaCl, 20mmol/L HEPES, 0.8mmol/L NaH2PO4, 5.6mmol/L glu-
cose, 5.4mmol/L KCl, 0.8mmol/L MgSO4] containing collagenase
(57.5U/mL) and pancreatin (1.5mg/mL). The suspension was
pre-plated to remove contaminating cells, before being cultured
on gelatin (Sigma) pre-coated 35mm petri dishes with a density
of 2 # 105 cells/ml. Cells were allowed to adhere for 24h, and
then transfected using Escort III (Sigma) following the manufac-
turer’s instruction as described previously (69).
Retroviral infection and myoblast differentiation
Retroviral constructs, together with an ectopic packaging plas-
mid, were transiently co-transfected into 293T cells to produce
non-replicating retrovirus and the supernatant harvested 48, 60
and 72h later. Retroviral infection was performed as described
previously (66). Briefly, C2C12 cells were plated in T25 flasks.
After 24h, the medium was replaced with a 1:5 dilutions of 293T
retroviral supernatant supplemented with 4 mg/ml polybrene
and incubated at 37 $C for 4–6h, and then changed into fresh
medium. FACS was performed to purify the infected GFP
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positive cells in 48h and these were used to in subsequent myo-
blast differentiation experiments. To induce differentiation, the
medium was replaced with the differentiation medium (DM)
containing 2% horse serum and 1% PSG, and cell lysates were
collected for further investigation at day 0, 2, 4 and 6.
Co-immunoprecipitation assays
U2OS cells were transfected using GFP-nesprin-1a2 WT/mutants
with HA-KLC-1/2WT/mutant as well as Myc-SUN2 respectively,
harvested about 24h later and kept in IP buffer [10mM Tris (PH
7.4), 50mM NaCl, 5mM EDTA, 1% Triton X-100] with protease in-
hibitor cocktail (Sigma) on ice for 30min, followed by 10 s sonic-
ation and centrifugation. About 500 mg of protein was pre-
cleaned with Protein A/G sepharose beads (Sigma) for 1h at 4 $C.
Beads were removed by centrifugation and 2.5 mg primary anti-
body was added to lysates and left rotating at 4 $C for 16h.
Beads were then added to reactions and incubated for 2h rotat-
ing at 4 $C. Samples were centrifuged and supernatant dis-
carded. Pellets were washed and re-suspended in sample
buffer, heated at 95 $C for 10min and analysed by WB as
described previously (13).
GST pull-down assays
GST fusion proteins and GST alone were induced from 100ml of
bacterial culture for 4h by addition of 0.2mM isopropyl-1-thio-
b-D-galactopyranoside. Purification of the proteins was per-
formed according to the Amersham Biosciences protocol using
glutathione-Sepharose 4B beads (Amersham Biosciences). Pull-
down assays were performed as described previously (70).
Briefly, 200 lg extracts from U2OS or C2C12 myoblasts/myotubes
were incubated with 50 ll beads with constant rotation for 16h
at 4 $C. Bound proteins were washed and eluted into sample
buffer, followed by WB. In particular, to investigate the inter-
action between nesprin-1 and its NE binding partners, protein
lysates from Myc-SUN2 transfected (for SUN binding) and
untransfected U2OS cells (for lamin A/C and emerin binding),
C2C12 myoblast and myotubes (for KLC-1/2 interaction) were
harvested and subjected to pull down using either GST-WT or
mutant nesprin-1a2 SR1-6 beads. To further confirm the bind-
ings, U2OS cells were transfected with either GFP-nesprin-
1a2WT or mutants, protein lysates were harvested and
subjected to pull-down using either GST-lamin A (amino acids
356–665) or GST-emerin (amino acids 1–176).
Quantitative RT-PCR (QPCR)
C2C12 Cells were cultured in T25 flasks in proliferation or differ-
entiation medium. Total RNA was extracted using RNA-STAT 60
(Amsbio) according to manufacturer’s protocol. Reverse tran-
scription synthesis of cDNA and qPCR was performed as
described previously (13). Relative expression of each myogenic
transcriptional factor between proliferating and differentiated
cells was measured in three replicates in at least three inde-
pendent experiments. Primers for myogenin, MHC, MyoD, V5
and GFP have been previously described and listed in
Supplementary Material, Table S6.
Zebrafish embryos
WT embryos from AB strain were used. Embryos were obtained
by natural matings and cultured in embryo medium (71).
Staging of the embryos was carried out as described by Kimmel
et al. (72). Ethical approval was obtained from the Animal Care
and Use Committee of Sichuan University.
In vitro synthesis of mRNA and microinjection
Capped GFP and nesprin mRNAs were synthesized using
mMESSAGE mMACHINEVR Kit (Ambion); Synthetic capped
mRNAs were injected into single-cell embryos. Injection dose
(60mg) was an optimised amount received by a single embryo.
Zebrafish whole-mount in situ hybridization
Whole-mount in situ hybridization was carried out as previously
described (73,74). After linearization by appropriate restriction
enzymes, antisense RNAs for in situ hybridization were synthe-
sized using DIG RNA Labelling Kit (SP6/T7) (Roche) and purified
by MEGAclear (Ambion). Signal area of whole-mount in situ hy-
bridization was measured by software ImageJ.
Statistical analysis
Cell counts for statistical analysis were performed on n ¼ 100–
200 cells/n¼ 10 confocal microscope fields (63# magnification)
for each control and experimental group, and results were veri-
fied in at least three independent experiments. The data were
analysed using GraphPad Prism software by the Student’s t-
tests, One way or Two-way analysis of variance (ANOVA) with
Dunnett’s multiple comparison test for two independent groups
or multiple comparisons, respectively. The values are expressed
as mean6 standard error of mean (SEM). The P-values< 0.05
were considered statistically significant.
Supplementary Material
Supplementary Material is available at HMG online.
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a b s t r a c t
The spatial compartmentalisation of biochemical signalling pathways is essential for cell function. Ne-
sprins are a multi-isomeric family of proteins that have emerged as signalling scaffolds, herein, we in-
vestigate the localisation and function of novel nesprin-2 N-terminal variants. We show that these ne-
sprin-2 variants display cell speciﬁc distribution and reside in both the cytoplasm and nucleus. Im-
munoﬂuorescence microscopy revealed that nesprin-2 N-terminal variants colocalised with β-catenin at
cell-cell junctions in U2OS cells. Calcium switch assays demonstrated that nesprin-2 and β-catenin are
lost from cell-cell junctions in low calcium conditions whereas emerin localisation at the NE remained
unaltered, furthermore, an N-terminal fragment of nesprin-2 was sufﬁcient for cell-cell junction locali-
sation and interacted with β-catenin. Disruption of these N-terminal nesprin-2 variants, using siRNA
depletion resulted in loss of β-catenin from cell-cell junctions, nuclear accumulation of active β-catenin
and augmented β-catenin transcriptional activity. Importantly, we show that U2OS cells lack nesprin-2
giant, suggesting that the N-terminal nesprin-2 variants regulate β-catenin signalling independently of
the NE. Together, these data identify N-terminal nesprin-2 variants as novel regulators of β-catenin
signalling that tether β-catenin to cell-cell contacts to inhibit β-catenin transcriptional activity.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Nesprins are a family of spectrin repeat containing proteins
that are encoded by four genes (SYNE1-4) [1–4]. Nesprins-1 and -2
are highly complex and multiple variants arise due to alternative
initiation and termination of the genes [5]. The giant nesprin-1
and -2 variants consist of an N-terminal paired calponin homology
domain (CHD) that has been shown to bind ﬁlamentous actin (F-
actin), a central rod region composed of numerous spectrin re-
peats and a C-terminal Klarsicht, ANC-1, SYNE Homology (KASH)
domain that is required for the nuclear envelope (NE) localisation
of these proteins [4,6,7]. To date, the best studied function of these
proteins is at the NE, where smaller variants function to organise
the inner nuclear membrane (INM) via interactions with lamins A/
C and emerin [6,8], whereas the nesprin giant variants reside on
the outer nuclear membrane (ONM) and are components of the
LInker of Nucleoskeleton to Cytoskeleton (LINC) complex. The LINC
complex physically couples the ONM to the INM via interactions
between the KASH domain of nesprins and the SUN domain of
SUN1/2 in the perinuclear space [9,10]. SUN1/2 span the INM and
interact with lamins A/C [11,12], thus forming a continuous bio-
physical network between the cytoskeleton and nucleoskeleton
[10–12]. In addition to the giant nesprin-1 and -2 isoforms, nesprin
variants that lack the KASH domain have been shown to localise to
the cytoplasm and nucleoplasm [5,13–15]. Although the functions
of these KASH-less variants remain to be fully deﬁned, they show
tissue and cell speciﬁc expression patterns, suggesting nesprins
are tailored for speciﬁc cellular functions.
Nesprins are comprised of multiple spectrin repeats that are
proposed to mediate protein-protein interactions, however, our
knowledge of nesprin binding partners remains limited [16]. At
the INM, nesprin variants interact with lamins A/C, SUN1/2 and
emerin [6,12]. Mutations in these nesprin variants result in emerin
mislocalisation, nuclear morphology defects and are associated
with Emery–Dreifuss muscular dystrophy (EDMD), suggesting that
nesprins perform a scaffolding role at the NE [1]. KASH-less var-
iants also perform a scaffolding role in the nuclear interior and we
have previously identiﬁed nesprin-2 as a nuclear ERK scaffold that
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tethers ERK1/2 at promyelocytic leukaemia nuclear bodies to
regulate proliferation [14]. Importantly, several cytoplasmic bind-
ing partners have also been identiﬁed for nesprin-1 and -2 in-
cluding the RNA binding proteins Dcp1a, Rck and Ago2, and
meckelin, respectively [13,17]. Moreover, nesprin-1 and -2 KASH-
less variants localise to focal adhesions and actin/microtubule ﬁ-
laments, suggesting that the cytoplasmic KASH-less variants may
perform a similar scaffolding role [5,13]. Nesprin-2 has also been
implicated in the WNT pathway that transfers signals from the
plasma membrane to the nucleus via nuclear translocation of the
transcription factor β-catenin [18–21]. Both α- and β-catenin in-
teract with spectrin repeats (SRs) toward the C-terminus of ne-
sprin-2 giant to attenuate β-catenin signalling [22]. In addition to
this direct interaction, nesprin-2 may also indirectly associate with
β-catenin at the INM, where the nesprin-2 binding protein emerin
interacts with β-catenin to facilitate its nuclear export [23].
In this study we investigate the role of recently identiﬁed
N-terminal nesprin-2 variants that retain the CHD but lack the
KASH domain. We show that these variants are novel components
of cell-cell junctions, where they colocalise and interact with β-
catenin. Importantly, these nesprin-2 variants anchor β-catenin to
cell-cell junctions to negatively regulate β-catenin mediated
transcriptional activity.
2. Materials and methods
2.1. Cell culture
Human bone osteosarcoma epithelial (U2OS), human umbilical
vein endothelial cells (HUVEC), mouse C2C12 myoblast, human
dermal ﬁbroblast and human vascular smooth muscle cells were
cultured as described previously [24,25]. The following nesprin-2
siRNA oligomers targeting the N-terminus of the giant variant
were used in this study: siN2CH2 (5′ AGGAAGACACCCAGAAGUU
3′), siN2CH3 (5′ CUUCAGAAUUGCAGAACAAUU 3′), siN2CH5 (5′
GCCUUCACGUGCUGGAUAAUU 3′), p220CHNesp2 3′UTR1 (5′ GA-
GAAUAGUCUGUGGAGAAUU 3′), p220CHNesp2 3′UTR2 (5′ GGAAC-
GUAGUGGAGGAUAUU 3′), p380CHNesp2 3′UTR1 (5′ AUCGAAAGC-
CAGAGAGUAAUU 3′) and p380CHNesp2 3′UTR2 (5′ AGUCAGAGGU-
CAACAACAAUU 3′) (Dharmacon). C-terminal nesprin-2 siRNA de-
signed to a region close to the KASH domain (siN2KASH) have
been described previously [14]. Emerin smart pool siRNA oligo-
mers from Dharmacon were used in this study. Transfection of
siRNA was performed using HiPerfect (Qiagen), as per manufac-
turer's instructions. DNA transfections of were performed with
Fugene (Promega) as per manufacturer's instructions.
2.2. PCR and 3′UTR ampliﬁcation
PCR for N-terminal nesprin-2 3′UTRs were performed using 3′
UTR speciﬁc primer sets as described previously [5].
2.3. Nesprin constructs
The following N-terminal nesprin-2 fragments were cloned
into pEGFP-C1 vector (Clontech): ABDN2 (amino acids 1-531). The
CHDN2 (amino acids 1-278) fragment was cloned into the pCMV-
Tag vector (Agilent Technologies). The SR 1-3 region (amino acids
279-531) was cloned into the pGEX4T-1 (Amersham) and pCMV-
Tag (Agilent Technologies) vectors.
2.4. Calcium switch assay
Cells were grown to 80–100% conﬂuency and serum starved
overnight. Next day, cells were incubated with 4 mM EGTA in
calcium free media for 1 h to promote cadherin mediated cell-cell
junction disassembly. Junction re-assembly was promoted by in-
cubating cells in media containing 1.8 mM calcium for 1 h. Cells
were ﬁxed and processed for immunoﬂuorescence microscopy.
2.5. Western blot analysis, antibodies and immunoﬂuorescence
microscopy
Cell lysates were run on 5% or 8% polyacrylamide gels and
subjected to Western blotting as described previously [6]. Anti-
bodies used for Western blot, confocal immunoﬂuorescence mi-
croscopy (IF) and immunoprecipitation were; GFP (ab290), GFP-
Sepharose (ab69314) (Abcam), Vinculin (Sigma), Emerin (VP-E602)
(Vector Labs), lamin A/C (sc-6215) (Santa Cruz), total β-catenin,
active β-catenin clone 8E7 (05-665) (Millipore), nesprin-2 CH3
and nesprin-2 N3 (Immune Systems). N2CH3 peptide blocking
experiments were performed as described previously using the
peptide KRDLDELKDHLQL (Immune Systems) [6]. Filamentous ac-
tin was observed by IF using Rhodamine phalloidin (Invitrogen).
Secondary antibodies for WB were horseradish peroxidase-con-
jugated anti mouse (NA931) or anti rabbit (NA94V) antibodies
from GE Healthcare. ECL chemiluminescent kit (RPN2132, GE
Healthcare) was used for detection according to manufacturer's
instructions. Invitrogen anti-mouse Alexa ﬂuor 568 (A11031) and
anti-rabbit Alexa ﬂuor 488 (A11034) were used as IF secondary
antibodies. For IF cells were cultured on cover slips, ﬁxed in 4%
paraformaldehyde (Sigma), permeabilised in 0.5% NP-40 (Sigma)
and processed as described previously [6]. All images were cap-
tured at 63 ! magniﬁcations using a Leica SP5 laser scanning
confocal microscope.
2.6. Immunoprecipitation, GST pull-downs and subcellular
fractionations
Subcellular fractionations were performed as described pre-
viously [14]. GST expression, puriﬁcation and pull-down assays
were performed as described previously [14]. For im-
munoprecipitation (IP), U2OS cells were transfected with either
GFP or GFP-ABDN2 and incubated overnight. Cells were processed
for IP as described previously [14]. GFP was immunoprecipitated
by incubating with anti-GFP coated Sepharose beads for 2 h at
4 °C. Beads were washed three times in IP buffer before bound
proteins were eluted in sample buffer, as described previously [14].
Coomassie staining was performed using the Bio-Safe™ Coomassie
stain (BIORAD) as per manufacturer's instructions.
2.7. Luciferase assays
U2OS cells were seeded onto a 6 well plate at a density of
2.5!105 cells per well. Next day cells were transfected with
mixtures of 1 mg TOP-FLASH or FOP-FLASH, 0.1 mg TK Renilla and
1 mg of GFP, GFP-ABDN2, FLAG or FLAG-SR 1-3 using Fugene
(Promega). Cells were incubated overnight. For analysis of siRNA
on transcriptional activity the TOP-FLASH or FOP-FLASH and TK
Renilla mix was added directly to siRNA transfection mixture
containing HiPerfect (Qiagen). Cells were incubated for 48 h. Lu-
ciferase and Renilla activities were assayed using the Dual-Glos
Luciferase assay system (Promega) as per manufacturer’s instruc-
tions. Control Luciferase activities were assigned a value of 1.
2.8. Statistical analysis
Results are presented as mean þ/# SEM. For comparison of
siRNA knockdown groups paired Student's t-tests or one way
ANOVA with Bonferroni's post-test were performed.
Q. Zhang et al. / Experimental Cell Research 345 (2016) 168–179 169
3. Results
3.1. Cell speciﬁc distribution of nesprin-2 variants
Recently, 3′UTRs encoding KASH-less N-terminal nesprin-2
variants (p220CHNesp2 and p380CHNesp2) were identiﬁed by EST
data base searches (Fig. 1A). These 3′UTRs display tissue speciﬁc
expression patterns [5]. To describe the cell speciﬁcity of these 3′
UTRs, we performed PCR analysis and we show that p220CHNesp2


































































Fig. 1. Cell type speciﬁc expression of N-terminal nesprin-2 variants. A) Schematic representation of the genomic organisation of 5′ and 3′ UTRs encoding the N-terminal
variants of nesprin-2 N-terminus. B) PCR analysis of cDNA derived from U2OS, dermal ﬁbroblast (HDF), vascular smooth muscle (VSMC), C2C12 myoblast and human
umbilical vein endothelial (HUVEC) cells for p220CHNesp2 and p380CHNesp2 3′UTRs. C) Schematic representation of nesprin-2 N-terminal variant structure and N-terminal
(N2CH3) and C-terminal (N2N3) nesprin-2 antibody epitope regions. D) WB of U2OS, VSMC and HDF whole cell lysates separated on 5% polyacrylamide gels.
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vascular smooth muscle cells (VSMC) but absent in human dermal
ﬁbroblast (HDF) and mouse C2C12 myoblast cells. The
p380CHNesp2 variant was abundant in U2OS, HDF and myoblast
cells, but lacking in human umbilical vein endothelial cells (HU-
VEC) and VSMCs (Fig. 1B). Western blot analysis (WB) was per-
formed on whole cell lysates using an antibody raised to the
N-terminus of the nesprin-2 giant (N2CH3) (Fig. 1C). To conﬁrm
the speciﬁcity of the N2CH3 antibody we performed peptide
blocking experiments and show that the activity of the antibody is
efﬁciently blocked by the target sequence on WB (Supplementary
Fig. 1A). In agreement with the PCR data, we show that U2OS cells
possess both the p220CHNesp2 and p380CHNesp2 variants whereas
VSMCs and HDFs possess either the p220CHNesp2 or p380CHNesp2
variant, respectively (Fig. 1D). Importantly, using the N2CH3 an-
tibody and a C-terminal nesprin-2 antibody (N2N3) we show that
the nesprin-2 giant is highly abundant in VSMCs but was not de-
tectable in U2OS and HDF cells tested (Fig. 1C and D). As previous
studies have shown that the nesprin-2 giant is present in HDF cells
at low levels, we performed subcellular fractionation experiments
to concentrate the nuclear proteins [26]. WB revealed that ne-
sprin-2 giant was weakly present in HDF nuclear fractions. Im-
portantly, nesprin-2 giant was not detected in U2OS nuclear
fractions, further conﬁrming that U2OS cells lack nesprin-2 giant
(Supplementary Fig. 1B).
Subcellular fractionation of U2OS cells demonstrated that
p220CHNesp2 and p380CHNesp2 reside in both the cytoplasmic and
nuclear fractions (Fig. 2A). In addition, smaller unknown nesprin-2
bands were observed in the cytoplasmic (55 kDa) and nuclear (60
and 70 kDa) fractions (Fig. 2A). The p220CHNesp2 variant was also
detected in both nuclear and cytoplasmic fractions in VSMCs
(Fig. 2B), however, the p380CHNesp2 variant was nuclear in HDF
cells (Fig. 2C). In all cell types tested, unknown variants were de-
tected, suggesting that our knowledge of nesprin-2 variants re-
mains incomplete (Fig. 2A–C).
3.2. Nesprin-2 variants localise to cell-cell junctions and interact
with β-catenin
Next, we employed confocal ﬂuorescence microscopy (IF) to
investigate the cellular localisations of these variants. IF demon-
strated that the nesprin-2 antibody raised to the N-terminus of
nesprin-2 giant (N2CH3) diffusely stained within the nucleus and
at the sites of cell-cell contact at the cell periphery, where nesprin-
2 colocalised with active β-catenin in U2OS cells (Fig. 3A and B). In
contrast, no colocalisation with β-catenin was observed in HDF
cells (Supplementary Fig. 2). To investigate the signiﬁcance of
nesprin-2 localisation at cell-cell contacts further, U2OS cells were
grown in high or low calcium conditions to promote or inhibit
cadherin mediated cell junction formation respectively. IF revealed
that, U2OS cells in the presence of high calcium, displayed colo-
calisation of nesprin-2 and active β-catenin at cell-cell junctions,
however, localisation of both nesprin-2 and β-catenin is rapidly
lost from the plasma membrane when cells were switched to low
calcium conditions to promote cadherin disassembly (Fig. 3B).
Localisation of nesprin-2 and β-catenin at cell-cell contacts was
rescued by replenishing calcium levels (Fig. 3B).
To further interrogate the localisation of nesprin-2 variants that
retain the CHD but lack the KASH domain, we employed an
overexpression strategy using an N-terminal nesprin-2 construct
that possessed the CHD and the antibody binding region (amino
acids 1-531) (Fig. 3A). IF demonstrated that the N-terminal frag-
ment (GFP-ABDN2) colocalised efﬁciently with active β-catenin at
cell-cell junctions in U2OS (Fig. 3C, left panel) and HDFs (Fig. 3C,
right panel). Importantly a similar fragment of nesprin-1 failed to
localise to cell-cell junctions and was predominantly nuclear,
suggesting that cell-cell junction localisation is speciﬁc for ne-
sprin-2 (Supplementary Fig. 3). To further deﬁne the requirements
for cell-cell junction localisation, we next expressed the CHD re-
gion (amino acids 1-279) of nesprin-2. IF revealed that the CHD
localised to cell-cell junctions, although some stress ﬁbre staining
was also observed (Fig. 3C).
Next, we investigated whether nesprin-2 interacted with β-ca-
tenin by performing immunoprecipitation experiments. WB re-
vealed that β-catenin was precipitated by the GFP-ABDN2 fragment
but not GFP-alone (Fig. 4A and B). Conversely, the GFP-ABDN2
fragment was efﬁciently precipitated by β-catenin IP, conﬁrming
the nesprin-2 is a novel β-catenin interacting protein (Fig. 4C). Next,
we mapped the β-catenin binding site by fusing the SR region of the
ABDN2 construct (SR 1-3 containing amino acids 278-531) to GST
(Fig. 4A). GST pull down assays conﬁrmed that β-catenin was pre-
cipitated by GST-SR 1-3, but not GST alone (Fig. 4D), conﬁrming that
this spectrin repeat region interacts with β-catenin.
3.3. Nesprin-2 disruption induces cell-cell junction disassembly and
augments β-catenin transcriptional activity
We next investigated the impact of nesprin-2 disruption on β-





































Fig. 2. N-terminal nesprin-2 variants reside in the cytoplasm and nucleus. WB of U2OS, VSMC and HDF of cytoplasmic (C) and nuclear (N) fractions separated on 8%
polyacrylamide gels. * mark unidentiﬁed nesprin variant bands.
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strategy that targeted nesprin-2 variants containing the CHDs.
U2OS cells were transfected with either control or nesprin-2
speciﬁc siRNA that targeted the N-terminus of p220CHNeps2 and
p380CHNesp2 (Fig. 5A). WB analysis conﬁrmed knockdown of
p220CHNesp2 using 3 independent nesprin-2 speciﬁc siRNAs
(Fig. 5B and C). Levels of the p380CHNesp2 variant remained
unaltered by our siRNA strategy (Fig. 5B and D), suggesting that
p380CHNesp2 is more stable than p220CHNesp2. WB also revealed
that protein levels of C-terminal variants that lack the siRNA target
sequence remain unaltered (Fig. 5B). Importantly, levels of active
β-catenin and total β-catenin remained unaltered by our nesprin-2










ABDN2 (amino acids 1-531)






GFP GFP-ABDN2 Flag-CHDN2 
Aβ-catenin 
GFP only         GFP-ABDN2     FLAG-CHDN2                         
Aβ-catenin  
Merge                            
25µm25µm
25µm
Fig. 3. N-terminal nesprin-2 variants colocalise with β-catenin at cell-cell junctions. A) Schematic representation of nesprin-2 CH3 antibody epitope position and nesprin-2
constructs used. B) IF of nesprin-2 (CH3) (green), active β-catenin (Aβ-catenin) (red) and DAPI (blue) localisation in U2OS cells before, during and after calcium depletion. C)
IF of GFP-ABDN2, Flag-CHDN2 (green) and active β-catenin (Aβ-catenin) (red) in U2OS (left panel) and ﬁbroblast cells (right panel). Scale bar¼25 mm.
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and p380CHNesp2 variants we designed siRNAs targeting the un-
ique 3′UTRs, however, WB revealed that this strategy was un-
successful and failed to deplete the p220CHNesp2 and p380CHNesp2
variants (Supplementary Fig. 4).
IF was performed to observe whether nesprin-2 depletion al-
tered β-catenin organisation in U2OS cells and revealed that ne-
sprin-2 depleted cells displayed reduced staining of active β-ca-
tenin at cell-cell junctions compared to control cells (Fig. 6A and B
and Supplementary Fig. 5A), suggesting that the p220CHNesp2
variant tethers active β-catenin to the sites of cell-cell contact.
Importantly, subcellular fractionation revealed that nesprin-2 de-
pleted cells displayed increased levels of nuclear active β-catenin
(Fig. 6C) and TOP-FLASH/FOP-FLASH luciferase assays conﬁrmed
that nesprin-2 depleted cells possessed augmented β-catenin
transcriptional activity compared to control cells (Fig. 6D). In
contrast, siRNAs targeting the C-terminus of nesprin-2 giant that
the p380CHNesp2 and p220CHNesp2 variants lack, failed to alter
luciferase activity (Fig. 6A and D), supporting the notion that
N-terminal variants are responsible for localising β-catenin to cell-
cell junctions. Next, we assessed the impact of overexpression of
the β-catenin binding fragments of the N-terminal nesprin-2
variants on β-catenin signalling. However, TOP-FLASH/FOP-FLASH
luciferase assays revealed that the β-catenin binding fragments
had no impact on β-catenin transcriptional activity (Supplemen-
tary Fig. 5B).
3.4. β-catenin localisation at cell-cell junctions is independent of
emerin
Previous studies have shown that nesprin disruption triggers
nuclear morphology defects, so we next performed IF to observe if
our siRNA strategy altered nuclear morphology. Analysis revealed
that control cells contained spherical nuclei, however, nesprin-2
depleted nuclei possessed a more convoluted morphology (Fig. 7A
and B). Next, we performed IF to observe the localisation of the
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Fig. 4. The N-terminus of nesprin-2 interacts with β-catenin. A) Schematic representation of the nesprin-2 constructs used. B) WB of GFP/GFP-ABDN2 immunoprecipitation.
C) WB of β-catenin IP. D) WB of GST-alone and GST-SR 1-3 construct pull downs. GST-loading was shown by coomassie stain.
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depleted cells display normal NE emerin staining (Fig. 7C). As
emerin has previously been implicated in β-catenin signalling, we
further investigated whether changes in β-catenin signalling were
due to impaired emerin function by performing emerin knock-
down experiments. WB conﬁrmed efﬁcient emerin depletion in
U2OS cells (Fig. 8A), however, β-catenin organisation and tran-
scriptional activity remained unaltered in emerin depleted cells
(Fig. 8B and C).
4. Discussion
Nesprins have emerged as signalling scaffold proteins that lo-
calise to multiple subcellular compartments, including the NE,
cytoplasm and nucleoplasm [5,6]. In this current study, we show
that nesprin-2 N-terminal variants colocalise with β-catenin at
cell-cell junctions. We show that a fragment containing the CHD
and SR 1-3 region (ABDN2) was sufﬁcient for both β-catenin
binding and cell-cell junction localisation. Further mapping iden-
tiﬁed the N-terminal SRs 1-3 of nesprin-2 as a novel β-catenin
binding region, although we did not rule out the possibility that
the CHD and β-catenin also interact. We propose that the
N-terminal nesprin-2 KASH-less variants tether β-catenin at cell-
cell junctions and inhibit β-catenin transcriptional activity. In
support of this notion, nesprin-2 depleted U2OS cells displayed
loss of β-catenin from cell-cell contacts, accumulation of active β-
catenin in the nucleus and augmented β-catenin transcriptional







































Fig. 5. Validation of nesprin-2 depletion strategy. A) Schematic representation of nesprin-2 CH3 and N3 antibody epitopes and the region targeted by siRNA siN2CH2–5. B)
WB of N-terminal (N2CH3) and C-terminal (N2N3) variants after control and nesprin-2 (siN2CH2/CH3/CH4) siRNA knockdown. Samples were separated on 8% poly-
acrylamide gels. Graphs show relative level of C) p220CHNesp2 and D) p380CHNesp2. Graphs represent combined data from 3 independent siRNA experiments for fold change
in densitometry ratio (*p¼o0.05, **p¼o0.001).


















C   N  C  N   C  N







Fig. 6. Nesprin-2 is required for β-catenin localisation at cell-cell junctions and negatively regulates β-catenin transcriptional activity. A) Schematic representation of
siN2CH2/siN2CH5 and siN2KASH target regions. B) IF of active β-catenin (Aβ-catenin) (green), F-actin (red) and DAPI (blue) in control and nesprin-2 (siN2CH2) depleted
U2OS cells. Scale bar¼25 mm. C) WB of control, siN2CH2 and siN2CH5 cytoplasmic (C) and nuclear (N) fractions. D) TOP/FOP Luciferase assay of control, siN2CH2, siN2CH5
and siN2KASH depleted cells. Graph shows combined data from 3 independent experiments repeated in triplicate (*p¼o0.05, **po0.001).
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unchanged in nesprin-2 depleted U2OS cells, suggesting that ne-
sprin-2 depletion triggers redistribution of active β-catenin from
cell-cell contacts to the nucleus. Our overexpression experiments
show that N-terminal CHD containing nesprin-2 fragments loca-
lise to cell-cell contacts, colocalise with active β-catenin but did
not alter β-catenin transcriptional activity. N-terminal nesprin-2
fragments that lack the CHD but retain the β-catenin binding site
also failed to alter β-catenin transcriptional activity. This suggests
that the association between active β-catenin and the N-terminal
nesprin-2 variants at cell-cell contacts is stable, further experi-
mentation is required to elucidate the functions/dynamics of these
N-terminal nesprin-2 variants at cell-cell contacts.
We also demonstrate that the p220CHNesp2 and p380CHNesp2















Fig. 7. Nesprin-2 disruption alters nuclear morphology but not emerin localisation. A) IF of nesprin-2 (green), emerin (red), and DAPI (blue) staining of control and nesprin-2
depleted cells. Scale bar¼10 mm. B) Quantiﬁcation of number of control and nesprin-2 depleted (siN2CH2 and siN2CH5) cells displaying convoluted nuclei. Graph show
combined data from 3 independent experiments counting 300 cells per group (**p¼o0.001 and ***p¼o0.0001). C) IF staining of DAPI (blue), N2CH3 (green) and emerin
(red) in control and nesprin-2 depleted U2OS cells. Scale bar¼25 mm.
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the nucleus and cytoplasm, raising the intriguing possibility that
these KASH-less variants may shuttle between these compart-
ments. However, further investigation is now required to clarify
whether KASH-less nesprin-2 variants associate with and organise
other components of the β-catenin pathway, as well as to identify
the exact nesprin-2 variant. Our knockdown strategy efﬁciently
depleted p220CHNesp2 but not p380CHNesp2 and presumably these
two variants display differences in protein turnover as both con-
tain the target sequence. This suggests that p220CHNesp2 is po-
tentially a good candidate for future investigation however, our
siRNA strategy targeted multiple nesprin-2 variants so the possi-
bility remains that an unidentiﬁed variant may localise to cell-cell
contacts and regulate β-catenin signalling.
4.1. N-terminal nesprin-2 variants regulate β-catenin signalling in-
dependently of the NE
Nesprin-2 variants organise the NE and several recent studies
have identiﬁed the NE as a novel regulator of β-catenin signalling
[22,23,30]. Firstly, β-catenin interacts with the C-terminus of the
nesprin-2 giant to positively regulate β-catenin signalling [22]. In
addition, the nesprin-1/2 orthologue ANC1 regulates β-catenin
signalling during neuronal development in Caenorhabditis elegans
[30]. Due to the sequence identity between nesprin-2 variants, our
knockdown strategy potentially targeted both KASH-less N-term-
inal and the KASH-containing nesprin-2 giant variants [5]. Im-
portantly, we show that U2OS cells lack nesprin-2 giant and β-
catenin transcriptional activity was enhanced by N-terminal ne-
sprin-2 depletion in U2OS cells. These data suggest that the
N-terminal nesprin-2 variants negatively regulate β-catenin tran-
scriptional activity in U2OS cells and highlight the complexity of
nesprin-2 function in regulating β-catenin signalling. Previous
studies have also demonstrated that emerin interacts with both
the C-terminal nesprin-2 variants and β-catenin at the INM to
negatively regulate β-catenin mediated transcription [23]. KASH-
containing nesprin-2 variants are essential for emerin organisation
at the NE [6], however, emerin organisation was unaltered by
depletion of N-terminal nesprin-2 variants in U2OS cells, sug-
gesting that changes in β-catenin signalling induced by our siRNA
strategy were NE independent. Furthermore, emerin depletion in
U2OS cells failed to displace β-catenin from cell-cell junctions or
alter β-catenin transcriptional activity, further suggesting that the
N-terminal nesprin-2 variants regulate β-catenin signalling in-
dependently of the NE.
Despite our evidence showing that nuclear envelope function
is not disrupted by our nesprin-2 siRNA strategy, nuclear mor-
phology was altered by our approach. Previous studies have de-
monstrated that actomyosin, cell morphology and adhesion all
contribute to deﬁning nuclear morphology and potentially, in
addition to disrupting cell-cell contacts, our nesprin-2 depletion
strategy induced cytoskeletal reorganisation that altered nuclear
morphology [27,28]. However, the potential role of the nesprin-2
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Fig. 8. Emerin disruption does not impact on β-catenin localisation. A) WB conﬁrming emerin knockdown. B) IF of active β-catenin (Aβ-catenin) (green), F-actin (red) and
DAPI (blue) in control and emerin depleted U2OS cells. Scale bar¼25 mm. C) TOP/FOP luciferase assay of control and emerin depleted cells. Graph shows combined data from
3 independent experiments repeated in triplicate.
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4.2. Nesprin-2 variants ﬁne tune β-catenin signalling for cell speciﬁc
functions?
Nesprin variants demonstrate complex tissue and cell-speciﬁc
distributions [5,29]. Nesprin giant variant expression is abundant
in the majority of human tissues, except cardiac and skeletal
muscle, which are enriched in shorter isoforms [29]. In addition,
the nesprin-2 epsilon-1 and epsilon-2 variants are highly ex-
pressed in embryonic stem cells (ESC) and heart respectively [29].
Here, we conﬁrm that the p220CHNesp2 and p380CHNesp2 variants
display cell-speciﬁc expression, suggesting that nesprin function is
tailored to speciﬁc cellular functions. In support of this, up reg-
ulation of nesprin variants and nesprin variant switching is ob-
served in ESC, mesenchymal stem cell and skeletal muscle differ-
entiation [26,30,31]. Nesprins have emerged as signalling scaffolds
for the ERK and β-catenin pathways and these pathways exist in
multiple cell types. Furthermore, recent evidence demonstrates
the importance of the signalling scaffolding functions of the ne-
sprin family during development, where the nesprin-1/2 ortho-
logue ANC1 regulates β-catenin signalling during neuronal de-
velopment in C. elegans [32]. However, we show that the nesprin-2
giant is not detectable in U2OS cells and potentially adaptation of
nesprin variant expression may ﬁne tune these pathways and fa-
cilitate cell-speciﬁc signalling. In support of this, we show that
U2OS cells display high levels of the p220CHNesp2, whereas ﬁbro-
blasts lack the p220CHNesp2 variant. In addition to changes in ne-
sprin-2 variant expression, the p380CHNesp2 variant displayed
differential compartmentalisation between U2OS and HDF cells,
therefore, differential nesprin variant expression/compartmenta-
lisation may contribute to cell speciﬁc functions for nesprin-2 in β-
catenin signalling. Further investigation is now required to clarify
the cell-speciﬁc functions of nesprin variants in regulating β-ca-
tenin signalling.
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